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1K/1C 1 Kidney 1 clip
2K/1C 2 kidney 1 clip
A192621 (2R, 3R, 4S)-2-(4-propoxy-phenyl)-4-( 1,3-benzodioxol-5-yl)-1-(N-
[(2,6-diethylphenyllace-tamido)pyrrolidine-3-carboxylate, nitrogen
ACh Acetylcholine
Ang II Angiotensin II
ANOVA Analysis of variance
ANP Atrial natriuretic peptide
ApoE Apolipoprotein E




BSA Bovine serum albumin
CAIP Calf Intestinal Alkaline Phosphatase
cAMP Cyclic adenosine monophosphate
CCT Cortical collecting tubule
cDNA Copy deoxyribonucleic acid
cGMP Cyclic guanosine monophosphate
CHO Chinese Hamster Ovary
CMV Cytomegalovirus
CNS Central nervous system
















ECE Endothelin converting enzyme
EDTA Ethylene dinitrilo-tetra-acetate
EGF Epidermal growth factor
ENaC Epithelial sodium channel
eNOS Endothelial nitric oxide synthase
ES Embryonic stem cell
ET Endothelin
ETa Endothelin receptor type A
ETb Endothelin receptor type B
ETC Endothelin receptor type C
FAK Focal adhesion kinase
FCS Foetal calf serum




GFP Green fluorescent protein
GFR Glomerular filtration rate
GPCR G-protein coupled receptor
GSL I-B4 Griffonia simplicifolia isolectin B4
IL Interleukin










MAP Mean arterial pressure
MAPK Mitogen activated protein kinase




nNOS Neuronal nitric oxide synthase
NO Nitric Oxide
NOS Nitric oxide synthase
OD Optical density
PA Phosphatidic acid
PBS Phosphate buffered saline
Pco2 Partial pressure of carbon dioxide
PCR Polymerase chain reaction
PDGF Platelet derived growth factor
PG Prostaglandin
PIP2 Phosphatidylinositol 4,5-bisphosphonate






p02 Partial pressure of oxygen
PSS Physiological saline solution
PT Proximal tubule
RAAS Renin angiotensin aldosterone system
RBF Renal blood flow
RIA Radioimmunoassay
RNA Ribonucleic acid
RSNA Renal sympathetic nerve activity
RVR Renal vascular resistance
s Piebald allele
S6c Sarafotoxin 6c
SDS Sodium dodecyl sulphate
SHR Spontaneously hypertensive rat
SHR-SP Spontaneously hypertensive rat-stroke prone
si Spotting lethal allele
SMC Smooth muscle cell
SM-MHC Smooth muscle myosin heavy chain promoter
STAT signal transducers and activators of transcription
Tie2 Tie2 promoter/enhancer Cre transgene
TK Thymidine kinase
TNF Tumour necrosis factor
TPR Total peripheral resistance
TVP Trypsin
UHP Ultra high purity
UV Ultra-violet
v/v Volume per volume
VSMC Vascular smooth muscle cell
W Wild type ETB receptor allele
w/v Weight per volume
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Studies in humans and animals have demonstrated the importance of the endothelin
(ET) system in the regulation of vascular tone, blood pressure and renal
haemodynamics (Gariepy et al., 2000, Haynes and Webb, 1994, King et al., 1989).
Two receptors, termed ETA and ETB, mediate the cardiovascular and renal effects of
the endothelins. The ETB receptor has multiple roles in different cell types, including
vasodilatation (Takayanagi et al., 1991), vasoconstriction (Sumner et al., 1992),
inhibition of renal sodium reabsorption (Gariepy et al., 2000) and clearance of ET-1
(Fukuroda et al., 1994). Each of these responses may independently modulate blood
pressure and regional blood flow. However, the relative importance of each response
to the complex homeostatic mechanisms of blood pressure control, particularly under
conditions of high salt intake, has yet to be determined. Currently available selective
ETB receptor antagonists are unable to block ETB receptors in individual cell types
without also causing blockade of ETB receptors expressed elsewhere. The aim of this
project was to precisely determine the role of the EC ETB receptor in the regulation
of vascular tone, blood pressure and clearance of ET-1.
METHODS
To examine the phenotypical effects of loss of EC ETB receptor signalling without
the confounding effects of ETB receptor blockade, or loss, in other cell types, I
utilised Cre-LoxP technology to conditionally regulate ETB receptor expression.
Mice featuring loxP sites flanking exons 2 and 3 of the ETB receptor gene (floxed
ETB receptor mice) were generated by standard gene targeting techniques in
embryonic stem cells. Floxed ETB mice were crossed with Tie2-Cre transgenic mice
to produce mice in which recombination-mediated removal of ETB receptor coding
regions was limited to EC and cells of the haematopoietic lineage (Flox/Flox Tie2).
EC ETB receptor binding of 125I ET-1 and in vitro aortic and tracheal ring myography
was performed to assess endothelial function and the response to selective ETB
receptor agonists. Blood pressure was measured under conscious, unrestrained
YV
conditions via in-dwelling carotid catheters in male mice aged 8-16 weeks fed for 21
days with either a normal (0.76% NaCl) or high (7.6% NaCl) salt diet. Plasma ET-1
was measured by radioimmunoassay. Wild type (W/W -/-) and single transgenic
littermates were used as controls in experiments.
RESULTS
Pulmonary EC ET-1 binding was decreased by ~80% in EC-specific ETB receptor
knockout mice (cpm/50 pg membrane protein ± SEM; Flox/Flox Tie2 581 ± 67;
W/W -/- 3175 ± 268; n = 3; /?<0.001). Cell-specificity of ETB receptor down-
regulation was demonstrated by maintenance of normal ETB receptor-mediated
tracheal constriction. Blood pressure was increased in Flox/Flox Tie2 mice (MAP
137.2 ± 6.4 mmHg (n = 5); W/W -/-, 113.7 ± 4.7 mmHg (n = 6; p<0.05) but was not
affected by dietary salt. Plasma ET-1 was increased ~4fold following EC ETB
receptor down-regulation (mean plasma |ET-11 pg/ml ± SEM; Flox/Flox Tie2 12.40
± 2.95; W/W -/- 2.94 ± 0.83; n = 6; /?<0.001). Aortic rings from Flox/Flox Tie2 mice
demonstrated impaired endothelium dependent vasodilatation to ETB receptor
selective agonists and acetylcholine but normal endothelium-independent
vasodilatation.
CONCLUSIONS
Recombination-mediated removal of exons 2 and 3 of the ETB receptor is sufficient
to prevent expression of functional ETB receptors. The 'floxed' ETB receptor mouse
thereby facilitates the cell type-specific down-regulation of ETB receptor expression
in vivo. The EC ETB receptor plays an important role in the determination of blood
pressure under normal physiological conditions. The mechanism underlying this
effect may involve loss of EC ETB receptor-mediated vasodilatation or impaired
clearance of ET-1 with a consequent increase in ETA receptor activity. In contrast to
global ETB receptor deficiency however, maintenance of ETB receptor signalling in
non-EC is sufficient to prevent salt-sensitive hypertension. The EC ETB receptor may





ET-1 is a local hormone and growth factor widely known for its potent vasoconstrictor
effects. ET-1 was originally isolated and characterised by Yanagisawa and colleagues
(Yanagisawa et al., 1988) from the culture media of aortic EC. Subsequently, two
further isoforms, termed ET-2 and ET-3, were identified. The endothelin family share
structural homology with the sarafotoxins, 4 potent cardiotoxic peptides isolated from
the venom of Atractaspis engaddensis. Each of the mature isoforms of endothelin are 21
amino acid peptides with rigid 3-dimensional structures stabilized by two disulphide
bonds. A highly conserved C-terminal sequence is mandatory for biological function of
the peptide. The structure of these peptides is illustrated in Figure 1.1. ET-1 is the
predominant isoform involved in cardiovascular regulation and is the only isoform
produced constitutively by EC (Inoue et al., 1989). The rapid development of selective
endothelin receptor antagonists has led to an explosion of research into the physiological
and pathophysiological roles of the endothelins. This work has demonstrated the
potential for pharmacological manipulation of the endothelin system in a range of
cardiovascular conditions, including hypertension, congestive cardiac failure, renal




Structure of the endothelin family of peptides, and the related snake venom peptide




The human genes for ET-1, ET-2 and ET-3 are located on chromosomes 6, 1 and 20,
respectively. Regulation of ET-1 synthesis is determined primarily at the level of
transcription of the preproET-1 gene through phorbol-ester-sensitive c-fos and c-jun
complexes (Inoue et al., 1989). Other regulatory sequences located in the upstream (5')
promoter region include binding sites for GATA-2 (Dorfman et al., 1992), AP-1 and
nuclear factor-1 (Benatti et al., 1994) and a hexanucleotide sequence (Inoue et al.,
1989). These sites regulate basal levels of gene transcription and responses to
angiotensin II (Ang II), transforming growth factor (3 and acute phase reactants,
respectively (Inouc et al., 1989). Synthesis of ET-1 may also be regulated by post-
transcriptional mechanisms. The non-translated 3' region of preproET-1 mRNA contains
'suicide motifs' that may permit its selective destabilisation (Inoue et al., 1989). These
motifs determine the short (~15 minute) half-life of preproET-1 mRNA and thereby
prevent excessive ET-1 production. Factors known to promote ET-1 production include
thrombin, insulin, cyclosporine, epinephrine, Ang II, Cortisol, inflammatory mediators,
hypoxia and vascular shear stress. ET-1 production is inhibited by NO, NO donor drugs
and dilator prostanoids via an increase in cellular cyclic guanosine monophosphate
(cGMP), and natriuretic peptides via an increase in cyclic adenosine monophosphate
(cAMP) levels (Gray, 1995). The factors affecting ET-1 generation and the synthetic








































Factors that influence ET-1 synthesis and the pathway for ET-1 generation. IL-1 =
interleukin-1; TGF|3 = transforming growth factor (3; LDL = low density lipoprotein;
ANP, BNP, CNP = atrial, brain and c-type natriuretic peptides.
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The mature ET-1 peptide is generated by sequential enzymatic cleavage of the initial
203 amino acid preproET-1 peptide. A short hydrophobic secretory sequence is first
removed to produce proET-1. Cleavage at dibasic amino acid pairs by the endopeptidase
furin then generates the 38 amino acid peptide 'big ET-1' (Yanagisawa et al., 1988).
Subsequent production of mature ET-1 by a proteolytic cleavage between Trp21 and
Val22 is catalysed by the metalloprotease endothelin-converting enzyme-1 (ECE-1).
Recently, a further endothelin peptide has been identified in humans formed by the
cleavage of big ET-1 at the Tyr31 and Gly32 bonds by a human chymase enzyme
expressed in mast cells. This product has been termed ET-l^, and has been shown to
produce vasoconstriction of airway smooth muscle (Nakano et al., 1997), although its
physiological relevance remains unknown.
1.3 ENDOTHELIN CONVERTING ENZYME
ECE-1 was isolated and purified by Ohnaka and colleagues (Ohnaka et al., 1990) from
aortic EC. ECE-1 is inhibited by the combined ECE and neutral endopeptidase (NEP)
inhibitor phosphoramidon, but not by selective NEP inhibitors such as thiorphan or
kelatorphan. The ECE protein is a transmembrane dimer consisting of two 758 amino
acid peptide chains linked by a single disulfide bridge. A short (1-56) N-terminal
intracellular region is followed by a 21 amino acid transmembrane region. A zinc-
binding and catalytic site (595-599) is essential for enzymatic activity. ECE-1 belongs to
the Neprilysin family of zinc endopeptidases that also includes NEP and the human Kell
blood group protein (Xu et al., 1994). However, ECE is unique in this group in that it
recognises a relatively long C-terminal portion of big ET-1 (residues His27 to Gly34) in
addition to the cleavage site between residues 21 and 22 (Takayanagi et al., 1998).
Additional ECE isoforms have been identified in animals (ECE-2 and ECE-3), but only
ECE-1 and ECE-2 have been demonstrated in humans (Russell and Davenport, 1999).
ECE gene knockout indicates that ECE-1 is the major functional ECE for all three
endothelin isoforms, but the presence of mature ET-1 in ECE-1 knockout embryos
suggests some degree of redundancy (Yanagisawa et al., 1998). ECE-2 may be
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distinguished from ECE-1 by a requirement for a lower pH for optimum activity. It is
postulated that ECE-2 is involved in the constitutive pathway of ET-1 release from
acidic secretory vesicles and may be particularly important under stress conditions such
as ischaemia when the intracellular pH is low (Russell and Davenport, 1999). Combined
knockout of both ECE-1 and ECE-2 results in cardiac malformations, indicating a
further role for ECE-2 during development (Yanagisawa et al., 2000). ECE-3 has
currently only been identified in bovine species where it is selective for the cleavage of
bigET-3 (Hasegawa et al., 1999).
The human ECE-1 gene is located on chromosome 1 at the p36 band (Valdenaire
et al., 1995). Four splice variants have been identified, termed ECE-la to ECE-ld.
These isoforms differ in structure only at the N-terminus where di-leucine motives may
determine the distinct subcellular locations of these isoforms (Valdenaire et al., 1999).
In humans, ECE-1 c is the predominant isoform, although the relative proportions of
each may vary in different tissues. Changes in the isoform expression pattern may
further occur in pathophysiological states including atherosclerosis (Davenport and Kuc,
2000). However, controversy still exists concerning the precise sub-cellular locations of
each isoform. This has potentially important implications for the design and delivery of
pharmacological antagonists of these enzymes. Current opinion suggests that the
majority of ECE-la is found in the plasma membrane, that ECE-lb is exclusively
intracellular and ECE-1 c is found both in the cytoplasm and at the cell membrane
(Valdenaire et al., 2001). However, Barnes and colleagues (Barnes et al., 1998) have
demonstrated that in EC, ECE-1 cycles between the Golgi apparatus, cytoplasmic
vesicles and the plasma membrane. They propose that ECE-1 is directed into secretory
vesicles wherein it generates mature ET-1 from big ET-1 during the passage to the
plasma membrane. Following release of ET-1, ECE-1 is re-cycled to the Golgi network
via endosomes.
Transfection studies have confirmed that endogenously generated ET-1 secreted
abluminaly is the most functionally important source of ET-1. Co-transfection of
preproET-1 and ECE-lb genes into cultured cells has shown that ECE-lb expressed at
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the cell surface is relatively inefficient at proteolysis of exogenous big ET-1, with only
around 10% converted to ET-1. In contrast, between 50-90% of the endothelin peptides
secreted by the cells were in the mature ET-1 form (Xu et al., 1994), suggesting
significant intracellular ECE-lb activity. This data supports a predominantly
autocrine/paracrine mechanism of action for ET-1, a theory given further credence by
the low (<5pM) circulating concentration of ET-1 in humans, concentrations probably
insufficient to activate endothelin receptors. The concentration of Ang II and atrial
natriuretic peptide (ANP) in plasma is normally up to ten times that of circulating ET-1.
Also, ET-1 has a half-life of less than five minutes in plasma, with clearance occurring
mainly in the lungs and liver (Fukuroda et al., 1994). It is likely that much higher
concentrations of ET-1 occur at the junctions between EC and VSMC and that at least
some of the plasma ET-1 represents overspill from this site.
1.4 SECRETION OF ENDOTHELIN-1
The secretion of ET-1 may occur by both constitutive and regulated pathways. Russell
and colleagues (Russell et al., 1998) have demonstrated the presence of ET-1 immuno-
reactivity in both cytoplasmic secretory vesicles and EC-specific storage granules.
Whilst constitutive ET-1 secretion is likely to originate from secretory vesicles, storage
granules that are sensitive to [Ca2+|j and mechanical stretch may provide a mechanism of
regulated ET-1 release. ECE-1 expression has been co-localised to these granules and
the release of mature ET-1 in response to calcium ionophores has been demonstrated in
vitro (Russell et al., 1998).
1.5 ENDOTHELIN RECEPTORS
Pharmacological analysis of receptor binding suggested the existence of at least two
endothelin receptor types in humans, termed ETA and ETB. This has been confirmed by
molecular characterisation of the receptors (Arai et al., 1990, Sakamoto et al., 1991,
Sakurai et al., 1990). The ETA receptor binds its endogenous ligands with the rank order
of affinity ET-l>ET-2>ET-3. The ETB receptor has equal affinity for each of the
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endothelin isoforms. ETA receptors are located on VSMCs (Arai et al., 1990, Hori et al.,
1992) and, when activated, produce a sustained vasoconstriction that is of slow onset. In
contrast, ETB receptors are located on both EC (Takayanagi et al., 1991) and VSMC
(Roubert et al., 1991, Sumner et al., 1992). Activation of ETB receptors on EC causes
vasodilatation (Takayanagi et al., 1991) through the release of dilator mediators acting
on VSMC, whilst activation of ETB receptors on VSMC produces vasoconstriction
directly (Moreland et al., 1992, Sumner et al., 1992, Williams et al., 1991). The agonist
binding characteristics of the endothelin receptors are shown in Table 1.1.
ETa ETb










Action Vasoconstriction Vasodilatation Vasoconstriction
Selective Agonists None
ET-3 (600-fold specific)
Sarafotoxin 6c (30000-fold specific)
Selective
Antagonists
A147627, BQ-123 A192621, BQ-788
Table 1.1
1.5.1 ENDOTHELIN RECEPTOR GENES
The human ETA gene is located on chromosome 4 and consists of eight exons and seven
introns spanning 40 kilobases (kb) (Hosoda et al., 1992). The human ETB gene on
chromosome 13 is somewhat smaller in size, spanning 24 kb and consisting of seven
exons and six introns (Arai et al., 1993). In the mouse, the ETA and ETB receptor genes
are located on chromosomes 8 and 14, respectively (Hosoda et al., 1994, Hosoda et al.,
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1992). Analysis of cDNA clones predicts an ETA receptor 427 amino acids in length and
an ETb receptor consisting of 442 amino acids. The sequence homology of these
receptor subtypes is ~58%. In a manner analogous to the preproET-1 gene, both the ETA
and ETB receptor genes have promoter regions which control gene transcription levels in
response to factors including nuclear factor-1, nuclear factor kappa-|3, RNA polymerase
II transcription factor and acute phase response proteins (Arai et al., 1993). The
transcription factors AP-1, GATA-2 and CCAAT/enhancer- binding protein (C/EBP)
have additionally been shown to regulate ETB receptor expression in VSMCs (Wagner et
al., 2000). Blockade of the interaction between transcription factors and cis regulatory
promoter regions markedly inhibits gene transcription. Decoy oligonucleotides
containing sequences from the ETa receptor gene promoter region were able to
competitively bind a nuclear protein and down-regulate ETA promoter activity by 75%.
Local environmental factors that mediate changes in transcription factor availability may
also be able to markedly up or down-regulate receptor expression. Such mechanisms
may underlie changes in the number or subtype of receptors expressed by a cell in
certain pathological states. For example, Wang and colleagues (Wang et al., 1996)
quantitatively and temporally examined mRNA expression following angioplasty of the
rat carotid artery. They demonstrated a 30-fold increase in ETA receptor mRNA 3 days
post-angioplasty. ETb receptor mRNA increased earlier, with a 15-fold induction on day
1. ECE-1 mRNA and preproET-1 mRNA increased 2-fold. This data suggests that the
increased expression of ET-1 and of ETA and ETB receptors plays an active role in the
pathogenesis of angioplasty-induced neointima formation. Furthermore, the local
environmental factors that regulate gene expression show quantitative and temporal
differences in their influence upon promoter activity of these genes.
1.5.2 DISTRIBUTION OF ENDOTHELIN RECEPTORS
Autoradiography using labelled ET-1 and in situ hybridization has allowed the
qualitative and quantitative assessment of both the tissue distribution and the receptor
subtype expressed in various tissues and cell lines. Such analysis has demonstrated the
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localisation of ETA receptors predominantly to the VSMCs of large and medium-sized
arteries, the highest densities being found in the aorta. In addition, renal arterioles,
bronchial SMC and glandular tissues, such as those of the pituitary and adrenal glands,
have been shown to preferentially express ETA receptors (Arai et al., 1990). In contrast,
EC are devoid of ETA receptors (Hosoda et al., 1991). ETB receptors are found on both
VSMC and EC in the vasculature. ETB receptors are also expressed on glial, striatal,
ependymal and choroid plexus cells within the brain and also in the trachea, lung,
myocardium, liver, kidney, bowel and adrenal glands. Human kidneys express ETB
receptors as the predominant receptor subtype, with the collecting ducts exhibiting the
highest density of ETB receptors (Hori et al., 1992). A detailed analysis of the
distribution of renal ET receptor expression is provided later in section 1.7.3. Human
cardiac tissue expresses both ETA and ETB receptors throughout the A-V node, His-
bundle, myocardium and endocardium (Molenaar et al., 1993).
1.5.3 STRUCTURE OF ENDOTHELIN RECEPTORS
ETa and ETB receptors belong to the 7 transmembrane G-protein-coupled receptor
superfamily. The consensus ET receptor topology includes three extracellular domains,
three intracellular loops and a cytoplasmic COOH-terminal tail, separated by seven
hydrophobic helical regions thought to span the lipid bilayer (reviewed by (Rubanyi and
Polokoff, 1994). The ETA and ETB receptor transmembrane domains and the
interconnecting cytoplasmic loops are highly conserved, in contrast to the N-terminal
region, which shows only 4% sequence homology between the receptor subtypes
(Elshourbagy et al., 1993). Similarly, there is almost no homology between the ETA and
ETb receptor in the COOH- terminal region (Sakurai et al., 1990, Takagi et al., 1995).
Site directed mutagenesis studies and receptor chimeras have each been utilised to




The role of the NH2-terminal region in ligand binding remains controversial. However,
the Asp75 and Pro93 in this region of the ETB receptor are thought to be responsible for
the high stability of the complex formed between ET-1 and the ETB receptor, compared
to the ETa receptor (Takasuka et al., 1994). Each ET receptor cDNA contains 2
consensus sequences for N-linked glycosylation of the NH2-terminal region (Asn-X-
Ser), though data on the carbohydrate content of purified receptors is lacking.
1.5.3.2 Transmembrane and extracellular domains
Endothelin receptors contain several important ligand interaction subdomains. A 5
amino acid sequence in the second extracellular region of the ETA receptor is the most
important for ligand binding. However, ligand selectivity is determined by the third and
fourth extracellular regions and their flanking transmembrane regions (Adachi et al.,
1993). Amino acids at the boundary between the first extracellular loop and the second
transmembrane domain are essential for binding of the selective ETA receptor antagonist
BQ-123, whist the Lys140 in this region is required for the high affinity binding of ET-1
to the ETa receptor (Adachi et al., 1994). In ETb receptors, transmembrane domains 4 to
6 and the adjacent loop regions are permissive of the high affinity binding of ETB
receptor agonists (Sakamoto et al., 1993).
1.5.3.3 Cytoplasmic loops
The cytoplasmic loops are known to mediate receptor/guanine nucleotide regulatory
protein (G-protein) coupling in other rhodopsin-like G protein receptors. Substitution of
the C-terminal end of the third cytoplasmic domain with the corresponding section of the
^-adrenoceptor results in no changes in the affinity of the ETA receptor for ET-1, but
receptor/1 igand binding fails to elicit the subsequent rise in intracellular calcium (|Ca2+];)
that normally follows receptor activation (Adachi et al., 1993). The precise structural





The COOH-terminal amino acids show marked sequence diversity between ET receptor
subtypes. However, a conserved Cys-Leu-Cys-Cys-X-Cys sequence is found close to the
end of the seventh transmembrane domain. This region is postulated to mediate correct
membrane anchoring via palmitoylation (Roos et al., 1998, Rubanyi and Polokoff,
1994).
1.5.4 POST TRANSLATIONAL MODIFICATION OF ENDOTHELIN
RECEPTORS
Both ETa and ETb receptors contain regions that may undergo post-translational
modification with subsequent alteration of linkage to intracellular effector mechanisms.
Most ETb receptors are phosphorylated at Ser 304'418'439'440'441 and palmitoylated at
Cys402 and Cys404, although non-phosphorylated receptors are also seen (Roos et al.,
1998). A Ser^Asn mutation has been identified in patients with Hirschsprung's disease
(Auricchio et al., 1996). Loss of phosphorylation at this site may, therefore, critically
affect ETb receptor signal transduction. Differential patterns of post-translational
modification may also provide a mechanism for the observation of two distinct ligand
affinities of ETB receptors in the rat brain (Sokolovsky et al., 1992). Palmitoylation of
conserved COOH-terminal Cys residues selectively regulates signal transduction by ETA
receptors (Horstmeyer et al., 1996). Replacement of Cys residues with non-
palmitoylated serine or alanine residues did not alter ligand binding affinity or
stimulation of adenylyl cyclase activity. However, ET-l-induced increases in [Ca2+]j and
phospholipase C activity were abolished by this mutation. The ETb receptor also
contains highly conserved palmitoylated Cys residues in its COOH-terminus suggesting
that these may also regulate signal transduction.
1.5.5 SIGNAL TRANSDUCTION
Binding of ET-1 to the ETA receptor on VSMCs initiates a complex cascade of events
resulting in a biphasic rise in |Ca2+|i, and ultimately, cellular contraction. Typically, the
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contractions induced by ET-1 develop slowly but are sustained and resistant to agonist
removal. These effects are mediated by the interaction of endothelin receptors with
specific G-proteins in the cell membrane (Bitar et al., 1992) and subsequent activation of
downstream second messengers. G-proteins consist of 3 non-identical subunits and are
involved in receptor signal transduction for a wide variety of cellular processes.
Evidence from G-protein inhibitors such as Bordatella pertussis toxin and subunit-
specific antisera suggest that the endothelin receptors can interact with at least 3
different Ga-proteins to activate downstream pathways. ETA and ETb receptor coupling
to phospholipase C (PLC) probably occurs via Gaq, whilst coupling to adenylate cyclase
occurs via G(lS in VSMCs (ETA receptors) and Gai in EC (ETb receptors) (Rubanyi and
Polokoff, 1994). The third and fourth intracellular loops and the COOH-terminal tail of
the ETb receptor contain sequences for the specific binding of the Gc^ subtype, whilst
the second intracellular loop binds the Gas subtype (Masaki, 200U). The second
messenger systems activated by ET receptor/G-protein signalling are summarised below
and illustrated in Figure 1.3. The precise signalling mechanisms utilised by the ETA and
ETB receptors may exhibit subtle differences, although a consensus opinion in this area
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Signal transduction pathways of the endothelin receptors. MAPK = mitogen activated
protein kinase. Adapted from Decker & Brock, 1998 with kind permission of the




Gaq-protein stimulated activation of PLC (Masaki, 2000) causes hydrolysis of
phosphatidylinositol 4,5-bisphosphonate (PIP2) to produce inositol 1,4,5-triphosphate
(IP3) and 5«l,2-diacylglycerol (DAG). The rise in IP3 concentration stimulates release of
Ca2+ from the sarcoplasmic reticulum via both ryanodine- and IP3-sensitive Ca2+
channels and is responsible for the rapid initial rise in [Ca2+]i seen following ET-1
(Marsden et al., 1989). DAG activates protein kinase C (PKC) allowing sensitisation of
the cellular contractile elements to changes in [Ca2+lj (see below).
1.5.5.2 Calcium
Endothelin receptor activation results in a rapid initial rise in |Ca2+][ followed by a
plateau phase dependent on the presence of extracellular Ca2+. However, although usual,
a rise in cellular IP3 via PLC activation is not mandatory to increase [Ca2+];. ET-3 and
S6c acting on ETB receptors appear to cause an IP3-independent rise in [Ca2+]j in VSMC
wherein both the initial and plateau phases of Ca2+ mobilisation are dependent on
movement of Ca2+ into the cell (Little et al., 1992). Entry of extracellular Ca2+ appears to
be necessary for the sustained increase in [Ca2+]; that permits prolonged cellular
contraction in response to ET-1. Both voltage operated and receptor operated calcium
channels are involved in this process. L-type calcium channel blockers (dihydropyridine
class) attenuate the sustained rise in [Ca2+]i by antagonism of voltage operated calcium
channels. Prolonged cellular contraction may also be prevented by nickel ions, which
selectively block receptor-operated channels. The T-type calcium channel is a putative
candidate for the receptor operated channel (Stasch and Kazda, 1989). The opening of
voltage dependent L-type calcium channels is dependent upon prolonged membrane
depolarisation. The precise mechanism for achieving and maintaining such a period of
membrane depolarisation remains controversial but is likely to involve calcium-activated
chloride channels with resultant efflux of chloride ions (James et al., 1994), and/or an
influx of cations through non-selective cation channels. Other candidates for the
mediators of the increased |Na+]i that produces membrane depolarisation include ATP-
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sensitive K+ channels, the Na+/K+-ATPase, or activation of the Na+/H+ antiporter
(Danthuluri and Brock, 1990, Meyer-Lehnert et al., 1989, Miyoshi et al., 1992).
1.5.5.3 Protein kinase C
PKC exists in multiple isoforms and is one of the key regulatory enzymes involved in
the ET-1 signalling process. Activation of endothelin receptors stimulates a rise in DAG
levels that, along with phosphatidylserine and Ca2+, results in the activation and
translocation of PKC from the cytosol to membranes within VSMC. Activated PKC then
catalyses the phosphorylation of heavy and light myosin chains along with caldesmons,
thereby increasing the sensitivity of the contractile elements to |Ca2+l; (Nishimura et al.,
1992). Specific PKC inhibitors block the sustained contractile responses to ET-1 and
reduce Ca2+ sensitivity. PKC also modulates the hydrolysis of PIP2 following activation
of endothelin receptors by exerting an inhibitory effect on PLC and may form part of a
negative feedback loop controlling PLD and arachidonic acid metabolism. The
mitogenic effects of ET-1 appear to be related to both PKC- and tyrosine kinase-
dependent mechanisms.
1.5.5.4 Phospholipase D
The rise in intracellular DAG levels in response to ET-1 occurs in a biphasic manner, the
initial rise resulting from PIP2 hydrolysis by PLC. The prolonged secondary rise in DAG
levels is thought to originate from phosphatidylcholine hydrolysis mediated by PLD and
lasts for up to 20 minutes. Activation of PLD occurs via PKC-dependent and PKC-
independent mechanisms (Liu et al., 1992). The phosphatidic acid (PA) produced
enhances Ca2+ influx and further enhances PLC activity (Shukla and Halenda, 1991). It





Phospholipase A2 (PLA2) catalyses the generation of arachidonic acid metabolites
including the leukotrienes, thromboxane A2 (TxA2) and prostacyclin (PGI2) from
membrane lipids. Inhibitors of the arachidonic acid metabolism cascade have been
shown to inhibit many of the actions of ET-1, and PGI2 production by EC can be
stimulated by ET-1. Linkage of endothelin-receptors to PLA2 may be direct via a G-
protein, or occur in response to ET-1-activated changes in |Ca2+]j (Barnett et al., 1994).
1.5.5.6 Tyrosine kinases
ET-l-induced tyrosine phosphorylation of cellular proteins modulates activation of PLD
and in part regulates its mitogenic effects. Stimulation of ETA receptors results in
phosphorylation of tyrosine residues on cytosolic proteins ranging in size from 45-225
kDa by members of the tyrosine kinase family known as Src, focal adhesion kinase
(FAK) and Janus kinase (JAK). Although the precise mechanisms are as yet unknown, it
seems likely that activation of transcription factors by these kinases in response to ET-1
stimulation are involved in the mitogenic response.
1.5.5.7 Nuclear/mitogenic signaling mechanisms
Alone, ET-1 is a weak mitogen, as measured by thymidine incorporation or expression
of the proto-oncogenes c-jun and c-fos. However, when combined with other growth
factors such as platelet derived growth factor (PDGF) and epidermal growth factor
(EGF) or co-mitogens such as insulin, it acts synergistically to produce marked
mitogenic effects (reviewed by (Rubanyi and Polokoff, 1994). As indicated earlier, a
precise mechanistic model is still awaited, but both phorbol ester-sensitive PKCs and
tyrosine kinase signal transduction mechanisms are involved. PKCs, activated by the
binding of ET-1 to its receptor, initiate the c-Raf-1 cascade leading to activation of
mitogen activated protein kinases (MAPKs). MAPKs are known to be critically
important in the transduction of mitogenic signals in a number of other growth factor
systems. Where the mitogenic response pathways of ET-1 differ from those of other
17
Chapter 1
growth factors, however, is in the proposed coupling of the activated ETA receptor to the
c-Raf-1 cascade via PKC. ET-1 activation of the tyrosine kinases Src, FAK and JAK
occurs in a non-PKC dependent manner. Their activation may result in the switching on
of transcription factors of the signal transducers and activators of transcription family
(STAT) and subsequent translocation of STATs to the nucleus where they interact with
promoter regions to initiate gene transcription (Decker and Brock, 1998). The study of
the mitogenic responses to ET-1 is currently in its infancy when compared to that of
other aspects of endothelin physiology. However, the similarities in the effector
mechanisms utilised in response to ET-1 and other growth factors provide interesting
parallels. ETA and ETB receptor activation is also known to increase the expression of
cellular adhesion molecules, induce chemotactic factors such as TNFa, IL-1 (3, IL-6, and
IL-8, and alter matrix synthesis (Douglas and Ohlstein, 1997). Thus, in addition to short-
term actions upon cellular contractility, the endothelin isoforms influence cellular
growth and differentiation, a process critically linked with the proposed role of ET-1 as a
mediator of vascular hypertrophy and cardiac remodelling seen in conditions such as
hypertension and chronic cardiac failure.
1.5.5.8 Nitric oxide and cGMP
The ETB receptor present on EC is responsible for vasodilatation in response to
activation by ET-1. This effect is produced by ETB receptor-stimulated release of the
vasodilator factors NO (Tsukahara et al., 1994) and PGI2. Recently, ETB receptor
activation has also been shown to modulate the release of the vasodilator peptide
adrenomedullin (Jougasaki et al., 1999). Activation of ETB receptor-coupled G-proteins
leads to an increase in PLC activity with generation of 1P3 and DAG. These release Ca2+
from intracellular stores (see above) with a resultant increase in the activity of the
constitutive Ca27calmodulin-dependent endothelial NO synthase enzyme (eNOS).
Liberated NO diffuses to the VSMC layer and initiates production of cGMP by soluble
guanylate cyclase. Increasing levels of cGMP activate mechanisms that ultimately
decrease |Ca2+|j leading to cellular relaxation (Lincoln, 1989). Inhibition of eNOS by L-
A^-monomethyl arginine (L-NMMA) has been shown to inhibit the vasodilatation that
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follows ETb receptor stimulation. Further mechanisms of NO production have been
proposed. These include a PKC-dependent pathway and direct production of cGMP via
activation of a pertussis toxin-insensitive G-protein by ET-1 on the kidney epithelial cell
line LLC-PK1 (Ozaki et al., 1994).
1.5.5.9 Adenylyl cyclase
ET-1 may directly inhibit the accumulation of cAMP induced by forskolin, cholera toxin
and isoproterenol in EC (Ladoux and Frelin, 1991). It is at present unclear whether the
effects of ET-1 on cyclic nucleotide levels are mediated directly via adenylyl cyclase or
indirectly as a result of PLC activation. However, in LLC-PK1 cells, ET-1-stimulated
inhibition of cAMP accumulation was sensitive to pertussis toxin, suggesting that this
effect is mediated by a pertussis toxin-sensitive G-protein (Ozaki et al., 1994).
Interestingly, in Chinese Hamster Ovary (CHO) cells expressing ETA receptors, ET-1
binding was followed by Gas-mediated activation of adenylyl cyclase. In contrast, ETB
receptor activation resulted in Gcq-mediated inhibition of this enzyme (Masaki, 2000).
1.5.6 FORMATION, DESENSITISATION AND INTERNALISATION OF
RECEPTORS
Bolus injection of ET-1 results in a brief period of vasodilatation mediated by ETB
receptors, followed by a sustained ETA-mediated vasoconstriction that resists agonist
removal by prolonged washout (Spokes et al., 1989). This characteristic pattern of
vasodilatation and vasoconstriction to ET-1 is a product of the receptor/Iigand binding
relationship, the signal transduction mechanisms thereby induced and the subsequent
processes of receptor/Iigand desensitisation and degradation. Saturation of ETA receptors
occurs within one minute of exposure to ET-1 at 37°C (Marsault et al., 1991). Once
bound, the binding of ET-1 to its receptors appears to be a 'pseudo-irreversible' process,
with a dissociation half-life in excess of 100 hours (reviewed by (Douglas and Ohlstein,
1997). Prior to this, the rate of dissociation of receptor and ligand are dependent upon
the duration of exposure, with studies using radiolabeled ET-1 showing a progressive
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decline in the proportion of dissociable ET-1 over 60 minutes (Wilkes and Boarder,
1991). Dissociable ET-1 is thought to represent the presence of surface bound/non-
internalised receptor complexes.
The mechanism of inactivation of receptor signalling following agonist binding
is controversial but may be receptor subtype-specific. Following agonist binding in CHO
cells, phosphorylation and deactivation of ETB receptor signalling occurs within 5
minutes, as measured by IP3 generation. In contrast, the ETA receptor is resistant to
ligand-induced phosphorylation and signalling is maintained for over 20 minutes
(Cramer et al., 1999). The kinetics of internalisation for each subtype is identical and
hence likely to be independent of phosphorylation. Thus, it is proposed that ETA
receptors are slowly inactivated by internalisation, whilst ETB receptors are rapidly
inactivated by ligand-induced phosphorylation (Cramer et al., 1999). This difference in
inactivation kinetics may underlie the classical vasodilator/vasoconstrictor response to
bolus ET-1. However, both ETA and ETB receptor phosphorylation by G-protein coupled
receptor kinases has been demonstrated in other cell types and shown to modulate
signalling (Freedman et al., 1997). The role of receptor phosphorylation as a mediator of
receptor desensitisation, therefore, awaits further clarification.
Agonist binding by ETB receptors is followed by receptor complex
internalisation by a clathrin-mediated endocytic pathway (Oksche et al., 2000). In
contrast, ETA receptors are internalised via caveolae (Chun et al., 1995). This process
occurs within 6 minutes for both ETA and ETB receptors (Cramer et al., 1999) suggesting
that ETa receptor-mediated signalling may still continue following internalisation.
Indeed, studies in CHO cells have demonstrated the presence of internalised but
undegraded ET-1/ETA receptor complexes for up to 2 hours (Chun et al., 1995). Once
internalised, separation of the ET-l/endothelin-receptor complex is thought to occur
within lysosomes where the local acidic environment favours dissociation. Re-cycling of
receptors back to the cell surface then occurs for ETA (Marsault et al., 1993), but not
ETb receptors (Oksche et al., 2000), perhaps due to a greater resistance of the ET-1/ETB
complex to acid degradation within the lysosome. Reappearance of ETB receptors at the
20
Chapter 1
cell surface is, therefore, dependent upon de novo receptor synthesis. These studies
provide a mechanism for the observed tachyphylaxis of ETB-mediated vasodilatation to
repeat bolus ET-1 injection in the face of a relatively preserved ETA-mediated
vasoconstrictor response (Le Monnier de Gouville et al., 1990). Degradation of receptor
complexes by neutral endopeptidases located within the plasma membrane may also
occur prior to internalisation (Loffler et al., 1991).
1.5.7 RECEPTOR DOWN REGULATION
Repeated exposure of VSMC to ET-1 results in the down-regulation of receptors without
a change in their affinity. This is manifest as a progressive decrease in tissue or cellular
responsiveness (Hirata et al., 1988). This phenomenon occurs in response to both
exogenous and endogenously produced endothelins and receptor downregulation is
agonist selective. Pre-treatment of cells with the ETB receptor-selective agonist S6c
results in the loss of further ETB receptor-agonist-mediated responses, but the response
to ETa receptor agonists is preserved (Henry, 1993). Repeated stimulation with ET-1
may also lead to the heterologous desensitisation of other receptor subtypes including
the insulin receptor (Ishibashi et al., 2001) and neurokinin receptor (Cyr et al., 1997) as
a result of depletion of common downstream signalling pathways.
1.5.8 CLEARANCE OF ENDOTHELINS
Removal of circulating ET-1 occurs predominantly in the lung and liver, and to a lesser
extent, in the kidneys and intestine. This process is mediated by ETB receptors
(Fukuroda et al., 1994). Enzymatic degradation of ET-1 occurs by several different
protease pathways, of which neutral endopeptidase is considered to be most important in
the kidney (Kohan, 1997). In common with other peptide hormones, clearance is
achieved by receptor-mediated endocytosis of bound peptide. This action may be
blocked by selective ETB receptor antagonists (Fukuroda et al., 1994). Following ETB
receptor blockade, circulating concentration of ET-1 increases in proportion to both the
dose and the affinity of the antagonist for the ETB receptor (Willette et al., 1998). This
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process is independent of ETB receptor-mediated NO production. Antagonism of the ETB
receptor may, therefore, produce adverse physiological consequences. In isolated rat
coronary arteries ETB antagonist-mediated increases in ET-1 concentrations were able to
stimulate ETA receptors and provoke coronary vasoconstriction (Brunner and Doherty,
1996).
1.5.9 FURTHER ENDOTHELIN RECEPTOR SUBTYPES
Two further subtypes of endothelin receptor have been isolated in Xenopus laevis but not
from mammalian species. The first of these receptor subtypes, termed ETAX, displays
agonist binding characteristics identical to the ETA receptor but is insensitive to the
selective ETA receptor antagonist BQ-123 (Kumar et al., 1994). The second, isolated
only from Xenopus laevis melanocytes, has a greater binding affinity for ET-3 than ET-1
and may represent a third morphological receptor subtype termed ETC (Karne et al.,
1994). The Xenopus ETC receptor cDNA has been isolated and characterised. The
predicted amino acid sequence shares 50% homology with the human ETA and ETB
receptors. Further analysis of human genomic DNA with cDNA probes of low
stringency has, as yet, failed to identify any other homologous sequences. Any putative
human ET-3-selective ETC receptor would, therefore, be likely to have a structure that
differs widely from the other endothelin receptors (Sakamoto et al., 1991).
Sub-division of the ETB receptor subtype has also been proposed. This stems
from the observation that activation of ETB receptors may produce either vasodilatation
or vasoconstriction. Vasodilatation in response to ETB receptor stimulation is mediated
by ETB receptors located on vascular EC through the production of NO and dilator
prostanoids (Takayanagi et al., 1991). In contrast, vasoconstrictor responses are
mediated directly by ETB receptors located on VSMC (Moreland et al., 1992, Sumner et
al., 1992, Williams et al., 1991). However, despite reports that production of two
receptor subtypes from a single gene is possible by varying transcription initiation sites
or post-translational modification (Shyamala et al., 1993), it is more likely that these
differing responses are due to differences in signal transduction pathways within the
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effector cell. There is currently no molecular evidence to support subdivision of ETb
receptors. Pharmacological differences in the responses of ETA receptors in various
tissues to antagonists such as BQ-123 have also been demonstrated (Sudjarwo et al.,
1994). This has led to suggestions that subtypes of the ETA receptor may also exist
though, again, validation by molecular studies has not been forthcoming.
1.6 TRANSGENIC AND KNOCKOUT STUDIES OF THE ENDOTHELIN
SYSTEM
1.6.1 ROLE OF ENDOTHELIN RECEPTORS DURING EMBRYOGENESIS
Targeted gene knockout studies have provided further insight into the multiple
physiological roles of the endothelin isoforms. Studies originally conceived to examine
the physiological effects of deletion of the genes for ET-1, ECE-1 and the ETA and ETB
receptors in the adult animal revealed a developmental role for the endothelins. Mouse
embryonic stem cells manipulated to carry a non-functional ET-1 allele were utilised to
produce ET-1 null mice (ET-1 (-/-)). Homozygous mutation was lethal and characterised
by abnormalities of the craniofacial and pharyngeal pouch structures. These structures
are derived from neural crest ectomesenchymal cells indicating that ET-1 is crucially
involved in the normal ontogeny of the pharyngeal arches (Kurihara et al., 1994).
Targeted disruption of the ECE-1 gene produces identical phenotypic abnormalities of
the craniofacial structures, as does deletion of the ETA receptor gene. Deletion of the
ETB receptor or ET-3 gene produces mice characterised by aganglionic megacolon and
coat colour spotting (Hosoda et al., 1994). The ETB receptor/ET-3 interaction, therefore,
appears to be critical for the normal migration of epidermal melanocytes and enteric
neurons. An elegant series of experiments utilising tetracycline-inducible ETB receptor
transgenes has demonstrated that the critical time period for maintenance of ETB/ET-3
signalling occurs between embryonic days 10 and 12.5 (Shin et al., 1999). Additionally,
ECE-1 knockout mice include the phenotype of ET-3/ETB knockout mice, suggesting
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that ECE-1 is functionally responsible for the conversion of bigET-3 to ET-3 (Baynash
et al., 1994).
Mis-sense and nonsense mutations of the human ETB receptor gene have been
documented in the neurocristopathies associated clinically with Hirschsprung's disease
(Puffenberger et al., 1994) and the Waardenburg-Shah syndrome (Attie et al., 1995) -
both of which are varieties of aganglionic megacolon. The results of endothelin receptor
knockout studies have obvious implications for the clinical use of ETA or ETB receptor
antagonists and ECE-inhibitors, rendering them unsuitable for use during pregnancy or
at the time of conception, corresponding abnormalities having been detected in
teratogenicity studies with endothelin antagonists in animals.
1.6.2 GENETIC KNOCKOUT OF ENDOTHELIN-1
Mice homozygous for deletion of the ET-1 gene develop a lethal phenotype as described
earlier. Interestingly, mice heterozygous (ET-1 (+/-)) for this gene deletion are
hypertensive (Kurihara et al., 1994), at odds with the predicted role of ET-1 as a potent
pressor agent. ET-1 (+/-) mice produce ~ 60% of the wild type concentrations of ET-1
and are morphologically normal. The expression of ET-2, ET-3 and of endothelin
receptors were unaffected by knockout of ET-1 (Maemura et al., 1995). Thus,
compensation by redundant expression of the remaining endothelin isoforms and/or
receptor upregulation could not explain this phenotype. Similarly, abnormal renal ET-1
signalling was thought unlikely to be responsible since administration of a high salt diet
had no increased effect on blood pressure in ET-1 (+/-) mice and changes in urine
volume and urinary sodium excretion were not significantly different between wild type
and heterozygous mice. However, on the high salt diet renal ET-1 content was
suppressed by a further 50% in ET-1 (+/-) mice (Morita et al., 1998).
Interestingly, ET-1 (+/-) mice were found to have a lower arterial p02 and a
higher arterial pC02 than wild type littermates. This was proposed to reflect a
disturbance of central cardiorespiratory control, leading ultimately to an increase in
mean arterial pressure (MAP) through an increase in sympathetic drive (Kuwaki et al.,
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1996). Measurement of renal sympathetic nerve activity (RSNA) in anaesthetised
heterozygotes confirmed an up-regulation of basal nerve activity and demonstrated an
upward resetting of the baroreceptor-mediated relationship between MAP and RSNA
(Ling et al., 1998). In addition, heterozygotes had attenuated RSNA responses to
hypercapnia but normal responses to hypoxia. The low arterial p02, therefore, appears to
stimulate an increase in sympathetic activity leading to increased blood pressure. The
upward resetting of the MAP-RSNA relationship is permissive of the hypertensive state.
The precise mechanism underlying the decrease in arterial p02is unknown but is likely
to involve altered ET-1/ETA signalling in central chemoreceptor areas, since ETB
receptor knockout mice have normal arterial p02and normal ventilatory responses to
hypercapnia (Clouthier et al., 1998). The effect on MAP of maintaining normoxia in
heterozygous ET-1 knockout mice awaits further investigation.
1.6.3 TRANSGENIC OVEREXPRESSION OF ENDOTHELINS
Transgenic overexpression of a gene of interest can provide a powerful tool for the
investigation of the physiological and pathophysiological role of the expressed peptide.
This strategy has been employed to investigate the functional role of ET-1 and ET-2 and
has provided a number of novel insights. Mice expressing the entire human ET-1 gene
under its natural promoter (8 kb of the upstream flanking region) develop age-related
glomerulosclerosis, interstitial fibrosis and renal cysts (Hocher et al., 1997). However,
despite a marked reduction in glomerular filtration rate (GFR), these mice remained
normotensive. Increased expression of human ET-1 was detected in the blood vessels of
these mice and lead to an increased media/lumen ratio, consistent with the proposed
hypertrophic effect of ET-1. The lack of a significant blood pressure increase in these
transgenic mice was unexpected and contrasts with earlier studies in which transient
overexpression of a human preproET-1 cDNA transgene under a cytomegalovirus
(CMV) promoter was achieved by adenoviral-mediated transfection in the rat (Niranjan
et al., 1996). In this model, mean arterial pressure was increased by ~30 mmHg,
mediated via an increase in ETA receptor signalling. This difference in blood pressure
response may reflect transgene expression levels. In the mouse model, plasma ET-1
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concentration was increased by ~35% but did not differ significantly from controls. A
significantly elevated ET-1 was only seen when tissue concentrations were measured in
the whole kidney. In contrast, plasma ET-1 in the rat model was 6 times greater than in
controls transfected with an adenovirus reporter construct. An alternative hypothesis is
that the chronic overexpression of the ET-1 transgene results in the development of
counter-regulatory mechanisms that normalise blood pressure, despite an activated
endothelin system. Such mechanisms may include up-regulation of the NO system,
receptor down-regulation or desensitisation, or changes in post-receptor signalling,
though these parameters were not tested in this study. The chronic activation of the renal
endothelin system did, however, provide insights into blood-pressure independent
mechanisms of progressive renal dysfunction. The mechanism of formation of renal
cysts was thought to involve an increase in the rate of apoptotic loss of renal tissue
(Hocher et al., 1998), or reflect a disturbance of flow within urinary tubules secondary to
interstitial fibrosis (Shindo et al., 2002). However, the pathophysiological mechanisms
underlying the observed glomerulosclerosis were less clear. A further strain of ET-1
transgenic mice has been produced in Japan (Shindo et al., 2002). These mice are also
normotensive and exhibit age-related pathological changes in the kidney similar to those
described by Hocher and colleagues. Detailed electron microscopic examination of
glomerular lesions in these animals revealed thickening of the basement membrane and
proliferation of the mesangium. This suggests that glomerulosclerosis may have been
due to direct ET-l-induced proliferation of epithelial and mesangial cells, respectively.
Alternatively, increased ET-1 may have produced glomerular hypertension and
subsequent sclerosis due to localised effects upon the afferent and efferent arterioles.
Cysts were also found in Bowman's capsule and were similar in appearance to a model
of chronic glomerulonephritis, suggesting that ET-1 may have a direct nephritogenic
effect (Shindo et al., 2002). The pathophysiological significance of the salt-sensitive
hypertension also seen in this model is unresolved, since glomerulosclerosis reduces
renal mass and hence the ability of the kidney to excrete a high salt load.
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Transgenic rats overexpressing human ET-2 are also normotensive and exhibit
progressive renal damage similar, but not identical, to ET-1 transgenic mice (Hocher et
al., 1996). In the kidney, transgene expression was limited to the glomerulus and the rats
developed age-related glomerulosclerosis and proteinuria but no decrease in GFR. These
findings further implicate an activated renal endothelin system as a primary mediator of
renal damage. The potential mechanisms underlying the observed normotension despite
overexpression of ET-2 have been studied in detail in this model and appear to be related
to an increase in the activity of the NO system. Differences were also observed in end-
organ structure but no evidence of endothelin receptor down-regulation or
desensitisation was found (Liefeldt et al., 1999).
1.6.4 CURRENT MODELS OF LOSS OF ETB RECEPTOR FUNCTION
A naturally occurring mutation of the ETB receptor is seen in so-called 'piebald' mice.
This mutation consists of a retroposon inserted into intron 1 of the ETe receptor gene
(Ohuchi et al., 1999). Mice homozygous for this mutation (s/s) produce ~l/4 the normal
tissue density of ETB receptors, exhibit reduced coat pigmentation but rarely develop
megacolon. These mice have provided a useful tool for the development of alternative
strategies to achieve adult ETB receptor-deficient mice. Ohuchi and colleagues crossed
homozygous piebald mice with mice heterozygous (ETB (+/-)) for targeted disruption of
the ETb gene. ETB (si-) mice expressed approximately l/8th of normal ETB receptor
levels and demonstrated an increase in mean arterial blood pressure of ~20 mmHg
compared with wild-type (+/+) or ETB (s/+) mice on a normal salt diet. The hypertensive
phenotype was not ameliorated by treatment with the selective ETA antagonist BQ-123,
and mice demonstrated no abnormalities of cardiorespiratory control. Thus, despite the
higher concentrations of circulating ET-1 in ETB (s/+) and (s/-) mice compared to wild-
type controls, an increase in ETA receptor mediated vasoconstriction did not appear to
contribute to the hypertensive state. Treatment of ETB (s/+) and ETB (+/+) mice, but not
ETb (s/-) mice, with the ETB receptor antagonist BQ-788 resulted in an increase in blood
pressure. These results suggest that the ETB receptor is responsible for tonic
vasodilatation in the mouse. Further investigation revealed that this hypotensive effect
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was mediated predominantly by the release of dilator prostaglandins, rather than NO
(Ohuchi et al., 1999). It should be noted, however, that because of the concomitant loss
of renal and vascular ETB receptors in this model, it is not possible to elucidate the site
of ETB receptor-mediated regulation of blood pressure.
A more severe form of ETB receptor mutation that produces no functional ETB
receptors, termed spotting lethal (si), has also been utilised in rescue approaches
(Gariepy et al., 1998). The si mutation consists of a 301 bp deletion spanning the
junction between exon 1 and intron 1. This results in the production of an aberrantly
spliced ETb receptor mRNA that lacks the coding sequence for the first and second
putative transmembrane domains of the receptor (Gariepy et al., 1996). Rats
homozygous for the spotting lethal mutation (sl/sl) have been rescued from the lethal
phenotype by the introduction of transgenes consisting of the wild-type ETB receptor
cDNA under the transcriptional control of the human dopamine B-hydroxylase promoter
(D[3H-ETb;ETb sl/sl) (Gariepy et al., 1998). This promoter is active in enteric neuronal
cell precursors and hence wild-type ETB receptors are expressed in these cells, allowing
normal enteric ganglionic development. All other cells, with the exception of adrenergic
tissues and neurons, do not express functional ETB receptors. On a sodium-deficient diet
D(3H-ETB;ETB sl/sl rats and control D|3H-ETB;ETB+/+ rats show no significant
differences in blood pressure. However, D(3H-ETB;ETB sl/sl rats develop severe
hypertension (~170 mmHg) when fed a high salt (8% NaCl) diet. This salt sensitive
hypertension in the setting of functional ETB receptor deficiency was accompanied by
appropriate down-regulation of the renin-angiotensin-aldosterone system. Interestingly,
the hypertension could be completely reversed by treatment with doses of amiloride
sufficiently low to be selective for epithelial sodium channels (ENaC) in the distal
nephron. In contrast, treatment of salt-loaded D|3H-ETB;ETB+/+ rats with amiloride did
not affect blood pressure. Acute administration of the selective ETA receptor antagonist
FR139317 to D|3H-ETb;ETb sl/sl rats did not completely reverse the hypertension,
although an increased acute depressor response was observed compared to ETB (+/+)
rats. Furthermore, no differences in blood pressure responses were observed between
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D|3H-ETB;ETB sl/sl and D|3H-ETB;ETB+/+ rats treated acutely with either L-NAME or
indometacin, each inhibitors of depressor pathways normally associated with ETB
receptor activation. Recent studies in young (21 day old) sl/sl rats have confirmed the
finding of a decrease in the fractional excretion of sodium in the setting of ETB
deficiency (Hocher et al., 2001). This effect was similarly reversed following treatment
with amiloride. In addition, sl/sl rats were mildly hypertensive (~7 mmHg), although the
significance of this finding in the setting of impending intestinal obstruction is
debatable.
These findings suggest that ETB receptor deficiency represents a single locus
model of severe salt-sensitivity. The blood pressure response to ENaC-selective doses of
amiloride implies that the effects of ETB receptor deficiency are predominantly mediated
through changes in distal tubular sodium transport by ENaC. In the absence of ETB
receptors, ENaC channels exhibit inappropriate sodium reabsorbtion in the face of a high
salt load, despite down-regulation of the renin-angiotensin-aldosterone system. In the
presence of a mineralocorticoid (DOCA salt), an even greater blood pressure response is
seen in ETB deficient rats (Matsumura et al., 2000). It is likely, therefore, that the normal
action of ETB receptors is one of tonic inhibition of ENaC activity. However, other
mechanisms may also contribute to the hypertensive phenotype of these animals. D|3H-
ETb;ETb sl/sl rats have circulating concentrations of ET-1 that are between 5 and 6 times
higher than those of D|3H-ETB;ETB+/+ rats (13.2±2.8 versus 2.1 ±1.8 pg/ml and 23.9±4.2
versus 4.4±1.4 pg/mL on both normal and high sodium diets respectively). This occurs
because ETB receptors act as clearance receptors for ET-1 (Fukuroda et al., 1994). High
plasma concentrations of ET-1 may lead to an enhanced pressor effect mediated through
ETa receptors, as evidenced by the acute depressor response to a selective ETA
antagonist in these rats. Indeed, Matsumura and colleagues recently demonstrated that
DOCA salt-induced hypertension in D|3H-ETB;ETB sl/sl rats could be entirely reversed
by chronic administration of the ETA receptor antagonist ABT-627 (Matsumura et al.,
2000). Such an increased ETA receptor mediated pressor effect could be particularly
important in the glomerulus where a subsequent reduction in GFR might affect renal
29
Chapter 1
sodium handling. In addition, the mitogenic effects of high ET-1 concentrations during
the development and maturation of the cardiovascular system may alter vascular
responses to other pressor agents.
1.6.5 HETEROZYGOUS RECEPTOR KNOCKOUTS
Homozygous ETA or ETB receptor knockouts develop lethal phenotypes as described
earlier. However, littermates heterozygous for gene deletion at these loci (ETA (+/-), ETB
(+/-)) survive normally into adulthood and are a useful model for the study of the
physiological responses to exogenous and endogenous ET-1. ETB (+/-) but not ETA (+/-)
mice are hypertensive (MAP ~90 mmHg and ~70 mmHg, respectively) (Berthiaume et
al., 2000) by a similar degree to that reported by Ohuchi and colleagues in the ETB (s/-)
model (Ohuchi et al., 1999). In contrast to the results of Ohuchi, however, the
hypertension in ETB (+/-) mice could be reversed with either a mixed or a selective ETA
receptor antagonist, but not with a selective ETB receptor antagonist. These results might
suggest that the hypertension in the ETB (+/-) mouse is, in fact, mediated by increased
binding of ET-1 to ETA receptors, as a result of an increased plasma ET-1 concentration.
This theory is supported by the demonstration that ETB (+/-) mice have impaired
clearance of exogenous l25I-ET-l and that a similar defect of clearance may be
reproduced in wild type mice by the administration of an ETB receptor antagonist
(Berthiaume et al., 2000). Unfortunately, the authors did not report on plasma ET-1
concentrations in ETB (+/-) or wild type mice and the effects of ETB receptor down-
regulation on renal sodium handling were not investigated.
The pressor response to exogenous ET-1 in ETA (+/-) and ETB (+/-) mice is
moderated by both selective ETA and selective ETB receptor antagonists (Berthiaume et
al., 2000). This is in contrast to other animal (Ishikawa et al., 1994) and human studies
(Verhaar et al., 1998) where selective ETB receptor antagonism was shown to potentiate
the pressor response to exogenous ET-1, consistent with an endogenous vasodepressor
role for the ETB receptor. The relative contribution of vasoconstrictor VSMC ETB
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receptors and vasodilator endothelial cell ETB receptors to vascular tone and blood
pressure in the mouse remains, therefore, controversial.
1.7 CARDIOVASCULAR PHYSIOLOGY OF THE ENDOTHELIN SYSTEM
The endothelins act in an autocrine and paracrine fashion. Studies involving the
administration of the endothelin isoforms, either by bolus or constant infusion are,
therefore, unlikely to reproduce the in vivo physiological effects of endothelin action.
Indeed, such studies may be frankly misleading, despite the presence of increased
circulating concentrations of ET-I having been documented in a number of pathological
conditions. Here, studies with antagonists are more informative, since they may reveal
more accurately the endogenous activity of an autocrine/paracrine system. These data
are reviewed below.
1.7.1 ROLE OF ENDOTHELIN IN THE MAINTENANCE OF VASCULAR TONE
In humans, there is clear evidence that the endothelin system plays an important role in
the maintenance of basal vascular tone. Intra-arterial infusion of the selective ETA
receptor antagonist BQ-123 into the forearm results in progressive vasodilatation that
persists for up to 1 hour (Haynes and Webb, 1994). These results have since been
confirmed by others (Berrazueta et al., 1997, Verhaar et al., 1998) and suggest that
endogenous ET-1 increases basal vascular tone mainly via the ETA receptor. Inhibition
of vascular ETB receptors with the selective ETB antagonist BQ-788 produces
vasoconstriction and, when co-infused with BQ-123, BQ-788 attenuates the vasodilator
response (Verhaar et al., 1998). Thus, the summation of effects of endogenous activation
of ETb receptors in the forearm of healthy humans is one of vasodilatation. This effect is
largely mediated via the generation of NO. Dilator PGI2 generation appears to contribute
little to this response because pre-treatment with aspirin has no effect. The results of
these local studies have since been confirmed in the systemic circulation (Spratt et al.,
1999, Strachan et al., 1999).
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In the rodent, the evidence for involvement of the ETB receptor is less clear.
Some early studies have shown no effect on vascular tone or blood pressure following
endothelin antagonism (reviewed by (Schiffrin, 1999)). However, more recently,
investigators have observed significant effects on blood pressure with either genetic or
pharmacological perturbation of ETB receptor function (Gariepy et al., 2000, Giardina et
al., 2001, Pollock and Pollock, 2001, Vassileva et al., 2003, Wessale et al., 2002). Taken
together, these data suggest that the ETB receptor mediates an endogenous hypotensive
effect in the rodent. This effect appears to become upregulated and assume greater
importance during conditions of high salt (Giardina et al., 2001, Pollock and Pollock,
2001). The mechanism of this effect upon blood pressure remains poorly understood and
may involve both vascular and renal tubular ETB receptors and increased ETA receptor
activity.
1.7.2 THE RENAL ENDOTHELIN SYSTEM AND BLOOD PRESSURE
REGULATION
The kidney is widely regarded as the most important regulatory organ in the
determination of systemic blood pressure. Radio-ligand binding, immunohistochemistry
and in situ hybridisation techniques have all been used to localise each component of the
endothelin system to the renal vasculature and nephrons (reviewed by (Kotelevtsev and
Webb, 2001). The greatest tissue concentrations of immunoreactive ET-1 are to be
found in the kidney (Kitamura et al., 1993) and urinary ET-1 is almost entirely of renal
origin, with little circulating ET-1 cleared into the urine (Abassi et al., 1992). The ETB
receptor is the predominant subtype found in the kidney and is likely, therefore, to
contribute importantly to the regulation of blood pressure and fluid balance.
Harris and colleagues (Harris et al., 1991) demonstrated that low doses of
exogenous ET-1 produce diuresis and natriuresis in the rat kidney. Higher doses of
exogenous ET-1 produce glomerular vasoconstriction, a decrease in sodium delivery to
the proximal nephron, and subsequent anti-natriuresis. These results exemplify the
difficulties that surround experimental analysis of the effects of ET-1 in the kidney.
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Namely, activation of the same receptor within different regions of a single target organ
may result in opposing physiological effects. This makes interpretation of antagonist or
agonist studies extremely problematic. However, the consensus of opinion now is that
intra-renal ET-1 regulates distal tubular sodium transport within the nephron, promoting
natriuresis and diuresis. In addition, locally generated ET-I may also regulate blood
flow within the kidney, particularly in the glomeruli and medulla (Gurbanov et al., 1996,
Kohan, 1996). In the medulla, ET-1 activates ETB receptors, increasing medullary blood
flow (Gurbanov et al., 1996) and promoting natriuresis. This effect is mediated via the
release of NO (Hoffman et al., 2000) and ETB receptor-dependent medullary
vasodilatation appears to be particularly important under high salt conditions (Pollock et
al., 2000, Pollock and Pollock, 2001, Vassileva et al., 2003). Specifically, the medullary
ETb receptor appears to regulate the relationship between perfusion pressure and
natriuresis during high salt conditions (Vassileva et al., 2003), though the precise
cellular location of this effect has not been determined.
1.7.2.1 Renal tubular effects ofET-1
In addition to effects in the distal nephron, ET-1 also modulates fluid and electrolyte
transport mechanisms within other tubular segments. In the proximal tubule (PT), ET-1
regulates activity of the Na7P; co-transporter, Na+/H+ exchanger, Na+/H+ antitransporter
and the Na7HC03" exchange transporter. The effects upon sodium and water transport in
the PT are biphasic and dependent on ET-1 concentration, with higher concentrations
promoting natriuresis. A biphasic effect is also seen in the distal nephron, although in
this region higher concentrations of ET-1 increase sodium reabsorbtion. Analysis of ET-
1 concentrations in the PT and CCT suggest that in each of these regions, ET-1 promotes
diuresis and natriuresis (Kohan, 1997). The effects of ET-1 are mutually antagonistic
with those of arginine vasopressin (AVP) in the CCT and IMCD. Both ET-1 and ET-3
reduce AVP-stimulated increases in osmotic water permeability through inhibition of
cAMP accumulation (Kohan and Hughes, 1993). In summary, ET-1 and ET-3 exert a
complex array of actions upon renal tubular transport processes throughout the nephron,
the net results of which are to promote the excretion of sodium and water.
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1.7.2.2 Renal vascular effects ofET-1
The renal vasculature is extremely sensitive to the vasoconstrictor action of ET-1, and to
a lesser extent, big ET-1. Administration of exogenous ET-1 results in a fall in GFR, an
increase in renal vascular resistance and a fall in RBF (reviewed by (Rubanyi and
Polokoff, 1994)). Cortical blood vessels appear more sensitive to the vasoconstrictor
effects of ET-1 than medullary vessels. Indeed, in Wistar rats, low doses of ET-1 (1
nmol/kg iv.) produce vasoconstriction of cortical vessels but vasodilatation of medullary
vessels (Gurbanov et al., 1996). Interestingly, the cortical response appears to be
mediated by ETA receptors, whilst the medullary vasodilator response is ETB receptor-
mediated. Studies in anaesthetised dogs have revealed that the glomerular actions of ET-
1 are predominantly mediated by the ETA receptor, whilst the diuretic and natriuretic
effects are mediated by ETB receptors in the nephron (Clavell et al., 1995). However,
inter-species variation in the distribution and function of each receptor subtype is well
documented, particularly in relation to the ETB receptor, which may also mediate
glomerular vasoconstriction in some species, including the rat (Matsuura et al., 1996).
Although exquisitely sensitive to exogenous ET-1, an endogenous ETA receptor-
mediated vasomotor tone has been more difficult to demonstrate in the kidney. Selective
ETa receptor antagonists do not alter renal vascular resistance in normotensive
anaesthetised rats (Matsuura et al., 1997, Qiu et al., 1995). In contrast, a selective ETB
antagonist decreased RBF and increased RVR by ~ 20%, an effect mediated by NO
and/or dilator prostaglandins (Matsuura et al., 1997). The recent finding of a markedly
decreased GFR in ETB receptor deficient rats further suggests an overall tonic
vasodilator role for glomerular ETB receptors in healthy rats (Hocher et al., 2001). The
balance between vasodilator EC ETB receptors and vasoconstrictor VSMC ETB receptors




1.7.3 AUTOCRINE AND PARACRINE SIGNALLING IN THE KIDNEY
The precise distribution of endothelin receptors within the rodent kidney merits further
detailed analysis as it forms the basis of the two current models of renal ET-1 action.
Cultured inner medullary collecting duct (IMCD) cells express both ETA and ETB
receptors and secrete ET-1 (Kohan and Fiedorek, 1991, Kohan et al., 1992). This has
prompted an autocrine model of endothelin action in the distal nephron (Kohan and
Padilla, 1992). In this model, ETB receptor activation by IMCD-derived ET-1 directly
inhibits sodium transport by the cell. An alternative hypothesis suggests a paracrine
signalling mechanism in this region (Kotelevtsev and Webb, 2001). ET-1 secreted from
the basolateral side of IMCD cells would activate ETB receptors located on the adjacent
abluminal membrane of EC of the vasa-recta. NO subsequently generated by either the
eNOS or nNOS isoforms of NOS found in EC would then diffuse back across to IMCD
cells where it would act to inhibit sodium reabsorbtion. A paracrine model would,
therefore, require that the ETB receptor were predominantly expressed upon EC of the
vasa-recta. The work of several groups supports this notion. Yukimura and colleagues
(Yukimura et al., 1996) used electron microscopic autoradiography with radiolabeled
ET-1 and the selective ETB receptor ligand IRL 1620 to demonstrate the presence of
binding sites on the vasa-recta and type 1 interstitial cells of the inner medulla. ETB
receptor binding was also seen on the basolateral membrane of IMCD cells, but to a
much lesser extent. This work is supported by in vitro and in vivo studies with
radiolabeled ET-1 and S6c that localised binding to the fenestrated EC of glomerular
capillaries and the peritubular capillaries of the rat kidney (Dean et al., 1996). In contrast
to these results, other groups have also demonstrated expression of ETB receptors by
cultured IMCD cells (Wong et al., 2000). Insight into whether the renal endothelin
system acts by predominantly autocrine or paracrine signalling may be gained by the use
of tissue-specific ETB receptor knockout models, selective for either IMCD cells or EC.
Such models will permit study of the effects of selective loss of, for example, IMCD




1.7.4 ROLE OF ENDOTHELIN IN THE CENTRAL REGULATION OF BLOOD
PRESSURE
Administration of ET-1 directly into the CNS stimulates a dose-dependent increase in
blood pressure and sympathetic nerve activity. This effect appears to be mediated by
ETa receptors (Nakamura et al., 1999). However, despite the presence of all the
elements of the endothelin system in brain regions responsible for autonomic control, a
role for endogenous ET-1 in the central regulation of blood pressure and sympathetic
nerve activity in normal rats remains controversial. Central administration of BQ-123
does not affect blood pressure in anaesthetised Wistar-Kyoto or SHR, although an effect
was seen in SHR-SP (Nakamura et al., 1999). These findings contrast with the
phenotype of ET-1 (+/-) mice in which loss of a single ET-1 gene allele resulted in a
marked disturbance of cardiorespiratory control. ET (+/-) mice exhibit increased
sympathetic nerve activity, increased blood pressure and show attenuation of hypoxia-
induced respiratory reflexes (Kuwaki et al., 1996). Mice deficient in ET-3 demonstrate
no similar abnormalities of cardiorespiratory control (Nakamura et al., 2001) despite the
demonstration that this peptide is an important neurotransmitter and that there is
widespread expression of ETB receptors within the brain.
1.8 ROLE OF ENDOTHELIN IN CARDIOVASCULAR
PATHOPHYSIOLOGY
The normal function of the endothelin system and the balance with other local and
hormonal cardiovascular regulatory mechanisms may become disrupted by a number of
pathophysiological mechanisms, including increased production, increased sensitivity or
decreased clearance of ET-1. Many cardiovascular diseases have been shown to be
associated with increased circulating concentrations of plasma ET-1, though whether
these represent primary or secondary phenomena is undetermined. Decreases in gene
expression for the endothelin precursors, endothelin converting enzymes or endothelin
receptors may cause congenital conditions such as Hirschsprung's disease and the
Waardenburg-Shah syndromes. More subtle genetic mutations may result in changes in
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receptor expression, affinity or selectivity, perhaps contributing to hypertension in some
patients. Enhanced receptor number or affinity is thought to mediate the hypertension
and renal dysfunction during cyclosporine treatment, and renal dysfunction may reduce
peptide clearance, thereby increasing ET-1 concentration. Enhanced production of ET-1,
in response to a number of factors including vasoactive hormones and tissue hypoxia,
may augment the neurohormonal activation seen in chronic heart failure and enhance the
effects of other mediators, such as Ang II. The actions and concentrations of ET-1 would
also be potentiated in conditions characterised by dysfunction of the L-arginine/NO
system, allowing uncompensated changes in vascular tone and vascular remodelling to
occur. This has been suggested as a mechanism for Raynaud's disease and cerebral
vasospasm, amongst others. For the purpose of this thesis, the contribution of the
endothelin to the pathophysiology of cardiovascular disease will be limited to a
discussion of the role of the endothelin system in hypertension.
1.8.1 WHAT ROLE MAY ENDOTHELIN PLAY IN HYPERTENSION?
ET-1 may be involved in the pathogenesis of hypertension through a number of different
mechanisms. Firstly, increased expression or decreased clearance of this powerful
vasoconstrictor may lead directly to an increase in vascular tone and blood pressure.
Alternatively, the balance between the vasoconstrictor and vasodilator responses
following ETb receptor activation may be altered to favour vasoconstriction (Cardillo et
al., 1999). Changes in renal endothelin signalling may also result in an increase in blood
pressure through increases in sodium reabsorbtion and resultant expansion of circulating
volume (Gariepy et al., 2000). Changes in endothelin signalling in the central and
peripheral nervous system could lead to alteration of the 'set point' for blood pressure.
Finally, the vascular hypertrophic effects of increased ET-1 signalling may lead to an
increase in vascular sensitivity to the vasoconstrictor effects of other pressor agents,
such as nor-epinephrine (NE) or Ang II. Some of these pathophysiological hypotheses
have been tested in experimental animal models of hypertension and in human
hypertension and are reviewed below.
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1.8.1.1 Experimental models ofhypertension involving endothelin
Although debate continues concerning the physiological role of the rodent endothelin
system in the regulation of normal blood pressure, there is good evidence to support a
role for ET-1 in the pathogenesis of hypertension in rats. ET-1 has been particularly
implicated in the pathogenesis of salt-sensitive models of hypertension including
DOCA-salt hypertension (Lariviere et al., 1993), DOCA-salt treated SHR (Schiffrin et
al., 1995), and Dahl salt-sensitive rats (Doucet et al., 1996). In addition, Ang II-infused
hypertensive rats (Moreau et al., 1997) and SHR-SP (Sharifi et al., 1998) also exhibit an
ET-1-dependent component. Each of these models demonstrates an increase in EC
preproET-1 mRNA expression and exhibits a significant hypotensive response to ET
antagonists (reviewed by (Schiffrin, 1999)). In contrast, ET receptor antagonists are
largely ineffective hypotensive agents in renovascular hypertension. 2 kidney 1 clip
(2K/1C) hypertensive (Li et al., 1996), 1 kidney 1 clip (1K/1C) hypertensive (Li et al.,
1996) and L-NAME-induced hypertensive rats (Sventek et al., 1997) show no consistent
hypotensive response to ET antagonism and feature only modest or no increased
expression of preproET-1. The apparent paradox between the involvement of the
endothelin system in the hypertension associated with exogenously administered Ang II,
but not with endogenously generated Ang II (2K/1C and 1K/1C models) remains
unexplained. However, this may relate to a greater permissive effect upon vascular
preproET-1 expression of a constant infusion of Ang II compared to the more
physiological pulsatile release of Ang II by the kidney. In SHR, the evidence implicating
the endothelin system is also contradictory. Some studies have shown no generalised up-
regulation of vascular ET-1 (Schiffrin et al., 1995) and no hypotensive effect of ET
antagonists (Li and Schiffrin, 1995). Other researchers (Hocher et al., 1995) have
demonstrated increased renal ETA and ETB receptor expression in SHRs and
hypertension that was sensitive to both BQ-123 and bosentan. These apparently




Despite the relatively consistent association between increased vascular
expression of ET-1 and sensitivity to endothelin antagonists in rodent models,
measurement of plasma and vascular ET-1 content in humans has failed to demonstrate a
clear association with hypertension (reviewed by (Schiffrin, 1999)). However, ET-
mediated vascular tone is increased in hypertensive patients (Cardillo et al., 1999,
Taddei et al., 1999) and ET antagonists lower TPR in normotensive humans (Spratt et
al., 1999). Interestingly, following treatment with a selective ETB receptor antagonist,
forearm blood flow is increased in hypertensive patients, but decreased in normotensive
controls (Cardillo et al., 1999). This suggests that the balance between vasodilator EC
and vasoconstrictor VSMC ETB receptors may be altered in pathophysiological states,
including hypertension. Clinical trial data supports a role for ET-1 in the maintenance of
vascular tone, which may be increased in hypertension. Bosentan was found to lower
blood pressure by ~6 mmHg in mild to moderate hypertensives (Krum et al., 1998), an
effect equivalent to 20 mg of Enalapril.
1.8.1.2 Salt sensitive models ofhypertension
Defective tubular ETB receptor signalling may be a causative factor in some forms of
salt-sensitive hypertension, as described earlier. In contrast, vascular ETB receptors may
actually play an important protective role in this setting. In DOCA-salt hypertensive rats,
ETa receptor antagonists decrease blood pressure and TPR acutely (Fujita et al., 1996,
Yu et al., 1998) and prevent the development of hypertension and cardiac hypertrophy
chronically (Matsumura et al., 1995). However, ETB receptor antagonists significantly
worsen the vascular hypertrophy and renal dysfunction in these animals (Matsumura et
al., 1999) and promote further increases in blood pressure (Pollock et al., 2000). This
may be due to a loss of tonic ETB-mediated vasodilator responses since selective ETB
antagonists acutely increase systemic blood pressure, decrease renal blood flow and
diminish the renal vasodilatation induced by ETA receptor antagonists in DOCA-salt
treated rats (Hashimoto et al., 1998). In addition, chronic ETB receptor antagonism may
further impair renal elimination of the high salt load, thereby increasing circulating
volume and blood pressure. DOCA-salt treated rats exhibit increased medullary ETB
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receptor expression (Pollock et al., 2000), perhaps to facilitate the excretion of salt.
Indeed, treatment of DOCA-salt rats with ETB receptor antagonists decreases their
ability to excrete salt and water (Pollock et al., 2000). DOCA-salt hypertension appears,
therefore, to be characterised by an increase in ETA receptor-mediated mitogenic and
vasoconstrictor effects and by upregulation of protective ETB receptor-mediated
vasodilator and natriuretic responses.
In a genetic model of salt-dependent hypertension, the Dahl salt-sensitive rat,
ETa receptor antagonists prevent the increase in ET-1 expression, vascular hypertrophy
and endothelial dysfunction seen during high salt loads (Barton et al., 1998). The
activation of the ET-1 system in response to salt may be related to NO release. Dalh-
sensitive rats are unable to upregulate renal NOS activity appropriately during salt
loading (Barton et al., 2000). In contrast, Dahl-resistant rats increase NOS activity by
~270% in response to salt but do not increase expression of ET-1 or develop
hypertension. The failure to upregulate NOS activity may, therefore, permit the
increased expression of ET-1 with subsequent renal structural and functional damage
mediated through ETA receptor activation (Barton et al., 2000). These results contrast
with the observation that pharmacological inhibition of NOS does not result in
upregulation of renal vascular ET-1 expression in Sprague-Dawley rats (Fujita et al.,
1995). This suggests that there may be further blood pressure regulatory defects in Dahl
salt-sensitive rats or that NOS-inhibitors may prevent ET-1 up-regulation by a
mechanism independent of NO.
1.8.1.3 Mechanism of increased endothelin expression in hypertension
Increased blood pressure per se does not appear sufficient to increase vascular ET-1
expression. Data from Dahl-sensitive rats (Barton and d'Uscio, 2000) and Ang-II infused
rats (d'Uscio et al., 1997) suggests that interactions with other vasoactive substances,
particularly the local RAAS and NO systems, may also be important. This correlates
with in vitro studies in which Ang II and NOS inhibition increase the expression of ET-
1. In DOCA salt-induced hypertension, AVP may also mediate increased ET-1
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expression. Plasma AVP is increased in DOCA salt-treated rats and vasopressin V,
antagonists prevent the increase in vascular preproET-1 expression, vascular
hypertrophy and increased blood pressure seen in this model (Intengan et al., 1998). The
observation that vasopressin-deficient rats do not become hypertensive or upregulate
preproET-1 expression following DOCA-salt, underlines the important interactions
between vasopressin and ET-1 in this pathogenic process (Intengan et al., 1998).
1.8.1.4 Vascular remodeling in hypertension
In hypertensive models featuring up-regulation of vascular preproET-1 mRNA, a
common pathological feature is vascular hypertrophy of a greater extent than might be
expected for the degree of hypertension (Schiffrin et al., 1995). This suggests that an
increase in vascular ET-1 expression might be a blood pressure-independent mediator of
vascular hypertrophy, as predicted by the in vitro mitogenic effect of ET-1 on VSMC
(Hirata et al., 1989). Endothelin antagonists reverse the vascular hypertrophy in salt-
dependent hypertensive models, particularly in resistance arteries, even if the
hypotensive effect is only moderate (Li and Schiffrin, 1995). In contrast, vascular
morphology is unchanged by ET antagonists in renovascular hypertension (Li et al.,
1996). The presence of vascular hypertrophy in normotensive ET-1 over-expressing
transgenic rats (Hocher et al., 1997) further supports a direct vascular hypertrophic role
for ET-1. These data suggest that ET antagonists may be particularly useful in human
hypertension for the prevention of end-organ damage.
In conclusion, the endothelin system has been strongly implicated in the
pathogenesis of experimental and genetic salt-sensitive hypertension, low renin
hypertension, exogenous Ang II hypertension and malignant hypertension. A direct
vascular hypertrophic effect of ET-1 may further exacerbate end-organ damage in the
setting of an increased blood pressure.
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1.8.1.5 Pathological changes in receptor expression
Genetic models of ETB receptor down-regulation demonstrate the importance of ETB
receptor signalling in the determination of systemic blood pressure (Gariepy et al., 2000,
Ohuchi et al., 1999). However, more subtle changes in the expression of ETB and ETA
receptors may also influence local blood flow and regulate tissue responses to other
vasoconstrictors. Qiu and colleagues recently demonstrated that the mixed endothelin
receptor antagonist, tezosentan, lowered RVR and increased RBF in rats with cardiac
and renal failure secondary to coronary artery ligation (CAL) (Qiu et al., 2001). This
contrasts with previous work in normal rats (Matsuura et al., 1997) demonstrating an
endogenous vasodilator role of ETB receptors in the kidney and suggests that in this
pathophysiological state the balance of ET receptor-mediated responses favour
vasoconstriction. Increased reactivity to exogenous ET-1 is seen in the coronary arteries
of hypertensive rats (Miki et al., 1998) and decreased pulmonary ETB receptor
expression may underlie the increase in circulating ET-1 in congestive heart failure
(Kobayshi et al., 1998). An increase in VSMC ETB receptor and ET-1 expression is also
found in atherosclerotic lesions of both humans and ApoE -/- mice (Fan et al., 2000).
Changes in the relative balance of vasoconstrictor and vasodilator responses to ET-1
within a particular arterial bed in pathophysiological states including heart failure,
hypertension and atherosclerosis may, therefore, have important therapeutic
implications. In conditions in which vasodilator ETB receptor signalling is maintained or
increased, selective blockade of ETA receptors may provide a therapeutic advantage,
particularly in view of further potential beneficial effects upon platelet aggregation and
vascular growth of ETB-mediated NO release. In contrast, a non-selective antagonist
might be preferable in conditions characterised by increased vasoconstrictor ETB
receptor signalling.
1.9 GENERAL AIMS
The ETb receptor has multiple roles in different tissues, including vasodilatation
(Takayanagi et al., 1991), vasoconstriction (Sumner et al., 1992), inhibition of renal
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sodium reabsorbtion (Gariepy et al., 2000) and clearance of ET-1 (Fukuroda et al.,
1994). Each of these responses may independently modulate blood pressure and regional
blood flow. However, the relative importance of each response to the complex
homeostatic mechanisms of blood pressure control, particularly under conditions of high
salt intake, has yet to be determined. Currently available pharmacological antagonists
are unable to selectively block ETb receptors in one tissue or cell type without also
blocking ETb receptors remote from the tissue or cell type of interest. Thus, the
measured physiological response to the antagonist is a sum of the concurrent effects of
receptor blockade upon that physiological variable in several tissues. This has made the
interpretation of such data complex. Such complexity might be overcome by utilising
drug delivery mechanisms that only release locally active concentrations of antagonists.
However, in many tissues the different ETB expressing effector cells lie in close
proximity and it is unlikely that selective targeting of a single cell type would be
feasible. Alternatively, the effects of antagonists might be studied in vitro and the results
extrapolated to an in vivo model. This methodology has provided the majority of the data
on which understanding of the physiology of the endothelin system is based. Knockout
of receptors provides a further mechanism whereby loss of function effects may be
studied in vivo. However, complete knockouts of ETe receptor function produce a lethal
phenotype that precludes study of in vivo adult physiology. Studies on young mice prior
to the onset of intestinal obstruction are possible, but the quality of data recorded is
likely to be compromised. A great deal of insight has been gained from the study of
rescued ETB receptor-deficient animals. However, the concurrent knockout of ETe from
multiple tissues suffers the same limitations as pharmacological antagonists in terms of
data interpretation. The advent of technologies that permit the spatial and temporal
regulation of gene expression now provides researchers with a powerful mechanism by
which the understanding of the physiological role of the ETb receptor in an individual
cell type may be deepened. Cell-specific regulation of ETb receptor expression can
permit observation of the effects of tissue-specific loss of ETb receptor function without
the confounding effects of receptor down-regulation or blockade at remote sites.
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Activation of ETB receptors on EC results in vasodilatation mediated by the
release of NO and/or dilator prostaglandins. In contrast, activation of ETB receptors on
adjacent VSMCs results in vasoconstriction. The relative balance of endothelial and
VSMC ETB receptors is, therefore, likely to influence vascular tone and blood pressure.
In humans, the relative balance of endothelial and VSMC ETB receptor activity appears
to favour vasodilatation (Verhaar et al., 1998). However, the contribution of the
endogenous endothelin system to the maintenance of normal vascular tone and blood
pressure in the mouse remains controversial. ETB receptor-deficient rats (Gariepy et al.,
2000) and mice (Murakoshi et al., 2002) rescued by the expression of a D|3H;ETB
transgene are hypertensive, an effect that may be secondary to loss of renal ETB
receptor-mediated regulation of ENaC channels. Mice in which expression levels of ETB
receptors are either l/8th of normal (ETB (si-)) (Ohuchi et al., 1999) or 1/2 of normal
(ETb (+/-)) (Berthiaume et al., 2000) are also hypertensive. Taken together, these data
suggest that the overall effect of ETB receptor activation is to lower blood pressure. This
theory is supported by the observation that acute administration of ETB receptor
antagonists to normal mice produces an increase in blood pressure (Ohuchi et al., 1999).
However, other researchers have found that ETB receptor antagonists have no effect on
basal arterial pressure and that ETB receptors mediate a significant part of the pressor
and vasoconstrictive effects of ET-1 (Berthiaume et al., 2000, Giller et al., 1997). The
mechanism of the increase in blood pressure in ETB receptor-deficient mice is
controversial. ETB (+/-) mice show a significant hypotensive response to ETA receptor
antagonists (Berthiaume et al., 2000). In contrast, ETA receptor antagonists have no
effect on blood pressure in ETB (s/-) mice (Ohuchi et al., 1999). The importance of an
increased plasma ET-1 concentration with consequent increase in ETA receptor binding
as a mechanism for the hypertension seen following ETB receptor blockade or knockout
is, therefore, unclear. Debate thus remains over whether or not endogenous ETB receptor
signalling produces a significant hypotensive effect in the mouse, and if so, whether this
effect is predominantly mediated by IMCD or vascular EC ETB receptors, or both. The
further role of ETB receptors in each of these cell types in the regulation of blood
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pressure under conditions of high salt also requires further study to clarify the
importance of EC ETB receptors in the regulation of natriuretic pathways.
To more precisely define the role of the ETB receptor expressed upon different
cell types to the regulation of complex homeostatic mechanisms, I have produced a
model (the 'floxed' ETB receptor mouse) that permits the cell-specific down regulation
of ETb receptor expression. The effects of loss of functional ETB receptors upon the
target cell of interest can now be examined in the context of preserved expression of ETB
receptors on all other cells. In order to study the role of the EC ETB receptor in the
regulation of blood pressure and vascular tone, I have produced a model of EC-specific
ETb receptor deficiency with which to test the following hypotheses:
1. The EC ETb receptor is a critical determinant of resting blood pressure in the
mouse.
2. The EC ETB receptor influences blood pressure through determination of
endogenous vascular tone in the mouse.
3. ETb receptors expressed upon IMCD cells regulate natriuretic pathways under
conditions of high salt and determine salt-sensitivity.
4. The EC ETB receptor is a clearance receptor for ET-1.
EC ETb receptor deficiency was achieved through intercross of mice featuring loxP sites
flanking coding regions of the ETB receptor gene ('floxed' ETB receptor mice) with
transgenic mice expressing Cre recombinase in an EC-specific pattern (Tie2-Cre mice).
Binding of 125I ET-1 was measured in isolated populations of pulmonary EC and
functional loss of EC ETB receptor-mediated vasodilatation was assessed in aortic rings
in vitro. Maintenance of normal vasoconstrictor ETB receptor signalling in SMC was
examined in the isolated trachea. The effects of loss of EC ETB receptors upon blood
pressure under conditions of normal and high salt diet and upon endothelial function
were then investigated. The following chapters describe the generation of the 'floxed'
ETb receptor mouse, its subsequent cross with Tie2-Cre transgenic mice and the
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2.1 MATERIALS AND METHODS
2.1.1 CONDITIONAL REGULATION OF GENE EXPRESSION
Gene targeting provides a mechanism to elucidate definitively the in vivo role of a
molecule. However, functional analysis of the resultant phenotype may be complex if
the molecule subserves different functions in different adult tissues or has a non-
redundant role during development. To overcome these difficulties, DNA recombination
systems may be used to disrupt gene expression in a pre-determined spatially regulated
pattern (Gu et al., 1994).
2.1.2 THE CRE/LOXP SYSTEM
The Cre/loxP system (Orban et al., 1992, Sauer and Henderson, 1989) is the best
characterised of the DNA recombination systems and consists of two basic elements.
The PI bacteriophage enzyme Cre recombinase is a 38 kDa protein that catalyses a site-
specific recombination reaction between two loxP sites. The 34 bp loxP site consists of
two 13 bp inverted repeats separated by an asymmetrical 8 bp core sequence. The core
sequence determines the orientation of the loxP site. A recombination reaction is
initiated when Cre recombinase binds to the inverted repeat sequence of the loxP site. A
synapse is formed consisting of four Cre subunits and two loxP sites orientated in the
same direction. Concerted cleavage and rejoining reactions occur between sites in the
core sequence region resulting in the excision of a circular molecule containing the loxP
flanked sequence of DNA. This system, therefore, enables the deletion of specific
regions of genes or chromosomes as determined by the introduction of loxP sites
flanking or 'floxing' the region of interest. The use of the Cre/loxP system in
mammalian cell systems is facilitated by the lack of requirement for further co-factors or
accessory proteins and the presence of basic peptides within Cre that direct it to the
mammalian nucleus (Lewandoski, 2001). The efficiency of Cre recombinase to direct
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heritable recombination events in vivo has been reported as between 87-99% and may be
dependent upon factors including the chromosomal location of loxP sites, distance
between loxP sites and the expression levels of Cre recombinase within the cell (Orban
et al., 1992). Temporal or spatial regulation of Cre-mediated recombination has now
become possible through tissue-specific promoters, developmental stage-specific
promoters and ligand inducible promoters regulating Cre recombinase expression
(Kisanuki et al., 2001).
2.1.3 TISSUE SPECIFIC KNOCKOUTS
In mice genetically targeted to contain a floxed gene, site-specificity of the
recombination reaction may be engineered by limiting expression of Cre to the target
cell of choice (Gu et al., 1994, Orban et al., 1992). This may be achieved by including
tissue-specific promoters within a Cre recombinase transgene. Mice expressing Cre
recombinase in a tissue-specific pattern ('effector mice') are usually generated
separately and crossed with floxed mice ('target mice') to produce offspring
homozygous for the floxed allele, and either homozygous or heterozygous for the Cre
recombinase transgene. Although all cells in the offspring contain floxed alleles,
expression of Cre recombinase will only occur in cells in which the tissue-specific
promoter is active, thereby limiting recombination exclusively to these cells. The
success of tissue-specific approaches is critically dependent on the precise restriction of
Cre expression to the desired target cell or tissue. 'Leaky' expression of Cre will result
in recombination in adjacent cells, whilst 'patchy' expression of Cre in target cells will
result in a reduced number of recombination events and a mosaic pattern of gene
deletion. Each of these events would serve to complicate the interpretation of any
observed phenotype. For many studies, it is also important that the activity of the
conditional allele is identical to the wild type allele, in order that normal gene function is
maintained in all cells in which Cre is not expressed. To achieve this, loxP sites are
generally targeted to intronic regions that are removed by splicing during gene
transcription. Antibiotic resistance genes in the targeting construct used for ES cell
selection are also usually removed prior to the generation of mice.
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2.1.3.1 Endothelial cell-specific knockout
Promoter and enhancer elements from the murine Tie2 gene have been used to drive
transgene expression in EC and cells of the haematopoietic lineage (Schlaeger et al.,
1997). The Tie2 gene encodes the tyrosine kinase angiopoietin receptor and activity of
the Tie2 promoter is apparent from the first appearance of EC (late primitive streak
stage). The expression pattern of transgenes driven by both promoter and enhancer
elements from the Tie2 gene mirror the expression pattern of the Tie2 gene and
expression is maintained throughout development into adulthood (Schlaeger et al.,
1997). Accurate assessment of the expression pattern of Tie2-Cre transgenic mice is
essential for predicting the pattern of recombination events in mice harbouring
functional loxP sites. This has been achieved by cross-breeding Tie2-Cre mice with the
reporter mouse strains CAG-CAT-Z (Kisanuki et al., 2001), ROSA26R (Kisanuki et al.,
2001) and EGFP (Constien et al., 2001), In each of these reporter strains a visible
marker (lacZ and GFP, respectively) is expressed only following Cre-mediated
recombination. LacZ expression was pan-endothelial in Tie2-Cre;CAG-CAT-Z double
transgenic mice and additionally seen in the endocardium and mesenchymal cells of the
atrioventricular canal and proximal cardiac outflow tract (Kisanuki et al., 2001).
Similarly, recombination rates of up to 90% have been described in haematopoietic cells
with no evidence of ectopic expression (Constien et al., 2001). Several groups have now
produced Tie2-Cre transgenic mice (Constien et al., 2001, Kisanuki et al., 2001, Theis et
al., 2001) using identical promoter and enhancer elements. Small variations in
expression patterns are observed between these mice, most likely secondary to
differences in transgene insertion sites. For the purposes of this study, we have utilised
that of Kisanuki, a kind gift of Professor M. Yanagisawa, University of Texas.
2.1.4 CHEMICALS AND SOLUTIONS
All stock solutions were prepared with autoclaved reverse osmosis water (Elgastat Prima
Reverse Osmosis Water Machine; Elga Ltd, High Wicham, UK). All chemicals were
supplied by BDH Laboratory Supplies (Merc Ltd, Lutterworth, UK) and were of
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analytical grade. Acids, alkalis and organic solvents were supplied by BDH laboratory
Supplies with the exception of absolute ethanol and redistilled Tris-buffered phenol
(Fischer Scientific, Loughborough, UK). Radionucleotides were supplied by Amersham
Pharmacia Biotech UK Ltd. (Little Chalfont, UK) and ICN Pharmaceuticals
(Basingstoke, UK). MWG-Biotech AG (Ebersberg, Germany). Hexaneucleotides and
dNTPs were supplied by Roche Molecular Biochemicals, Mannheim, Germany. Kodak
XOMAT XAR-5 film was used for all autoradiographs and was supplied by IBI Ltd
(Cambridge, UK). SeaKem LE agarose (FMC Bioproducts, Rockland, USA) was used
for all agarose gel electrophoresis.
2.1.5 PRIMERS
All oligodeoxynucleotide primers for sequencing and PCR reactions were supplied by
Sigma Genosys (Pampisford, UK). Primer sequences and the complementary regions of
the ETb receptor gene locus are illustrated in Figure 2.1, Figure 2.2 and Figure 2.3. A list
of primer sequences is provided in Table 2.1.
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Intron1 19493 bp ..catccagagggtcatgacccacaggttgagaatcactgttctaaagtgcc M250F
Exon 2 113 bp
Intron 2 132 bp













412 R TGGACAGCAGTAGAAATTGTTTTAjfifrTTGGGTGGTCTCTGTGGTTCTG^pTG 78F
TCCCCGAAGCCATAGGTTTTGATATGATTACGTCGGACTACAAAGGAAAGCC
CCTAAGGGTCTGCATGCTTAATCCCTTTCAGAAAACAGCCTTCATGCAG
Intron 3 1267 bp gtacgttcactttgcttgttctttctgcactttccttataaatatttcacta
tttcccccagttccccaccttggtaggctattgatttattactacctttggc
Exon 4 150 bp






















Exon 5 134 bp agacgagaagtggccaagacagtcttctgcc|tggtcctcgtgtttgc|tctct| 32f
Exon 5R|g|ttggcttccccttcacctca|gccggatcctgaagctcaccctgtatgacca
GAGCAATCCACACAGGTGTGAGCTTCTGAG






Sequence alignment of primers used for PCR and sequencing with complementary
regions the ETB receptor. Black boxes = forward primers; Red boxes = reverse primers.
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454F Intron 1 TCAGTTGTAATGAGACACAGAC
M250F Intron 1 ATCCAGAGGGTCATGACCCAC
671R Exon 1 GGGTATGTCTATGATGATGTGC
149F Exon 1 TCCAGACTGAAAACAGCAGAGCGG
81R Exon 2 CTTAGAGCACAAAGACTCAGCAC
81F Exon 2 AGTGCTGAGTCTTTGTGCTCTAAG
681R Intron 3 AGCCATAAAGTCACAGCCATTC
INT 3F Intron 3 GGATTTGGAATGGCAGCCTG
INT 3R Intron 3 GTTGTTTAGGACAGTGCT
584R Intron 3 TCACTAGTGATGGTTAACCTCACAG
412R Exon 3 CAGAACCACA GAGACCACCCAAAT
78F Exon 3 TTTGGGTGGTCTCTGTGGTTCTGG
417R Exon 4 GTAGAAACTGAACAGCCACCAATC
5To4R Intron 5 GAACAGCTGCCACGTCTC
Exon 5R Exon 5 TGAGGTGAAGGGGAAGCCAACAGAGA
32F Exon 5 TGGTCCTCGTGTTTGCTCTCTG
359R Exon 6 TACAGAGCGATTGGATTGATGC
LTNLF LTNL cassette GCCTCTGTTCCACATACACTTCATTC
Tie2 98F Cre cDNA CGCATAACCAGTGAAACAGCATTGC
Table 2.1
Sequences of primers used in the generation of EC-specific ETB receptor knockout mice.
2.1.6 ENZYMES
Genecraft NeoThermMinus (Genecraft, Germany) Taq polymerase or the Expand Long
Template PCR system (Roche Molecular Biochemicals, Mannheim, Germany) was
utilised for all PCR genotyping reactions. PCR fragments for cloning reactions were
prepared using pfu DNA polymerase (Promega, Madison,USA) unless otherwise stated.
T4 polynucleotide Kinase (Product number EK0031) and T4 DNA ligase (Product
number EL0335) were supplied by MBI Fermentas (St Leon-Rot, Germany). Calf
intestinal alkaline phosphatase (CAIP) (Product number 713023) and Klenow enzyme
(Product number 1008404) were supplied by Roche Molecular Biochemicals. Roche




All plasmids were maintained in XLI Blue Escherichia coli (E. coli) of genotype supE
hsdR lac F' proAB+ lacf /acZAM15 (Bullock et al., 1987) unless otherwise stated. X
bacteriophage vectors were propagated in LE392 E. coli of genotype supE supF hsdR
(Borck et al., 1976). X bacteriophage were converted to plasmids in BNN132 strain E.
coli, produced by infecting JM107 cells of genotype endAI, gyr96, thi, hsdR17, supE44,
relAI, A( lac-proAB), (F\ traD36, proAB*, lacIqZAMI5) with AKC as described by
Elledge et al (Elledge et al., 1991).
2.1.8 PROBES, PLASMIDS AND CLONING VECTORS
A probe used for screening of the TPS 129/SV genomic library, consisting of a fragment
of the mouse ETB receptor gene cDNA (Hosoda et al., 1994) spanning from position 563
to 1363, was a kind gift of Dr Paula Smith (University of Edinburgh, Edinburgh, UK).
The loxP-thymidine kinase-neomycin-loxP (LTNL) selection cassette (illustrated in
Figure 2.4) used in the construction of the pAPW and pAPNoDT targeting vectors was a
kind gift of Dr Noboru Komiyama (Centre for Genome Research, University of
Edinburgh, Edinburgh, UK) and was cloned into the Xba I site of pBluescript® II KS+
(Stratagene, Heidelberg, Germany; illustrated in Figure 2.5). pCAGGS-dt, a plasmid
containing a diphtheria toxin gene under the transcriptional regulation of a chicken actin
promoter (illustrated in Figure 2.6), the Cre-recombinase expression plasmid pMC-Cre
(Araki et al., 1995) and the LoxP2ROSA plasmid (illustrated in Figure 2.7) were kindly
donated by Dr A. Smith (Centre for Genome Research, University of Edinburgh,
Edinburgh, UK) and were used in the construction of pAPW. The diphtheria toxin gene
cassette was subcloned into the plasmid pSP72polyl (Figure 2.8), a gift of Dr M. Sharp
(University of Edinburgh, Edinburgh, UK). This vector was constructed by removal of
the polylinker from pSP72 (Promega, Southhampton, UK) and insertion of annealed,
complementary oligodeoxynucleotides (S. Morley et al., unpublished data). The plasmid
pAP (illustrated in Figure 2.9) was generated by automatic subcloning from a APS clone
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and was subsequently modified through the addition of an Xho I site to produce the















4 LoxP ATAACTTCGTATA ATGTATGC TATACGAAGTTAT
Figure 2.4
LoxP/Thymidine Kinase/Neomycin phosphotransferase/LoxP (LTNL) in pBluescript
KS+. MCI; Mario Capped-1 promoter. PGK; Phosphoglucokinase promoter. Black
triangle; loxP site. Primer sequences are illustrated in Figure 2.5 . The 3.8 kb Xba I
fragment was sub-cloned into the targeting constructs and permitted the selective
propagation of targeted ES cell clones in neomycin-containing culture media.
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fl (+) origin 35-44 '
i'-galactosidasc <'-fragment 460-8' 6
multiple cloning site 653 760
lac promoter R' 7 938
pUC origin ' "58-" 825
ampicillin resistance (bla) ORF 976-2833
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Figure 2.5
The pBluescript KS plasmid (upper panel) was utilised as a vector during preparation of






pCAGGS-dt; 5372 bp. The Diphtheria toxin (DT) gene and associated human
cytomegalovirus immediate early enhancer (CMV-IE), chicken (3-actin promoter and
rabbit (3-globin polyadenylation signal were excised as a 2857 bp Spe I - Hind III
fragment and sub-cloned into a pSP72 poly 1 shuttle vector. The Xho I (blunt) - Not I




CCT AGG ATA ACT TCG TAT AAT GTA TGC TAT ACG AAG TTA TCC CCT AGG
Avr II LoxP Avr II
Figure 2.7
LoxF^ROSA construct used during the construction of the targeting vectors pXPW and
pAPW(NoDT). LoxP sites (black triangles) are head-to-tail and fragments cloned





pSP72polyl shuttle vector used in the construction of p)d?W. This plasmid was
constructed by Dr Steve Morley (University of Edinburgh) through modification of the





The plasmid pXP was produced by automatic subcloning (Nehls et al., 1994) of the
bacteriophage AP, identified from a XPS 129/SV mouse genomic DNA library. M5
contains a 14748 bp region of the mouse ETB receptor gene spanning from the final
12104 bp of intron 1 to the Bam HI site located 54 bp after the start of exon 5. Shaded










pXPXho was produced by the addition of an Xho I site adjacent to the Apa I site within
the pBluescript SK polylinker region of pXP and was used in the construction of
targeting vectors. Shaded rectangles = Exons; single line = introns; solid rectangles =
pBluescript KS vector.
2.1.9 EMBRYONIC STEM CELLS
E14Tg2a ES cells were a kind gift of Dr J. Ure (Centre for Genome Research,
Edinburgh, UK). All culture was performed in media prepared with filter sterilised UHP
water (Elgestat Prima Reverse Osmosis Filter and Elgastat UHP water purifier). Media
was supplemented with 10% foetal calf serum (FCS) and DIA/LIF (1:1000 dilution of
100 units/ml stock solution, titres prepared by D. Rout, Centre for Genome Research) as
previously described (Smith et al., 1988, Williams et al., 1988). Batches of foetal calf
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serum were tested prior to use in established ES cell cultures by Mr D. Rout (University
of Edinburgh, Edinburgh, UK).
2.1.10 ANIMALS
The inbred mouse line C57BL/6 was used for the derivation of blastocysts for the
production of chimaeric mice. Blastocysts were implanted in foster mothers of the
outbred MF1 Swiss albino strain. Chimaeric mice were crossbred with BKW mice
(B&K Universal Ltd., Hull, UK) to test for germline transmission. Floxed ETB mice
produced in this study were bred at the Centre for Genome Research and the Medical
Faculty Animal Area, University of Edinburgh. Tie2-Cre transgenic mice were produced
by injection of a Tie2Cre transgene into fertilised C57BL/6 x SJLF, oocytes (Kisanuki et
al., 2001) and were a kind gift of Professor M. Yanagisawa, University of Texas. All
mice were ear tagged for identification. Mice were given free access to standard
breeding chow (0.8% NaCl) or high salt chow (7.6 % NaCl; Special Diet Services,
Witham, UK) and water. Twelve hour diurnal cycles were maintained throughout.
Animal house humidity was maintained at 50% ± 10% and the temperature held at 21°C
± 2°C. All breeding, maintenance and experimental protocols were performed in
accordance with the Animals (Scientific Procedures) Act (UK) 1986.
2.1.11 MOLECULAR BIOLOGY METHODS
2.1.11.1 Alkaline lysis miniprep
Three ml of Luria-Bertani medium (L-Broth; 10g/l bacto-tryptone, 5.0 g/1 bacto-yeast
extract, 10g/l NaCl, pH 7.2)) containing ampicillin (100 pg/ml) were inoculated with a
single bacterial colony and incubated overnight at 37°C with continuous shaking (225-
250 rpm). The following day, 1.5 ml of the culture was transferred to an Eppendorf tube
and the bacteria pelleted by centrifugation (12,000 x g, 5 minutes). The supernatant was
withdrawn and the pellet resuspended by vortexing in 100 pi of lysis buffer (25mM Tris
HC1 pH 8.0, 10 mM EDTA and 10% (w/v) glucose). Two hundred pi of 0.2M NaOH
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and 1% (w/v) SDS were added and the tube inverted gently 5 or 6 times. Tubes were
then incubated on ice for 5 minutes before the addition of 150 pi of ice-cold
neutralisation buffer (3.0M potassium acetate, 2.0M acetic acid). The contents were
mixed by vortexing and incubated on ice for 5 minutes. Tubes were then spun (12,000 x
g, 5 minutes) to pellet cell debris and chromosomal DNA. The supernatant containing
circular plasmid DNA was removed to a fresh tube and one volume of
phenol:chloroform:isoamyl alcohol (25:24:1) added. The aqueous phase was separated
by centrifugation (12,000 x g, 5 minutes) and removed to a fresh tube. Two volumes of
ice cold 100% ethanol were added and plasmid DNA precipitated by centrifugation at
12,000 x g at 4°C. The pellet was then washed with 70% ethanol and air-dried for 10
minutes. DNA was dissolved in 50 pi of TE, pH 8.0 containing 20 pg/ml DNase-free
pancreatic RNase and stored at -20°C until use. This method routinely yielded ~5pg of
DNA.
2.1.11.2 Large scale plasmid DNA preparation
Up to 200 pg of plasmid were prepared using Qiagen HiSpeed Plasmid Midi kits™
(Qiagen (UK) Ltd, Crawley, UK; Product number 12643). A single colony of bacteria
was inoculated into a 3 ml starter culture of L-broth containing 100 pg/ml of ampicillin.
The culture was incubated at 37°C with continuous shaking for 8 hours. The starter
culture was then diluted in 50 ml of L-broth containing lOOpg/ml of ampicillin and
incubated overnight at 37°C with continuous shaking. The culture was transferred to a
50 ml Falcon tube and the bacteria harvested by centrifugation (6000 x g, 15 minutes) at
4°C in a Beckmann J6B centrifuge. The supernatant was removed and the bacterial
pellet resuspended in 6 ml of ice cold Buffer PI (50mM Tris CI pH 8.0, lOmM EDTA
and 100 pg/ml of DNase-free RNase). Six ml of Buffer P2 (0.2mM NaOH and 1% (w/v)
SDS) were added and the contents mixed by gently inverting the tube 5 times. Samples
were incubated at room temperature for 5 minutes before adding 6 ml of ice cold Buffer
P3 (3.0M potassium acetate pH 5.5). The contents were mixed by gentle inversion and
transferred immediately to a QIAfilter™ cartridge (Qiagen (UK) Ltd, Crawley, UK).
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This was left for 10 minutes at room temperature to allow the precipitate of protein,
genomic DNA and detergent to float to the surface. The cell lysate was then filtered
through the QIAfilter™ cartridge and the cleared lysate collected into a HiSpeed Midi™
column previously equilibrated with 4 ml of Buffer QBT (750mM NaCl, 50mM MOPS
pH 7.0, 15% (v/v) isopropanol and 0.15% Triton® X-100 (v/v)). The column selectively
binds plasmid DNA and allows degraded RNA, cellular proteins and metabolites to be
washed out by the subsequent addition of 20 ml of a medium salt buffer (Buffer QC
containing 1.0M NaCl, 50mM MOPS pH 7.0 and 15% isopropanol (v/v)). After
washing, plasmid DNA was eluted with 5 ml of a high salt buffer (Buffer QF; 1.25mM
NaCl, 50mM Tris CI pH 8.5 and 15% isopropanol (v/v) and collected into a 15 ml falcon
tube. Plasmid DNA was precipitated over 5 minutes with 0.7 volumes of room
temperature isopropanol and recovered with a QIAprecipitator Module™ (Qiagen (UK)
Ltd, Crawley, UK). This filter traps DNA as a thin layer, allowing removal of
isopropanol and air-drying. DNA was eluted into an Eppendorf tube by the addition of
0.5 ml of TE pH 8.0.
2.1.11.3 Quantitation ofNucleic Acids
Optical absorbance at 260nm (OD260) of DNA-containing solutions was measured using
a Pharmacia Biotech spectrophotometer (model number 80-2092-26). The
spectrophotometer was zeroed at 260nm and 280nm with a 200 pi sample of dH20 prior
to sample measurement. DNA samples were diluted 1:100 in dH20 to a final volume of
200 pi. OD250 of samples was multiplied by 50 for double-stranded DNA plasmids and
then by 200 to produce a concentration of DNA in pg/ml. For more concentrated
solutions, dilutions of the stock plasmid solution were prepared such that
spectrophotomeric readings were between 0.1 and 1.
2.1.11.4 Sequencing ofplasmids
All sequencing reactions were performed by Mrs Nina Kotelevtsev (University of
Edinburgh, UK) using an ABI 377 Prism Sequencer (Perkin Elmer Applied Biosystems
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Division, Foster City, USA) and the Big Dye Terminator Ready Reaction Kit™
according to the manufacturer's protocol.
2.1.11.5 Restriction digestion
All restriction digestion reactions were performed according to the guidelines of
Sambrook et al (Sambrook et al., 1989) at 37°C unless otherwise stated. DNA was
digested at a concentration of 0.1-0.5 pg/pl with less than 10% (v/v) of enzyme
(equivalent to less than 5% (v/v) of glycerol). After the appropriate incubation time,
reactions were checked for completion by running an aliquot containing 0.1-1.0 pg of
DNA on a 0.8% agarose gel. Reactions were terminated by heat inactivation of the
enzyme (65°C for 15 minutes) or, for thermostable enzymes, by
phenol:chloroform:isoamyl alcohol extraction followed by ethanol precipitation of the
digested DNA.
2.1.11.6 Agarose gel electrophoresis
DNA molecules were separated according to size using 0.8% agarose gel electrophoresis
unless otherwise stated. All gels were prepared with SeaKem LE agarose (FMC
Bioproducts, Rockland, USA) using 1 x TAE solution (40mM Tris-acetate, ImM
EDTA) and were stained with 0.5pg/ml of ethidium bromide (Sigma-Aldritch,
Steinheim, Germany; Product code E-8752). Samples were mixed with 6 x loading dye
solution (0.09% bromophenol blue, 0.015% xylene cyanol FF and 10% glycerol) to a
final concentration of 1 x before electrophoresis. All sizes were judged according to
standard size markers run concurrently on the same gel. The size markers used were X
DNA digested with Hind III (DNA fragment sizes 23130, 9416, 6557, 4361, 2322, 2027,
564 and 125 base pairs), ~h DNA digested with Hind III and EcoR I (DNA sizes
21226,5148, 4973, 4268, 3530, 2027, 1904, 1584, 1375, 947, 831, 564 and 125 base
pairs) and the GeneRuler™ 100 bp DNA ladder (DNA fragment sizes 1000, 900, 800,
700, 600, 500, 400, 300, 200, 100 and 80 bp; MBI Fermentas, St Leon-Rot, Germany).
DNA was visualised on the gel by UV transillumination and photographed with a
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Polaroid MP4 Land Camera (Polaroid (UK) Ltd, St. Albans, UK) with Polaroid 667
(IS03000/36°) film (Polaroid, UK). Gel images were also digitally photographed using
a transilluminator and digital acquisition system (Ultra-Violet Products Ltd., Cambridge,
UK.)
2.1.11.7 DNA fragment recovery from agarose gels
DNA fragments utilised in ligation reactions were recovered following agarose gel
electrophoresis using a QIAEX II™ kit (Qiagen (UK) Ltd, Crawley, UK; Product
number 20021) according to the manufacturer's instructions. 3-5 pg of plasmid DNA
were digested with the appropriate restriction enzyme(s) at 37°C until completion. Prior
to reaction termination, a 2 pi aliquot was run on a 0.8% TAE mini-gel to ensure
completion of the restriction digestion. The remaining sample was then loaded into a
single slot agarose gel. Eollowing electrophoresis, the desired fragment was cut from the
gel with a sterile scalpel and the gel slice dissolved in 3 volumes of solubilisation Buffer
QX1 (3.0M NaCl, 4.0M sodium perchlorate, lOmM Tris-HCl pH 7.0, lOmM sodium
thiosulphate) for fragments between 100 bp-4 kb, or 3 volumes of Buffer QX1 and 2
volumes of dH20 for fragments >4 kb. For 2-10 pg of DNA, 30 pi of QIAEX II™
solution containing resuspended silica gel particles was added and the tube incubated at
50°C for 10 minutes with vortexing every 2 minutes. The high salt solution promotes
dissociation of DNA binding proteins and the efficient adsorption of DNA to the silica
particles. Once completely solubilised, the solution was centrifuged (12,000 x g, 30
seconds) and the supernatant discarded. The pellet was resuspended in a further 500 pi
of Buffer QX1 and centrifugation repeated to remove any remaining agarose, proteins,
salt or ethidium bromide. The pellet was washed twice with 500 pi of Buffer PE (70%
(v/v) ethanol, lOOmM NaCl, lOmM Tris-HCl, pH 7.5) and air dried for 20 minutes. The
DNA fragment was then eluted from the silica particles by resuspending the pellet in 20
pi of TE buffer, pH 8.0. Following centrifugation, the supernatant containing the DNA
fragment was removed and yield checked on a 0.8% agarose gel. The remainder was




Ligation of DNA fragments was performed with T4 DNA ligase (MBI Fermentas).
Quantification of DNA fragments prior to ligation was achieved by visualisation of an
aliquot of each fragment on a 0.8% agarose gel. For cloning small fragments into
plasmid vectors, a molar excess of approximately 3:1 (fragment:vector) was used. The
DNA fragment and vector cut were mixed with 2 pi of 10 x ligation buffer (400mM Tris
HC1, lOOmM MgCl2, lOOmM DTT and 5mM ATP, pH 7.5), 1 unit of T4 ligase and
dH20 to a final volume of 20 pi. A control reaction containing each of the above
ingredients with the exception of the DNA fragment was also set up. Ligations were
performed in a MJ Research Peltier Thermal Cycler PT-200, using the following
programme: 16°C for 30 seconds, 24°C for 30 seconds, repeated for 60 cycles. The
reaction was then held at 16°C until used.
2.1.11.9 Creating blunt ends for ligation
The large fragment of DNA polymerase 1 (Klenow fragment) (Roche Diagnostics
GmbH, Mannheim, Germany; Product number 1008404) was used to fill the recessed 3'
termini created by DNA digestion with restriction enzymes (Klenow and Henningsen,
1970). Reactions were performed in the restriction enzyme buffer used for the preceding
digestion reaction following heat inactivation of the enzyme. For heat stable enzymes,
the enzyme was removed by phenol:chloroform:isoamyl alcohol extraction, ethanol
precipitation of DNA and resuspension in TE buffer. A restriction enzyme buffer
required for subsequent digestion reactions or DNA polymerase buffer (50mM Tris-HCl,
15mM (NH4)2S04, 7mM MgCl2, O.lmM EDTA, lOmM 2-mercaptoethanol, 0.02 mg/ml
BSA, pH 8.8) was then added, supplemented with 33 pM dNTPs. Reactions were





5' phosphate residues were removed from digested vector DNA with Calf Intestinal
Alkaline Phosphatase (CAIP) (Boehringer Mannheim GmbH, Mannheim, Germany;
Product number 713023). Restriction enzymes were heat inactivated, 1 unit of CAIP
added and the reaction mixture incubated for 30 minutes at 37°C. CAIP was removed
prior to subsequent ligation reactions by phenol:chloroform:isoamyl alcohol extraction
and the remaining DNA precipitated with ethanol.
2.1.11.11 Methodsfor cloning ofPCR products
2.1.11.12 Klenow-Kinase-Ligase
PCR products were cloned into plasmid vectors other than PCR2.1 using the Klenow-
Kinase-Ligase procedure, as described by Lorens (Lorens, 1991). This method produces
cancatemeric DNA molecules that facilitate restriction digestion by the internalisation of
enzyme recognition sites. PCR products from 3-5 50pl reactions were pooled and
extracted with phenol:chloroform:isoamyl alcohol (25:24:1) followed by precipitation
with 2.5 volumes of ice cold 100% ethanol. DNA was pelleted by centrifugation (12,000
x g, 15 minutes) at 4 °C and washed in 70% ethanol. The pellet was then air-dried for 5
minutes and resuspended in 12.6 pi of dH20. 2.5 pi of 10 x ligase buffer (400mM Tris-
HC1, lOOmM MgCl2, lOOmM DTT and 5mM ATP, pH 7.8), 0.2mM dNTPs, 5 units of
Klenow enzyme, 4 units of T4 polynucleotide kinase and 2 units of T4 DNA ligase were
then added such that the final volume of mixture was 25 pi. The mixture was incubated
at 25 °C for 60 minutes during which time the PCR products self-ligate to produce
multimeric DNA substrates for subsequent cleavage by restriction enzymes. This is
achieved by polishing, phosphorylating and ligating PCR termini to produce
cancatemeric DNA substrates. Completion of this process was checked on a 0.8%
agarose gel to demonstrate the presence of cancatemers of the appropriate molecular
weight. The reaction mixture was extracted with phenol:chloroform:isoamyl alcohol
(25:24:1) and precipitated with ethanol to remove contaminating enzymes and dNTPs.
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The pellet was then washed with 70% ethanol, air-dried and resuspended in 10 pi of TE,
pH 8.0. 2 pi of 10 x restriction enzyme buffer, lpl of restriction enzyme and 7 pi of
dH20 were added. Enzymatic cleavage of cancatemeric DNA at 37°C for 4 hours was
followed by a further phenol:chloroform:isoamyl alcohol (25:24:1) extraction and
ethanol precipitation. The washed and dried pellet was resuspended in 20 pi of TE pH
8.0.
2.1.11.13 TA Cloning® ofPCR products
PCR products were cloned into the vector PCR®2.1 using the TA Cloning® kit
(Invitrogen BV, The Netherlands). Genomic DNA was amplified with Taq polymerase
to produce PCR products with a single deoxyadenosine at the 3' terminus. One pi of the
PCR reaction mixture was mixed with 1 pi of lOx ligation buffer (60mM Tris-HCl pH
7.5, 60mM MgCl2, 50mM NaCl, lmg/ml bovine serum albumin (BSA), 70mM (3-
mercaptoethanol, ImM ATP, 20mM dithiothreitol and lOmM spermidine), 50 ng of
PCR2.1 vector, 1 pi of T4 DNA Ligase (4.0 Weiss units) and dHzO to a final volume of
10 pi. The linear PCR2.1® vector (illustrated in figure Figure 2.5) contains a single 3'
deoxythymidine residue in the cloning site that facilitates the ligation of PCR products
with 3' deoxyadenosine overhangs. Reactions were incubated for 16 hours at 14 °C
before being centrifugation briefly and placed on ice. Two pi of the ligation mixture
were then used for electroporation of XLI E. coli. Colonies were plated on LB agar
plates containing ampicillin (100 pg/ml) and grown overnight at 37°C. Individual
colonies were selected at random and plasmid DNA isolated by alkaline lysis miniprep.
Restriction enzyme digestion and DNA sequencing were used to confirm the presence
and orientation of the ligated PCR product.
2.1.11.14 Preparation ofelectrocompetent cells
Electroporation was performed with the XLI Blue strain of E. coli prepared using a
method adapted from Chung (Chung et al., 1989). This method typically produces 1-10
x 108 transformants/pg of DNA. A scraping of a frozen aliquot of E. Coli was streaked
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on an LB plate and incubated overnight at 37°C. Fifty ml of LB media were inoculated
with a single bacterial colony and incubated for 12-16 hours at 37°C with continuous
shaking at 200-225 rpm in a 250 ml flask. This starter culture was diluted into 1 L of LB
medium and grown at 37°C with continuous shaking until the optical density at 550 nm
(OD550) was between 0.5 and 0.6. The culture was transferred to 4 x 250 ml pre-chilled
centrifuge bottles. All subsequent manipulations were performed at 4°C to achieve
maximum electrocompetence of the bacteria. Cultures were spun at 2000 x g for 15
minutes and the supernatant decanted. The cell pellet was resuspended in 250 ml of ice-
cold sterile dH20 and the cells centrifuged at 2000 x g for a further 15 minutes. The
supernatant was decanted and the cells resuspended in 125 ml of ice-cold dH20.
Following a further 15 minute centrifugation step, the supernatant was decanted and the
cells resuspended in 10 ml of sterile 10% glycerol using a pre-chilled pipette. The
solution was transferred to a sterile 50 ml centrifuge tube, spun (4000 x g, 15 minutes)
and the glycerol decanted. Cells were resuspended in 1 ml of ice-cold sterile 10%
glycerol. The cell suspension was snap frozen in 100 pi aliquots using an ethanol/dry ice
bath and stored at -80°C.
2.1.11.15 Transformation ofE.Coli by electroporation
Electroporation of competent XLI Blue E. Coli was performed using a Bio-Rad Gene
Pulser II (Bio-Rad Inc., Hemel Hempstead, UK; Product number 165 2112) with the
capacitor set to 25 pF, 2.5 KV and pulse controller at 200 £2. Forty pi of competent cells
were defrosted on ice and immediately mixed with 3-4 pi of ligation mix (~0.5-2 pg of
DNA). The mixture was transferred to an ice cold sterile electroporation cuvette and the
pulse applied, typically producing a pulse of 12.5 KV/cm with a time constant of 4.6-4.8
msec. Cells were immediately resuspended in 300 pi of room temperature SOB medium
(5mM MgS04, 5mM MgCl2, 20mM glucose) and incubated at 37°C for 40 minutes to
permit the expression of plasmid antibiotic resistance genes. Aliquots of 5, 50 and 200




2.1.11.16 Colony and Plaque lifts
Bacterial cells or bacteriophage plaques were plated at suitable density onto the
appropriate selection media and incubated overnight at 37°C. Petri dishes were then pre-
cooled for 30 minutes at 4°C to prevent smearing of colonies before lifts were taken.
Using blunt ended clean forceps, 8cm diameter Hybond N™ (Amersham Pharmacia
Biotech) positively charged nylon membranes were gently lowered onto the surface of
the agar and marked asymmetrically with 5 pinholes to facilitate orientation of the final
autoradiograph. For bacterial colonies, the membrane was transferred colony-side up
onto a fresh agar plate and both plates were incubated for 2 hours at 37 °C to allow
further growth of the transferred and residual colonies. DNA was recovered from
colonies or bacteriophage particles by denaturing membranes for 3 minutes on 3MM
paper soaked with a solution of 0.5M NaOH and 1.5M NaCl. Membranes were
neutralised for 3 minutes with 1.5M NaCl, 0.5M Trizma base solution (pH 7.4) before
being washed vigorously in 2 x SSC to remove cellular debris. Discs were then air-dried
and DNA fixed to the membrane by oven baking for 2 hours at 80°C or by UV
crosslinking at a constant energy of 1200J (UVP CL-1000 UV crosslinker, UVP Inc,
Upland, USA; Product number 95-0174-02).
2.1.11.17 Preparation of random primed radio-labeled probes
Probes were synthesised using a protocol modified from Feinberg (Feinberg and
Vogelstein, 1983). Approximately 50 ng of gel purified template DNA, 2.5 pi of lx
hexanucleotide solution (55 O.D. units/ml) and dH20 were mixed to a final volume of
14 pi and boiled for 5 minutes. The solution was cooled immediately to -20°C and
centrifuged briefly before the addition of 5 pi of 5x oligodeoxynucleotide labelling
buffer (250mM Tris-HCl pH 8.0, 25mM MgCl2, 5mM (3-mercaptoethanol, 2.0mM DTT,
2.0mM dATP, 2.0mM dGTP, 2.0mM dTTP, 1M HEPES pH 6.6 and lmg/ml
oligonucleotides), 5 pi a32P-dCTP (3000 Ci/mmol; lOpCi/pl) and 1 pi of Klenow
enzyme (2.0 units/pi). The probe was labelled for 2 hours at 37°C before removal of
unincorporated nucleotides using a NAP-5 column (Pharmacia Biotech). The reaction
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mixture was diluted to a final volume of 400 pi with TE (pH 8.0) and loaded onto an
equilibrated column. The sample was eluted in 600pl of TE and denatured by boiling for
5 minutes. The probe was immediately cooled on ice before addition to the hybridisation
solution. Radioactivity of a 2 pi aliquot of the probe diluted into 2.5 ml of Ultragold
solution was measured using a Packard 1600CA Series scintillation counter (Packard,
Pangborne, UK). Only probes with activity of 2.5-5.Ox 107 counts/minute (cpm) were
used for hybridisation experiments.
2.1.11.18 Southern Blot Analysis
Approximately 5 pg of genomic DNA were digested overnight with 10 units of
restriction enzyme. Reactions were terminated by heat-inactivation of the enzyme at
65°C for 15 minutes. The entire sample was loaded on a 0.8% agarose gel and DNA
fragments separated by electrophoresis. A photograph of the gel was taken alongside a
transparent ruler. The DNA fragments were transferred by capillary action onto a
positively charged nylon membrane (Boehringer Maanheim, Germany; Product number
1209272) as described by Southern et al (Southern, 1975). Capillary transfer was
performed by a modified rapid alkaline (0.4M NaOH, 1M NaCl) transfer procedure as
described previously (Chomczynski and Qasba, 1984, Reed and Mann, 1985). Nylon
membranes were then neutralised with 2 x SSC for 15 minutes and DNA fixed to the
membrane by UV crosslinking at 254nm followed by baking at 80°C for 2 hours.
Membranes were washed in 25ml of pre-hybridisation solution (0.25M Na2HP04 (pH
7.2), 7% (w/v) SDS, l.OmM EDTA and 50-200 pg/ml of sheared and denatured salmon
sperm DNA) in a pre-warmed Techne hybridisation bottle (Techne (Cambridge) Ltd,
Cambridge, UK) at 68°C for 1 hour. The bottles were continuously rotated using a
Techne hybridisation oven (Techne (Cambridge) Ltd, Cambridge, UK. Product number
HB-1D). The pre-hybridisation solution was then discarded and replaced with a further
25 ml pre-warmed to 68°C and containing the heat denatured radio-labelled probe at
106-2.5 x 106 cpm)/ml. Membranes were washed for 16 hours by continuous rotation at
68 °C before the hybridisation solution was discarded. Membranes were then washed
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twice for 10 minutes in 25 ml of 20mM Na2HP04 (pH 7.2), l.OmM EDTA (pH 8.0) and
5% (w/v) SDS, followed by 2 further 10 minute washes in 20mM Na2HP04 (pH 7.2),
l.OmM EDTA (pH 8.0) and 1% (w/v) SDS. Once dried, membranes were covered with
Saran Wrap and placed in an autoradiography cassette with two enhancement screens
and Kodak X-Omat film. Autoradiographs were exposed for a minimum of 16 hours at -
70°C prior to development.
2.1.12 SCREENING OF THE BACTERIOPHAGE X 129/SV MOUSE GENOMIC
DNA LIBRARY
The X 129/SV library (Nehls et al., 1994) was a kind gift of Dr Andrew Smith
(University of Edinburgh, Edinburgh, UK).
2.1.12.1 Preparation ofplating bacteria
A single colony of LE392 E. coli was inoculated into 50 ml of LB media supplemented
with 0.2% maltose and grown overnight at 37°C with continuous shaking. Bacteria were
collected by centrifugation at 4000 x g for 10 minutes and the supernatant discarded.
The pellet was resuspended in sterile 0.01M MgS04 to an OD^ = 2 (-1.6 x 109 cells/ml)
before storage at 4°C.
2.1.12.2 Plating ofbacteriophage X
Tenfold serial dilutions of bacteriophage plaques were prepared in SM media (50mM
Tris CI (pH 7.5), lOmM MgS04, 0.1M NaCl, 0.01% geletin). One hundred pi of each
bacteriophage dilution were then mixed with 100 pi of plating bacteria and incubated at
37°C for 20 minutes. The bacteriophage/bacteria mixture was mixed with 3 ml of molten
(45°C) top agar (L broth supplemented with 1% agar and lOmM MgS04), vortexed
briefly and poured onto pre-dried LB agar plates. Plates were gently rotated to ensure an
even distribution of bacteria before overnight incubation at 37°C.
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2.1.12.3 Picking ofbacteriophage A plaques
A plug of plaque and underlying agar was picked using a Pasteur pipette. Plugs were
inoculated into 1 ml of SM containing a single drop of chloroform and left at room
temperature for 2 hours before storage at 4°C. For long term storage, DMSO (7% v/v)
was added and the solutions stored at -70°C.
2.1.12.4 Screening ofbacteriophage A plaques by in-situ hybridization
Bacteriophage APS was grown at an appropriate density on agar plates as described in
section 2.1.12.2. Bacteriophage particles and DNA were then transferred to
nitrocellulose membranes using a protocol modified from the method of Benton and
Davies (Benton and Davis, 1977). Once baked, membranes were wetted with 2 x SSC
and transferred to a glass crystallising dish containing 60 ml of pre-hybridisation
solution (50% formamide, 5 x SSPPE and 0.5% SDS) and 0.5 ml of salmon sperm DNA
(a kind gift of Nina Kotelevtsev, University of Edinburgh) denatured by boiling for 5
minutes. The dish was gently rotated for 60 minutes at 42°C before the pre-hybridisation
solution was replaced with a further 60 ml containing 0.5 ml of denatured salmon sperm
DNA and denatured 32P-labelled probe at a concentration of 2 x 105 - 1 x 106 cpm/ml.
Probes were prepared according to the method described in 2.1.11.17. Membranes were
incubated overnight at 42°C with continuous rotation then washed twice for 15 minutes
at 42°C in 500 ml of 2 x SSC and 0.1% SDS, followed by a further wash at 68°C for 15
minutes in 500 ml of 1 x SSC and 0.1% SDS. Membranes were then dried and covered
with Saran Wrap. In a dark room, the membranes were attached to Kodak X-Omat film
and 'pre-flashed' with UV light to facilitate later orientation of the filters. The film and
filters were placed in an autoradiography cassette with two enhancement screens and
exposed for a minimum of 16 hours at -70°C prior to development. Positive plaques
were identified by alignment of the pinholes in the filters with the corresponding image
on the autoradiograph and then identifying positive hybridisation signals.
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2.1.12.5 Conversion ofA phage P to plasmid pkP
108 phage were incubated with 1 ml of a fresh overnight culture of Cre recombinase-
expressing BNN132 cells in lOmM MgCl2 for 30 minutes. Two ml of LB were added
and the mixture incubated for 1 hour at 30°C with continuous shaking. Cultures were
plated on 150 mm LB + ampicillin plates (100 pg/ml) supplemented with 0.1% glucose
and incubated overnight at 37°C. Scrapings of cells were cultured in 50 ml aliquots of
Terrific Broth containing ampicillin (100 p.g/ml) until the stationary phase. Plasmid
DNA was isolated from cultures using a Qiagen HiSpeed Midi-prep kit as described in
section 2.1.11.2. Isolated plasmid DNA was used to transform XL I E. coli as described
in section 2.1.11.15.
2.1.13 TISSUE CULTURE METHODS
E14 TG2a IV ES cells were grown at 37°C in a humidified incubator (Heraeus; model
B5060 EC/C02) with C02maintained between 6.0 and 7.5% as previously described
(Smith etal., 1988). All manipulations were performed inside a laminar flow hood
(Gelair ICN Flow Hood (Class 3), ICN Pharmaceuticals Ltd, Thame, UK). Sterilisation
of the hood interior and of hands and forearms was performed on each occasion with
70% industrial methylated spirits (BDH). ES cells were grown on Corning culture grade
plasticware (Bibby Sterilin, Stone, UK) coated with 0.1% geletin (Sigma-Aldritch,
Steinheim, Germany; Product number G-2500). Standard ES cell culture media
consisted of 1 x GMEM (Gibco-BRL; Product number 12541-025) supplemented with
10% (v/v) foetal calf serum (Globepharm, Surrey, UK), 0.23% (w/v) sodium bicarbonate
(Gibco-BRL; Product number 11140-035), 1.0 x MEM non-essential amino acids
(Gibco-BRL; Product number 118110-017), 2.0mM L-glutamine (Gibco-BRL; Product
number 25030-024), LOmM sodium pyruvate (Gibco-BRL; Product number 11360-039)
and 0.1 pM |3-mercaptoethanol (Sigma-Aldritch, Steinheim, Germany). Media was
prepared in a laminar flow hood in 500ml aliquots and stored at 4°C. Newly prepared
media was tested for bacterial contamination by incubating a 5ml aliquot with 5ml of
Tryptose Phosphate broth at 37°C for at least 2 days prior to use. Immediately before use
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the media was supplemented with DIA/LIF (1:1000 dilution). The term 'ES cell media'
will be used throughout to refer to DIA/LIF-supplemented media. Cells were routinely
frozen in ES cell media containing 10% (v/v) DMSO as described later.
2.1.13.1 Washing ofES cells
ES cells were washed between manipulations with filter sterilised phosphate buffered
saline (PBS; 137mM NaCl, 4.3mM Na2HP04, 2.7mM KC1 and 1.4mM KH2P04, pH 7.3)
prepared by dissolving 1 PBS tablet (Unipath, Basingstoke, UK; Product number
BR14A) in 100 ml of UHP filter sterilised H20. PBS was added to flasks by gently
running the solution down the flask wall opposite the cell layer.
2.1.13.2 Passage ofES cells
Media was aspirated and cells washed twice with 5 ml of PBS. Sufficient TVP (0.025%
trypsin (Gibco-BRL; Product number 25090-010), 1.0% chicken serum (Gibco-BRL;
product code 16110-033) and 0.5mM EDTA dissolved in PBS) was added to just cover
the cells. Flasks were then incubated at 37°C for 1-2 minutes and tapped to dissociate
cells. The trypsin was neutralised by the addition of 4 ml ES cell culture medium/ml of
TVP added. Dissociated cells were pelletted by centrifugation (1,200 rpm; 5 minutes
(200 x g in a Denley BS400 bench top centrifuge; Supplied by Life Sciences
International (UK) Ltd, Basingstoke, UK)) then resuspended in 5 ml of media. Cells
were counted in a haemocytometer and 1 x 106 cells seeded into a 25 cm2 flask coated
with 0.1% geletin and containing 10 ml of warmed ES cell media. Proportionately larger
volumes of media were used for larger flasks. Flasks were gassed with 5% C02, 95% air
for 10 seconds prior to incubation.
2.1.13.3 Thawing ofES cells
Vials of ES cells were retrieved from liquid nitrogen storage (Minnesota Valley
Engineering Cryogenics; Product number XLC110) and immediately defrosted by
floatation in a 37°C water bath. Once thawed, the vial was dried, sprayed with 70% IMS
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and transferred to the laminar flow hood. Cells were diluted into 9.5 ml of pre-warmed
ES cell media and pelleted by centrifugation (1,200 rpm; 3 minutes). The cell pellet was
gently resuspended in 10 ml of pre-warmed media and transferred to a 25 cm2 coated-
coated flask, gassed with 5% C02/95% air and incubated at 37°C. ES cell media was
replaced after 8 hours to remove dead cells and to further dilute remaining DMSO. For
cells frozen in 24 well plates, the entire plate was thawed by floatation in a water bath
for 1 minute. Freezing media was aspirated and 2 ml of ES cell media added to the
appropriate wells. The cell suspension was then transferred to a 1% coated-coated 12
well plate and incubated overnight at 37°C. Cells were then washed twice with PBS to
remove dead cells and the ES cell media refreshed.
2.1.13.4 Freezing ofES cells
Cells were washed twice with PBS and dissociated with TVP as previously described.
Cells were resuspended in 9 ml of ES cell media and 10% (v/v) DMSO added. Cells
were then collected by centrifugation (1,200 rpm; 3 minutes), resuspended in 1 ml of ES
cell media containing 10% (v/v) DMSO and divided equally between 2 labelled freezing
vials. Vials were immediately frozen at -80°C and transferred the following day to a
liquid nitrogen cell bank for long-term storage.
2.1.13.5 Freezing of24 well plates
Prior to freezing, confluent wells were washed twice with 1 ml of PBS and dissociated
by adding 100 pi of TVP and incubating at 37°C for 2 minutes. Once completely
dissociated, typsinisation was terminated by the addition of 200 pi of 'Quenching'
media (1:1 (v/v) 100% FCS: ES cell media containing G418 (200 pg/ml)). Three
hundred pi of ES cell media supplemented with G418 (200 pg/ml) and 20% (v/v)
DMSO was added to each well, resulting in a final DMSO concentration of 10% (v/v).
The media and cells were mixed by gentle rotation, the plate sealed with adhesive tape,
labelled and immediately stored at -80°C. Wherever possible, whole plates were brought
to confluence simultaneously in order that they could be frozen in situ. Where this was
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not possible, the preceding method was used but the final cell suspension in 10% (v/v)
DMSO was transferred to a fresh plate and the lid labelled with the clone identity.
2.1.13.6 Isolation ofES cell DNA
In contrast to 'freezing' plates, 'DNA' plates were allowed to grow beyond confluence
in order that all cells could be lysed simultaneously. The following protocol was
modified from Laird et al (Laird et al., 1991). Cells were washed twice with 1 ml of
PBS before the addition of 500 pi of 'lysis buffer' (lOOmM Tris-HCl pH 8.5, 5mM
EDTA, 0.2% (w/v) SDS, 200mM NaCl and 100 pg/ml Proteinase K (Boehringer
Maanheim, Germany; Product number 745723)). Plates were incubated overnight at
37°C and the lysate transferred to appropriately labelled Eppendorf tubes. One volume
of phenol:chloroform:isoamyl alcohol (25:24:1) was added to each and the phases
separated by centrifugation at 12,000 x g for 5 minutes. The aqueous phase was reserved
and transferred to a fresh tube. DNA was then precipitated by the addition of 2 volumes
of ice cold ethanol and gentle inversion of the tube for 5 minutes. DNA was pelleted by
spinning at 12,000 x g for 10 minutes. The pellet was washed with 70% ethanol, air
dried for 10 minutes and then dissolved in 100 pi of TE (pH 8.0) containing 50 pg/ml
DNase-free RNase (Sigma-Aldritch, Steinheim, Germany). To completely dissolve the
DNA, many samples required incubation at 37°C for 1-2 hours followed by gentle
pipetting up and down using a 'cut-off blue tip.
2.1.13.7 Electroporation ofES cells with pXPW andpXPW(NoDT)
Seventy five pg of targeting vector were digested overnight with 10 units of the
appropriate restriction enzyme. Aliquots of each were checked for complete digestion by
electrophoresis on a 0.8% agarose gel. Reaction mixtures were extracted with
phenol:chloroform:isoamyl alcohol and DNA precipitated by the addition of 2.5
volumes of ice cold ethanol. DNA was pelleted by centrifugation at 4°C (12,000 x g; 15
minutes) and the pellet dissolved in 150 pi of TE (pH 8.0). The sample was transferred
to the laminar flow hood and the DNA re-precipitated with 2.5 volumes of ethanol. The
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pellet was recovered by centrifugation (12,000 x g; 5 minutes), washed with 70%
ethanol, air-dried, then dissolved in 150 pi of TE (pH 8.0). To prepare ES cells for
electroporation, 2 confluent 175cm2 flasks were washed 3 times each with 20 ml of PBS.
Cells were dissociated with 5 ml of TVP as previously described, resuspended in 10ml
of pre-warmed ES cell media and transferred to two 50 ml universal tubes. Cells were
pelletted by centrifugation (l,200g; 3 minutes), resuspended in 5ml of ES cell media and
pooled. A 50 pi aliquot diluted x 10 with media was used for counting cells. 5 x 107 - 1 x
108 cells were taken, pelletted by centrifugation (1,200 rpm; 3 minutes) and resuspended
in PBS to a final volume of 600 pi. 75 pg of targeting vector was added and the mixture
incubated at 37°C for 10 minutes. Electroporation was performed in a 40 mm cuvette
using a Biorad Gene Pulser (Biorad Laboratories Ltd; Model number 1652087) and
Capacitance Expander (Biorad Laboratories Ltd; Model number 1652078) with to the
following settings: 0.8 kV, 3.0 pF, capacitance expander 960 pF. This typically
produced a time constant of 0.1 seconds. Mixtures were transferred to a universal and
left for 10 minutes at 37°C before the cells were resuspended in 10 ml of ES cell media.
5 ml of the suspension was divided equally between five 90 mm 0.1% geletin-coated
petri dishes. A further 10 ml of ES cell media was added to each dish and the dish
rotated gently to spread the cells before incubation at 37°C. The remaining cells were
diluted x 2 with ES cell media and a further 5 ml plated out as described. This process
was repeated until 5 plates each of 1:1, 1:2, 1:4 and 1:8 dilutions were established.
Duplicate plates of cells electroporated with no plasmid DNA were also established as
controls for the later selection of G418-resistant colonies.
2.1.13.8 Electroporation of targeted ES cells with Cre recombinase-expressing
plasmid
ES cell clones identified as having undergone a homologous recombination event
following targeting with either pXPW or pAPW(NoDT) were grown to confluence in 25
cm2 flasks. G418 selection was removed 48 hours prior to electroporation. Cells were
washed, dissociated and resuspended for counting as described in section 2.1.13.1. A
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total of 5 x 105 cells were mixed with 50 pg of pMC-Cre (Araki et al., 1995) in a final
volume of 600 pi using a plasmid preparation and electroporation protocol identical to
that described in section 2.1.13.8. A further 5 x 106 cells of the same clone underwent
electroporation without the addition of pMC-Cre. Following electroporation, cells were
seeded into 75 cm2 flasks pre-coated with 1% geletin and grown without G418 selection
for 4 days until confluent. Cells were again washed, dissociated and counted and the
following cell numbers seeded onto individual 1% coated-coated petri-dishes: 1 x 102, 5
x 102, 1 x 103, 5 x 103 and 1 x 104. Duplicate dilution series were cultured either with or
without 2.5 pM Gancyclovir (Sigma-Aldritch, Steinheim, Germany).
2.1.13.9 Production of chimaeric mice
Chimaeric mice were generated by a modification of the method described by Bradley
(Bradley, 1987). With the exception of the expansion of targeted ES cells, Dr J. Ure,
(Centre for Genome Research, University of Edinburgh) performed all procedures. A
total of 40 blastocysts were harvested from the fallopian tubes of C57BL/6J female mice
on day 4 of pregnancy by flushing with Buffer PB1 (prepared by dissolving 822 mg
NaCl, 300 mg Na2HP04, 104 mg glucose, 21 mg KC1, 20 mg KH2P04, 6.2 mg penicillin,
4.5 mg sodium pyruvate and 1.0 mg MgCl2 in 100 ml of dH20 and adding 0.01% (v/v)
phenol red, pH 7.0-7.2)). The buffer was supplemented with 10% (v/v) FCS prior to use.
Harvested blastocysts were transferred to pre-warmed ES cell media and incubated at
37°C to promote development of the blastocoel cavity. Blastocysts and trypsinised ES
cells were then transferred to hanging drops of PB1 buffer supplemented with 10% FCS
suspended on a siliconised (Repelcote™; BDH; Product number 63216 4J) coverslip.
The coverslip was placed over a custom-made manipulation chamber (G. Robertson,
Centre for Genome Research, University of Edinburgh) containing liquid paraffin and
the chamber chilled at 4°C for 10 minutes. Injection of blastocysts was performed using
vacuum pressure to immobilise the blastocyst on a rounded holding pipette (20 pm
internal diameter). ES cells were then individually collected by vacuum pressure onto a
heat-polished, flat-ended injection pipette (15 pm internal diameter). Between 15 and 20
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ES cells were injected into each blastocyst. The procedure was visualised with an IMT2
image-corrected microscope (Olympus Optical Company (UK) Ltd, London, UK).
Injection and holding pipettes were manufactured in-house by stretching lOO^m internal
diameter glass capillary tubes with an electrode puller (Camden Instruments,
Loughborough, UK) followed by heat polishing with a microforge (DeLonbrune;
Supplied by Micro Instruments Ltd., Witney, UK). The pipettes were attached to
instrument holders and manoeuvred with precision manipulators (both produced by
Ernst Leitz, Wetzlar, Germany). Vacuum pressure was adjusted by means of injectors
(Narashige International Ltd., London, UK for the holding pipette; DeLonbrune for the
injection pipette) connected via paraffin-filled plastic tubes to the pipettes.
Lollowing injection, blastocysts were transferred to pre-warmed ES cell media
and incubated at 37°C for 2-3 hours prior to implantation in pseudo-pregnant ML1 mice.
The recipient females were mated with vasectomised ML1 males 2.5 days prior to
implantation and successful coitus was confirmed by the presence of 'plugging'. Live to
ten blastocysts were typically implanted in the uterine horn of each recipient mouse.
Chimaeric pups derived from this procedure were identified by the presence of sandy-
coloured patches amidst the normally black fur. Germline transmission of targeted ES
cell DNA was assessed by the coat colour of pups produced by the cross of chimaeric
mice with BKW mice. Black pups will have inherited a full complement of C57B1/6
chromosomes derived from the parent blastocyst and, hence, will not carry the targeted
mutation. In contrast, sandy coloured pups will have inherited a complement of
chromosomes derived from 129/SV ES cells and have, therefore, a 1 in 2 chance of
carrying the targeted mutation. PCR screening and sequencing of tail tip DNA was used
to confirm germline transmission. Heterozygous mice were then inter-crossed to produce
offspring homozygous for the targeted mutation.
2.1.13.10 Preparation ofgenomic DNA from tail biopsy
Tail tip biopsy was performed under either general (Halothane-Vet, Merial Animal
Health Ltd., Harlow, UK; Product number H3006/2) or local (ethyl chloride B.P. spray,
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Roche, Welwyn Garden City, UK) anaesthesia in weaned pups up to 28 days old. A 1
cm length of tail was cut and stored at -20°C until DNA extraction. Mice were ear-
tagged as appropriate. Tail biopsies were minced with scissors in 600 pi of tail buffer
(200 mM Tris HC1 pH 8.0, 400 mM EDTA, 4.0M NaCl and 10% (v/v) SDS) and 35 pi
of 10 mg/ml Proteinase K. Tails were then rotated continuously overnight at 55°C in a
Techne Hybridiser HB-1D oven (Techne (Cambridge) Ltd, Cambridge, UK). The
following day, 20 pi of 20 pg/ml DNase-free RNase (Sigma-Aldritch, Steinheim,
Germany) was added and tails incubated for 60 minutes at 37°C. Six hundred pi of Tris-
saturated phenol and 37.5 pi of 2 M mercaptoethanol were added to each tube. Tubes
were rotated on a vertical rotor (horizontal axis of rotation) for 15 minutes, followed by
centrifugation at 12,000 x g for 5 minutes. The aqueous phase and interphase were
transferred to a fresh Eppendorf tube and extracted with 1 volume of
phcnol:chloroform:isoamyl alcohol (25:24:1), followed by 1 volume of
chloroforrmisoamyl alcohol (24:1). DNA was precipitated from the aqueous phase with
600 pi of room temperature isopropanol by gentle rotation for 5 minutes. The stringy
genomic DNA precipitate was pelleted by centrifugation (12,000 x g, 2 minutes) and
washed in 200 pi of 70% ethanol. DNA was air dried for 10 minutes then dissolved in
200 pi of TE, pH 8.0. Samples were then left to dissolve completely for 30 minutes at
37°C before being mixed gently and stored at -20°C until required.
2.1.13.11 Polymerase chain reaction ofgenomic DNA
Approximately 1 pg of genomic tail tip DNA was used for PCR screening of floxed ETB
receptor mice. Reactions were performed in a total volume of 25 pi containing 500pM
of each deoxyribonucleotide, 300nM of each primer, 1 pg of genomic DNA, 2.5 pi of 10
x Expand™ Buffer number 3 (22.5mM MgCl2, detergents, pH 9.2, Roche
Pharmaceuticals) and 1.875 units of Genecraft Biotherm™ Taq polymerase. Samples
were amplified using a MJ Research Peltier Thermal Cycler PT-200 with a heated lid
with the following protocol: initial denaturation at 92°C for 5 minutes followed by 30
cycles of 92°C for 30 seconds, 60°C for 30 seconds and 68°C for 2 minutes. A final
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extension period of 10 minutes at 68°C completed the reaction. Reaction mixtures were
mixed with 2 pi of 6 x loading dye and 18 pi of this mixture was then run on a 2%
agarose gel stained with ethidium bromide.
2.1.14 PHYSIOLOGICAL TECHNIQUES
2.1.15 WIRE MYOGRAPHY
The isometric tension developed in mouse aortic rings in response to agonists was
measured using the technique of wire myography as originally described by Mulvany
(Mulvany and Halpern, 1976) and according to their later modifications of this technique
(Mulvany et ai, 1978).
2.1.15.1 Dissection of the mouse aorta and trachea
Mice were culled by inhalation of increasing concentrations of C02 and immediately
transported to the laboratory for dissection of the aorta and trachea. The trachea was
exposed and cut at the level of the larynx and 8-9 tracheal rings removed. The excised
trachea was covered with ice-cold physiological saline solution (PSS; 119mM NaCl,
4.7mM KC1, 2.5mM CaCl2, 1.17mM MgS04, 25mM NaHC03, 1.18mM KH2P04, 0.027
EDTA and 5.5mM Glucose) and dissected free of connective tissue. The trachea was
bisected and the two segments mounted individually onto the wire myograph as
described in section 2.1.15.2. The thoracic aorta was carefully dissected off the posterior
thoracic wall and removed along with the heart and lungs. The heart was removed and
weighed. The aorta was then cleaned of connective tissue and divided at the junction of
the thoracic aorta and the aortic arch. Proximal and distal aortic rings (-2 mm each)
were mounted on the wire myograph as described in section 2.1.15.2.
2.1.15.2 Mounting ofaortic and tracheal rings
The mounting procedure is illustrated in Figure 2.11. Briefly, vessel rings were
suspended between two intra-luminal mounting wires (40 pm diameter, ~2.2 cm in
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length) in a 10 ml myograph organ bath (Multi-myograph model 610M; JP Trading,
Aarhus, Denmark). One wire was attached to the stationary support driven by a
micrometer whilst the second wire was attached to an isometric force transducer. Care
was taken not to damage the endothelium during the mounting procedure. Vessels were
bathed in PSS at 37°C and, following a 10 minute equilibration period, vessel
dimensions were normalised as previously described (Mulvany et al., 1978). Previous
studies in our laboratory had determined that a tension of 1.5 g (7.36 mN) was required
for aortic rings and 0.5 g (2.45 mN) for tracheal rings. Periodic adjustments were made
to maintain this tension over the subsequent 60 minute equilibration period. This tension
was defined as zero for all following measurements. 95%/5% 02/C02 was bubbled
through the solution of PSS at all times during the experiment. Signals from the
myograph were processed by a MacLab/4e analogue-digital converter and displayed
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Figure 2.11
Mounting of vascular and tracheal rings upon the wire myograph.
2.1.15.3 Aortic and Tracheal wake up protocol
Following equilibration, aortic and tracheal rings were contracted three times to obtain
the maximum contraction to KPSS solution (123.7mmol KC1, 2.5mmol CaCl2.2H20,
1.17mmol MgS04.7H20, 25mmol NaHC03, 1.18mmol KH2P04, 0.027mmol EDTA,
5.5mmol Glucose). A 10 minute wash with PSS was performed prior to each treatment
with KPSS. Rings were then given a final wash with PSS solution and allowed return to
baseline over a 10 minute period prior to further experiments. The complete
experimental protocols are illustrated in Figure 7.1, Figure 7.2, Figure 7.3 and Figure
7.4.
2.1.15.4 Preparation ofstock solutions
Stock solutions of 102M carbachol (Sigma-Aldritch, Steinheim, Germany; product
number C-4382), ACh (102M; Sigma-Aldritch, Steinheim, Germany; product number
A7000) and 2,2'-(hydroxynitrosohydrazono)bis-ethanimine (a diazeniumdiolate,
henceforth referred to as deta/NO); 102M; Sigma-Aldritch, Steinheim, Germany;
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product number D-185) were each prepared in dH20. Stock solutions of 10"4M S6c
(Calbiochem, La Jolla, USA; product number 05-23-3813) were prepared in 5% acetic
acid and diluted with PSS containing lOmg/ml of BSA. A192621 (2R, 3R, 4S)-2-(4-
propoxy-phenyl)-4-( 1,3-benzodioxol-5-yl)-1 -(N-[(2,6-diethylphenyl |ace-
tamido)pyrrolidine-3-carboxylate, nitrogen; 10 4M; Abbott Pharmaceuticals) and L-
NAME (Nw-nitro-L-arginine methyl ester hydrochloride; 104M; Sigma-Aldritch,
Steinheim, Germany; product number N5751) were dissolved in DMSO. NE (10~2M;
Sigma-Aldritch, Steinheim, Germany; product number A-0937) was dissolved in 0.1 M
ascorbic acid.
2.1.16 BLOOD PRESSURE MEASUREMENT IN CONSCIOUS ANIMALS
Mean blood pressure was measured by direct cannulation of the right common carotid
artery in adult mice (8-12 weeks old) as previously described (Davisson et al., 1998).
Cannulae were produced by flaming and stretching the tip of a section of Micro
Renathane tubing (internal diameter = 12 pm; Braintree Laboratories Inc., Braintree,
Massachusetts, USA; Product number MRE025). Animals were anaesthetised by
continuous inhalation of isoflurane and body temperature maintained throughout with a
heating pad. The common carotid was exposed via a mid-line incision and ligated
distally. With the proximal end held under tension, the cannula was inserted and secured
in place with a further silk suture. The cannula was then tunnelled beneath the skin to
emerge in the intra-scapular region where it was secured with Germolene Newskin™
tissue adhesive. After flushing with heparinised saline (100 lU/ml), the cannula was
plugged with a blunted 26G needle filled with paraffin wax. Carotid cannulation and
measurement of blood pressure following high salt diet was performed by Dr Nick
Kelland (University of Edinburgh, Edinburgh, UK).
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2.1.17.1 Isolation ofpulmonary endothelial cell-enriched populations from murine
lung tissue
Pulmonary endothelial cell-enriched populations were isolated using the general
approach described by Dong (Dong et al., 1997). Briefly, 150 mg of pulmonary tissue
were removed from freshly culled 8-10 week old mice and minced into -1mm particles.
The tissue was then digested for 60 minutes in 1ml of HEPES-Ringer buffer (118mM
NaCl, 17mM Hepes, 16mM Na Hepes, 14mM Glucose, 3.2mM KC1, 2.5mM CaCl2,
1.8mM MgS04, 1.8mM KH2P04; pH 7.4; 285 mosm) containing lmg/ml of Collagenase
A (Boehringer Mannheim, Germany). Digested tissue was then and forced through a 100
pm Falcon Strainer filter using a 'cut off' blue pipette tip and the resultant suspension
was washed twice with PBS and re-suspended in 1 ml of PBS.
2.1.17.2 Preparation ofBiotinylated Griffonia simplicifolia isolectin B4 (GSLI-B4)-
coated magnetic beads
GSL I-B4 (Vector Laboratories, Peterborough, UK; product number B-1205) was bound
to streptavidin-coated Dynabeads (CELLection™ Biotin Binder Kit, Dynal Ltd.,
Bromborough, UK; product number 115.21) according to the manufacturer's
instructions. Briefly, 100 pi of Dynabeads (-4 x 107 beads) were washed with 1 ml of
PBS with 0.1% tween and resuspended in 100 pi of this buffer. Eight pg of GSL I-B4
were added and the mixture incubated at room temperature for 30 minutes. The beads
were recovered with a magnetic particle concentrator, washed 3 times with 1 ml of PBS
and 0.1 % tween and resuspended in a final volume of 100 pi.
2.1.18 ANALYSIS OF RESULTS
Blood pressure on standard and higher salt chow was compared by 2 factor ANOVA
with Bonferroni post-test analysis. Pulmonary EC 125I ET-1 binding was analysed using
an unpaired student's t test. Concentration response curves were analysed by 2 factor
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ANOVA. EG* and EMax values, S6c-induced vasodilatation and plasma ET-1
concentration were each compared by repeated measures ANOVA with Dunnett's
multiple comparison post-test analysis. P-values quoted in the text were accepted as




3.1 IDENTIFICATION, CLONING AND PARTIAL SEQUENCING OF PXP
3.1.1 INTRODUCTION
Manipulation of the mammalian genome has been achieved through the technique of
gene targeting. This process involves the homologous recombination of exogenous DNA
sequences with chromosomal DNA. In order to maximise the efficiency of homologous
recombination, the homology arms of the replacement-type targeting construct are
designed to be isogenic to the locus of interest. Homology arms may be produced by
PCR or by the cloning of fragments of isogenic genomic DNA from phage display
libraries. This chapter describes the identification of a bacteriophage clone, XP, from a
129/SV mouse genomic DNA library constructed using the XPS vector (Nehls et al.,
1994). XP contains a 14748 bp region of the mouse ETB receptor gene spanning from the
last 12104 bp of intron one to 54 bp after the start of exon 5. XP was converted by
automatic subcloning to the plasmid pXP from which the 5' and 3' homology arms of the
targeting vectors pXPW and pXPW(NoDT) were constructed. In addition, the
amplification by PCR of regions of the mouse ETB receptor gene using a genomic DNA
template is described. These PCR products were used to sequence intronic regions of the
ETb receptor gene for the first time. Although not available at the start of the cloning
experiments, the complete sequence of the mouse ETB receptor gene (27.02 kb) has now
been published as part of the mouse genome sequencing project (Ensembl gene
reference number: ENSMUSG00000022122).
3.1.2 METHODS
3.1.2.1 PCR amplification of the mouse ETB receptor gene
129/SV genomic tail tip DNA was provided by Dr Matthew Sharp (University of
Edinburgh, Edinburgh, UK) and used as a template for the amplification of short regions
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of the ETb receptor locus by PCR. Primers were designed complementary to sequences
of the mouse ETB receptor cDNA (PubMed accession number NM 007904 (Hosoda et
al., 1994) using Gene Con Kit™ software. Regions of the ETB receptor locus
complementary to the primers used are illustrated in Figure 2.1, Figure 2.2 and Figure
2.3. PCR was performed using the Expand™ Fong Template PCR system (500pM of
each deoxyribonucleotide, 300nM of each primer, 1 pg of genomic DNA, 2.5 pi of 10 x
Expand™ Buffer number 3 (22.5mM MgCh, detergents, pH 9.2) and 1.875 units of
Genecraft Biotherm™ Taq polymerase) in a final volume of 25 pi. Amplification was
achieved using the following cycling parameters: 92°C for 2 minutes, 35 cycles of 92°C
for 30 seconds, 50°C for 30 seconds and 68°C for 3 minutes, followed by a final
extension period of 15 minutes at 68°C.
3.1.2.2 Cloning ofPCR products
The Expand™ PCR system generates PCR fragments with mainly 3' single A
overhangs. Cloning of PCR products into a pCR2.1® vector (Figure 2.5) was achieved
using the TA cloning® kit as described in section 2.1.11.13. Successful cloning results
in PCR products flanked by EcoR I sites. Plasmid DNA isolated from overnight cultures
of XLI Blue E. coli was screened for the fragment of interest by restriction digestion
with EcoR I.
3.1.2.3 Construction ofa 129/SV mouse genomic DNA library
The 129/SV mouse genomic DNA library was a kind gift of Dr Andrew Smith
(University of Edinburgh, Edinburgh, UK). The library was constructed by partial
Sau3Al digestion of high molecular weight genomic DNA isolated from 129/SV-derived
ES cells. Fragments between 18-22 kb in length were selected by sucrose gradient
centrifugation and then cloned into a XPS vector as described by Nehls and colleagues
(Nehls et al., 1994). The 7.PS vector features an automatic subcloning facility based
upon Cre-recombinase-loxP-mediated recombination. The plasmid portion of XPS is
flanked by direct repeats of loxP sites. In the presence of Cre recombinase, a site-
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specific recombination reaction is catalysed, resulting in the conversion of the phage
form of the vector to a plasmid. Recombination reactions may be initiated by
transforming Cre recombinase expressing BNN132 cells with XPS vectors (Elledge et
al„ 1991).
3.1.2.4 Probes utilized for screening of the APS 129/SV genomic DNA library
In-situ hybridisation using 32P-labelled DNA probes was utilised to identify XPS clones
containing regions of the ETB receptor gene as described in section 2.1.12.4. Two probes
were used for this purpose. The first probe was complementary to exon 1 of the ETB
receptor gene and was produced by PCR amplification of 129/SV mouse genomic DNA
using the primers Exon 1 149F (TCCAGACTGAAAACAGCAGAGCGG) and Exon 1
671R (GGGTATGTCTATGATGATGTGC; illustrated in Figure 2.2). PCR was
performed using the Expand™ PCR system and the following parameters: 92°C for 2
minutes, 30 cycles of 92°C for 30 seconds, 62°C for 30 seconds and 68°C for 2 minutes,
followed by a final extension period of 10 minutes at 68°C. A Mg2+ concentration of 1.7
mM was found to be optimal. Contaminating dNTPs and primers were separated from
the 522 bp PCR product as described in section 2.1.11.7. The second probe, a fragment
of the mouse ETB receptor gene cDNA (Hosoda et al., 1994) spanning from position 563
to 1363, was a kind gift of Dr Paula Smith (University of Edinburgh, Edinburgh, UK).
Probes were labelled with 32dCTP as described in section 2.1.11.17 and the library
screened as described in section 2.1.12.
3.1.2.5 Primary and secondary screening ofAPS 129/SV genomic DNA library
The primary library screen was performed by simultaneous hybridisation with both
radiolabeled probes. Multiple agar plugs from the regions corresponding to strong
hybridisation signals were picked as described in section 2.1.12.3 for each of the clones
identified. Serial dilutions of each clone were prepared and plated out as previously
described. Bacteriophage particles from each plate were then transferred in duplicate to
nitrocellulose membranes and a secondary screen performed. For the secondary screen,
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duplicate membranes were individually incubated with either the radiolabeled Exon 1
probe or the ETB cDNA probe to identify the particular regions of the ETB receptor gene
contained within the APS vector. This process was repeated until all colonies derived
from a single agar plug produced positive hybridisation signals with the appropriate
probe, thus indicating that a pure clonal population had been isolated
3.1.2.6 Subcloning ofXP into pXP
The phage vector AP was converted to the plasmid pAP by the automatic subcloning
technique described by Nehls (Nehls et al., 1994) and outlined in section 2.1.12.5.
Plasmids isolated using this technique were subsequently electroporated into the XL I
Blue strain of E. coli that lacks Cre-recombinase expression.
3.1.2.7 Sequencing and mapping ofpXP
The plasmid pAP (illustrated in Figure 2.9) was mapped by direct sequencing and
restriction digestion. All sequencing reactions were performed as described in section
2.1.11.4. The primers M13-20 (GTAAAACGACGGCCAGT) and M13R
(AACAGCTATGACCATG), complementary to regions of the pBluescript™ vector
flanking the polylinker site (illustrated in Figure 2.5), were used to sequence the 3' and
5' regions of pAP, respectively, and to determine insert orientation. Intronic regions were
sequenced with the primers 81R (CTTAGAGCACAAAGACTCAGCAC), 78F
(TTTGGGTGGTCTCTGTGGTTCTGG), and 417R
(GTAGAAACTGAACAGCCACCAATC). The regions complementary to all
sequencing primers are illustrated in Figure 2.1, Figure 2.2 and Figure 2.3. Sequence
data were compared to the available published ETB receptor gene sequences using




3.1.3.1 PCR amplification ofgenomic DNA
Exons and intronic regions of the ETB receptor locus were amplified by PCR from a
129/SV mouse genomic template. The results are illustrated in Figure 3.1. The entire









PCR amplification of regions within the ETB receptor locus from a genomic DNA
template. Lane 1, 78F/417R (exon 3 - exon 4); Lane 2, 78F/359R (exon 3 - exon 6);
Lane 3, 81F/412R (exon 2 - exon 3); Lane 4, 81F/417R (exon 2 - exon 4); Lane 5,
81F/359R (exon 2 - exon 6); Lane 6, 32F/359R (exon 5 - exon 6); Lane 7, XIEco
Rl/Hind III. PCR products were later subcloned into the pCR2.1 plasmid vector.
3.1.3.2 TA cloning® ofPCR products
The results of EcoR I restriction digestion of plasmid DNA following TA cloning® of
PCR products amplified from genomic DNA are illustrated in Figure 3.2. Successful
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cloning of cells electroporated with the 81F/359R PCR product (upper panel) resulted in
2 additional bands (lane 2). The sum of the sizes of the 2 addition bands was similar to
the size of the original PCR product, suggesting that this region contains an internal
EcoR I site. Cells electroporated with the 32F/359R PCR product (lower panel)
produced a single additional band (lane 2) of ~1.2 kb, consistent with successful cloning
of this gene fragment. No plasmids containing the 78F/417R PCR product were










Restriction digestion of pCR2.1 plasmid DNA with Eco Rl following TA cloning of
PCR products amplified using the primers 81F/359R (above) and 32F/359 (below).
Along with the 3.9 kb vector, lane 2 in each case demonstrates additional bands of the










Plasmids featuring the 81F/359 PCR product insert were termed pCR2-6 and insert
orientation was determined by restriction digestion with Bam M, illustrated in Figure
3.3. Plasmids pCR2-6.2 and pCR2-6.20 (lanes 3 and 5 respectively) demonstrate an
insert orientation opposite to that of pCR2-6.18 (lane 4). Insert orientation was
confirmed by direct sequencing of pCR2-6.2 and pCR2-6.18 with the primers Ml3-20
and M13R, complementary to regions of the pCR2.1 vector polylinker. In the plasmid
pCR2-6.18, exon 2 of the ETB receptor gene lay immediately 3' of the BamH I site of the
plasmid polylinker. Detailed sequencing of pCR2-6.18 was performed with the primers
78F, 412R (CAGAACCACAGAGACCACCCAAAT) and 417R. pCR5-6 (lane 2) was
sequenced using the primers Ml3-20, M13R, 32F and 359R. Alignment of these
sequencing data permitted the formation of a contiguous sequence of the mouse ETB
receptor gene spanning from exon 2 to exon 6. Sequence data obtained by this method
were compared with the available published ETB receptor gene sequences and found to









The insert orientation of ligated 81F/359R PCR products within the PCR2.1 plasmid was
determined by Bam HI digestion. PCR2-6.18 (lane 4) demonstrates an insert orientation
opposite to that of pCR2-6.2 and pCR2-6.20 (lanes 3 and 5, respectively). Lane 2
demonstrates a band of ~1200 bp following Eco Rl digestion, consistent with successful
cloning of the 32F/359R PCR product into the PCR2.1 plasmid. Lane 1 ElEco RllHind
III DNA.
3.1.3.3 Primary and secondary screens ofEPS phage library
An initial screen of the library identified 3 clones, XP, XH and XI, each of which
produced a positive hybridisation signal when simultaneously incubated with the Exon 1
and ETb cDNA probes. In the secondary screen, XP produced positive hybridisation
signals only with the ETB cDNA probe, suggesting that this phage did not contain any
sequences originating in exon 1. In contrast, XH and XI produced positive hybridisation
signals only with the Exon 1 probe and were unlikely, therefore, to contain any further
exons of the ETB receptor gene. Representative autoradiographs of the library screening









Upper panel: Autoradiograph of primary screen of APS phage library by hybridisation
with probes complementary to exon 1 of the ETB receptor gene and to a fragment of the
ETB receptor cDNA. The circled colony P was selected and serially diluted until a pure
clonal population was achieved. Hybridisation of the ETB receptor cDNA probe to all




Sequenced regions of pAP were isogenic with available publishes sequences. The 3'
region of p^P terminated at a BamH I site 54 bp downstream of the start of exon 5,
consistent with the method used to construct the APS library. In addition, the presence of
intronic restriction sites predicted from pCR.2-6.18 sequencing data and available
published data were confirmed by analytical restriction digestion of pAP (data not
shown). pAP plasmid DNA was used as a template for PCR amplification using the
primer pairs and reaction conditions utilised for genomic templates. With the exception
of primer pairs complementary to sequences within exon 1, all primer pairs successfully
directed amplification of the appropriate regions, producing PCR products of identical
size to those seen with a genomic DNA template. Examples of sequence alignment




580 590 600 610 620 630 640 650
I I I I I I I I
AATTTGGGTGGTCTCTGTGGTTCTGGCTGTCCCCGAAGCCATAGGTTTT GATATGATTACGTCGGACTACAAAGGAAAGCCC
AATTTGGGTGGTCTCTGTGGTTCTGGCTGTCCCCGAAGCCATAGGTTTT GATATGATTACGTCGGACTACAAAGGAAAGCCC
I I I I I I I I
210 220 230 240 250 260 270 280
660 670 680 690 700 710 720 730
I I I I I I I I
CTAAGGGTCTGCATGCTTAATCCCTTTCAGAAAACAGCCTT CATGCAGGTACGTTCACTTTGCTTGTTCTTTCTGCACTTTC
CTAAGGGTCTGCATGCTTAATCCCTTTCAGAAAACAGCCTTCATGCAGGTACGTTCACTTTGCTT GTTCTTTCTGCACTTT C
I I I I I I I I
290 300 310 320 330 340 350 360
740 750 760 770 780 790 800 810 820
I I I I I I I I I
CTTATAAATATTTCACTATTTCCCCCAGTTCCCCACCTTGGTAGGCTATTGATTTATTACTACCTTTGGCATAAATTAAGAG
CTTATAAATATTTCACTATTTCCCCCAGTTCCCCACCTTGGTAGGCTATTGATTTATTACTACCTTTGGCATAAATTAAGAG
I I I I I I I I I
370 380 390 400 410 420 430 440 450
830 840 850 860 870 880 890 900
I I I I I I I I
TTTGGATCCCAAGACTGTGAGGTTAACCATCACTAATGACCCAACCTGCAAGAGTCAGGATAATTACTTCTCCAAGAACACC
••••••••• • •• • • • • • •• • • | •• • • *|
TTTGGATCCTAGTTCTAGAATAACTTCGTATAATGTATGCTAT ACGAAGTTATCCCCTATGCCTAGANCGGCCGCCACCGCN
I I I I I I I I
460 470 480 490 500 510 520 530
910 920 930 940 950
I 1 I I I
CTGGGGATCCAGATAAATCAAGTTCCTGCAAGAATGGCTGTGACTTTATGGCTTTT
••• | •••• • • • • • • • ••• • • •••
GTGGANCTCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCT
I I I I I I I I





Sequence alignment of pAP sequenced with the 81F primer (top) with the published ETB
receptor sequence from exon 2 to the first 254 bp of intron 3 (bottom).
102
Chapter 3






I I I I I I I I
10 20 30 40 50 60 70 80
20 30 40 50 60 70 80 90
I I I I I I I I
AAGTGCCAGTAAGCCACTGGGGCATTGGCCTTTCTGAGGAGAGCCTGATTGTGCCACTGTCTGCACATAAAAAAAAAATCTC
AAGNGCCAGTAAGCCACTGGGGCATTGGCCTTTCTGAGGAGAGCCTGATTGNGCCACTGTCTGCACATAAAAAAAAAATCTC
I I I I I I I I
90 100 110 120 130 140 150 160
100 110 120 130 140 150 160 170
I I I I I I I I
ATAAACCAGCTGCACTTGTGTTACTTCCAGTGTGTTCTATATTGGACACAGGTGCCTTTTCAAAGGGCAGTT CTTCCTTCCC
ataaaccagctgcacttgtgttacttncagtgtgttctatattggacacaggngccttttcaaagggcagttcttccttccc
I I I I I I I I
170 180 190 200 210 220 230 240
180 190 200 210 220 230 240 250




I I I I I I I I
250 260 270 280 290 300 310 320
260 270 280 290 300 310 320 330 340
I I I I I I I I I
TCGCAGAGGACTGGCCATTTGGAGCTGAGATGTGTAAGCTGGTGCCCTTCATACAGAAGGCTTCTGTGGGAATCACAGTGCT
TCGCAGAGGACTGGCCATTTGGAGCTGAGATGTGTAAGCTGGTGCCCTTCATACAGAAGGNTTCTGTGGGAATCACAGTGCT
I I I I I I I I I
330 340 350 360 370 380 390 400 410
350 360 370 380 390 400 410 420
I I I I I I I I
GAGTCTTTGTGCTCTAAGTATTGACAGGTAAGAGTCTATTCTCAGGCCAAGGCGATCCTAATCCAACATACAACTGTTATGT
GAGTCTTTGTGCTNTAAGTATTGACAGGTAAGAGTCTATTCTCAGGCCAAGGCGATCCTAATCCAACATACAACTGTTATGT
I I I I I I I I
420 430 440 450 460 470 480 490
430 440 450 460 470 480 490 500
I I I I I I I I
CACTTAGGAGATAAACTTTGCAATT CAATACAACCAAGCT CTACCTGCTAGACAAATCATTCTGTTTATATCTTCAGATATC
CACTTAGGAGATAAACTTTGCAATTCAATACAACCAAGCTCTACCTGCTAGACAAATCATTCTGTTTATATCTTCAGATATC
I I I I I I I I
500 510 520 530 540 550 560 570
Figure 3.6
Sequence alignment of pXP sequenced with the 412R primer (bottom) with published
ETb receptor sequences spanning from the final 254 bp of intron 1 to intron 3 (top).
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pLPM13Rftop1 r Intron If bottom")
10 20 30 40 50 60 70 80
I I I I I I I I
CTCCTAAGGGAACAAAAGCTGGTACCGGGCCCCCCCTCGAAGGATCTCTGATTTTCCTAGACATTTGTCACCAGCACTTTAT
GATCTCTGATTTTCCTAGACATTTGTCACCAGCACTTTAT
I I I I
10 20 30 40
90 100 110 120 130 140 150 160
I I I I I I I I
TTAATTTGTCACTGCAAAGTCAGAGTTTTATTCAGTCGTAGAAATTTTCCACAGCCTTGTGAATAGATGAAACAGGTTCCCA
TTAATTTGTCACTGCAAAGTCAGAGTTTTATTCAGTCGTAGAAATTTTCCACAGCCTTGTGAATAGATGAAACAGGTTCCCA
I I I I I I I I
50 60 70 80 90 100 110 120
170 180 190 200 210 220 230 240
I I I I I I I I
GAGCCTCTGCTTTACACAACTATGAATGTCGATGTfTTGTTGGGATCTACTTAAGCGCTCTCCTGAGACACTAGTTGATATC
GAGCCTCTGCTTTACACAACTATGAATGTCGATGTCTTGTTGGGATCTACTTAAGCGCTCTCCTGAGACACTAGTTGATATC
I I I I I I I I
130 140 150 160 170 180 190 200
250 260 270 280 290 300 310 320
I I I I I I I I
ATTTCTGGCCACATATTTCTAGCTCACACATAGCTTAATGTTTAAGTGACTATTGTACTTTGATTGATGATAAAGACATATA
ATTTCTGGCCACATATTTCTAGCTCACACATAGCTTAATGTTTAAGTGACTATTGTACTTTGATTGATGATAAAGACATATA
I I I I I I I I
210 220 230 240 250 260 270 280
330 340 350 360 370 380 390 400 410
I I I I I I I I I
ATTTATGTTTGTCCCTGAGGACATATATACCATATTTTTTTTAAATGATACTATGGACTTAACCAGGAGCATAACATAAGTT
ATTTATGTTTGTCCCTGAGGACATATATACCATATTTTTTTTAAATGATACTATGGACTTAACCAGGAGCATAACATAAGTT
I I I I I I I I
290 300 310 320 330 340 350 360
420 430 440 450 460 470 480 490
I I I I I I I I
CTCTCAATGTATAAATAAGAGCAATTCGGACACAGAAGTTCTGAATGAGACTAACCTATCTTGNTAAAATGGNAGTTTAAAA
••••••••••••••••••••••••••••••••••••••••a • • • • |• ••• *| •• •••
CTCTCAATGTATAAATAAGAGCAATTCGGACACAGAAGTTCCTGAATGAGACTAACCTATCTTGTTAAAATGGTAGTTTAAA
I I I I I I I I I
370 380 390 400 410 420 430 440 A
500 510 520 530 540 550 560 570
I I I I I I I I
CTCCCCCACCAAAATAAAACTTATCTGCTACAGGAAACTGAGATTAAAGAAAAAAAAAGACTATTTNCTTTCCTAATGGTTG
• ••• • ••• ••• • • •• • • • •••••••• •• | • •• • • •••
ACTCCCCCACCAAAATAAAACTTATCTGCTACAGGAAACTGAGATTAAAGAAAAAAAAAGACTATTTCCTTTCCTAATGTTT
Figure 3.7
Sequence alignment of the 5' end of pXP sequenced with the M13R primer (bottom)





The successful PCR amplification of the ETB receptor gene region spanning from exon 2
to exon 6 from genomic DNA permitted detailed sequencing of intronic regions of the
mouse ETb receptor gene for the first time. Interrogation of this sequence data were
utilised to predict the presence of restriction sites within this region and to formulate a
cloning strategy for the production of targeting vectors as described in chapter 4.
However, it was not possible to amplify intron 1 in its entirety (19493 bp), despite the
use of the Expand™ Long Template PCR system. This system has previously been
shown to amplify fragments of up to 22 kb from human genomic DNA (Cheng et al.,
1994) with a low error frequency. Failure to amplify this region and the potential for the
introduction of significant mutations during PCR amplification, prompted the adoption
of a cloning strategy based upon the use of fragments of the ETB receptor gene isolated
from a APS phage genomic DNA library.
The APS phage library was constructed from 129/SV genomic DNA isogenic to
the ES cells utilised for subsequent targeting experiments. This has been shown to
increase the efficiency of targeting events (te Riele et al., 1992). Traditionally, the
characterisation of DNA clones isolated from such phage display libraries involved the
subcloning of insert fragments into plasmid vectors. This process is often time
consuming and of limited efficiency. The use of phage vectors featuring automatic
plasmid excision greatly simplifies the mapping of genomic DNA inserts and the
subsequent construction of targeting vectors. APS libraries prepared by cloning size-
selected partially Sa«3AI-digested genomic DNA typically feature inserts of between 15
kb and 19 kb (Nehls et al., 1994). It was predicted, therefore, that inserts would
encompass a significant portion of the ETB receptor gene locus. In addition, the
relatively large insert size permitted the design of constructs with large regions of
isogenic DNA flanking the genetic marker. Thus, it was possible to generate a targeting





4.1 DESIGN AND CONSTRUCTION OF THE TARGETING VECTORS
PXPW AND PXPW(NODT)
4.1.1 INTRODUCTION
The advent of techniques to introduce site-specific modifications into the genome by
homologous recombination (gene targeting) has revolutionised the field of mouse
genetics and the study of in vivo gene function. This chapter will describe the design and
construction of two gene targeting vectors, pXPW and pXPW(NoDT). These 'tri-lox'
replacement targeting vectors were designed to introduce loxP sites into the intronic
regions flanking exons 2 and 3 of the ETB receptor gene locus. A removable selection
marker was included in each vector to permit selective propagation of targeted ES cell
clones. Following clone selection, this marker was removed from the targeted locus to
prevent possible interference with gene expression (reviewed by (Muller, 1999). To
maximise the efficiency of homologous recombination events, vectors were designed
with long regions of homology flanking the targeted locus and, with the exception of a
short PCR-generated fragment spanning exons 2 and 3, all genomic regions of the
vectors were constructed from isogenic fragments of the ETb receptor gene subcloned
from the plasmid pXP. The addition of a diphtheria toxin gene to the extreme 3' end of
pAPW was further intended to reduce the number of clones featuring random integration
of the targeting vector (Yagi et al., 1990). Such events would result in the stable
integration and transcription of the diphtheria toxin gene and consequent cell death. In
contrast, during homologous recombination the non-homologous diphtheria toxin gene
would be excised, thereby permitting cell survival.
4.1.1.1 Structure of targeting vectors
The targeting vectors each consisted of a 5' homology arm comprising ~11.9 kb of the
3' region of intron 1, loxP sites flanking exons 2 and 3, and a neomycin
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resistance/thymidine kinase selection cassette flanked by a third loxP site. The 3'
homology arm consisted of intron 3, exon 4, intron 4 and either the first 54 bp of exon 5
(for pXPW(NoDT) or a diphtheria toxin gene cassette (for pXPW). Briefly, the targeting
vectors were constructed by the following steps (illustrated in Figures 4.1-4.7): Firstly,
PCR directed amplification of a 956 bp region of the ETB receptor gene spanning from
intron 1 to intron 3 was performed. A BamR I site was incorporated into the 5' end of
the PCR product to facilitate cloning into the LoxP2ROSA targeting vector. The LTNL
selection cassette was then sub-cloned downstream of the PCR product. The 3'
homology arm of pXPW(NoDT) consisted of the Hpa I-Not I fragment of pXP, spanning
from intron 3 to first 54 bp of exon 5. In pXPW, the Hpa \-Not I fragment was cut with
ZfaeRI to remove part of intron 4 and exon 5. This region was replaced with a Diphtheria
toxin gene cassette. The 3' homology arm of each construct was then sub-cloned
downstream of the LTNL selection cassette. The 5' homology arm was prepared by the
addition of a Xho I site to the 5' end of pXP and subsequent subcloning of the ~11.9 kb
Xho I-Nae I fragment of pXP into the 5' LoxP2 ROSA polylinker region.
4.1.2 METHODS
4.1.2.1 PCR amplification ofexons 2 and 3 of the ETB receptor gene
The region comprising the final 288 bp of intron 1 to the first 155 bp of intron 3 was
amplified by PCR using the primers M230F
(TCCGGATCCAGAGGGTCATGACCCAC) and 584R
(TCACTAGTGATGGTTAACCTCACAG; illustrated in Figure 2.1). This region
encompasses exons 2 and 3 of the ETB receptor gene, essential for the production of
functional ETb receptors during embryonic development and adult life. PCR was,
therefore, performed using high fidelity proof-reading Pfu DNA polymerase enzyme to
minimise the potential for the introduction of mutations. Twenty pg of pXP template
DNA were amplified using 1.25 units of Pfu DNA polymerase, 0.5 pM of each primer,
200 pM dNTPs and 1 x Pfu DNA polymerase buffer (20mM Tris-HCl (pH 8.8), 10mM
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KC1, lOmM (NH4)2S04, 2.0mM MgS04, 0.1 mg/ml nuclease-free BSA and 0.1%
Triton® X-100) in a final volume of 50 pi. Reactions were performed with the following
cycling parameters: denaturation at 94°C for 5 minutes followed by 30 cycles of 94°C
for 45 seconds, 60°C for 45 seconds and 72°C for 2 minutes. A final extension was
performed at 72°C for 10 minutes before cooling to 4°C. A 5 pi aliquot of the reaction
mixture was run on a gel to confirm successful amplification of the desired region. The
remaining mixture was extracted with phenol:chloroform:isoamyl alcohol, ethanol
precipitated, re-dissolved in dH20 and cancatermerised by the Klenow-Kinase-Ligase
technique, as described in section 2.1.11.12. Following this procedure, PCR products
were cut with 40 units of BamU I for 2 hours at 37°C before further
phenol:chloroform:isoamyl alcohol extraction, ethanol precipitation and resuspension in
TE buffer. All PCR products were sequenced extensively prior to further use.
4.1.3 PREPARATION OF PXP2-3





The loxF^ROSA vector was linearised by restriction digestion with Bam HI and Spe I.
The M250F/512R PCR product was then ligated into this vector to create the plasmid
p>J>2-3. Filled triangles ( i ), LoxP sites; Shaded rectangles, exons.
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4.1.3.1 Preparation of the LoxP2ROSA26 vector
Ten pg of the vector LoxF^ROSA were linearized by overnight digestion with BamW I.
Following heat inactivation of BamW I, cut ends of the vector were dephosphorylated
with 1 unit of CIAP to minimise self re-ligation. The mixture was extracted with
phenol:chloroform:isoamylalcohol to inactivate CAIP, ethanol precipitated and
resuspended in 20 jil of TE. A 5 |il aliquot of the reaction mixture was run on a gel to
check for complete linearization of the vector.
4.1.3.2 Cloning ofM230F/584R PCR product into LoxP2ROSA vector
Prepared vector and insert were mixed in an approximate 1:3 molar ratio and mixed with
lx ligation buffer, 1 unit of T4 DNA ligase and dH20 to a final volume of 20 pi. A
control reaction was set up containing each of the above reagents with the exception of
the PCR fragment insert. Ligation was performed as described in section 2.1.11.8.
Following ligation, 3 jil of the reaction mixture were used to transform 40 pi of
electrocompetent XL1 Blue E. Coli by electroporation as described in section 2.1.11.15.
Plasmid DNA was isolated by alkaline lysis of overnight cultures and analysed by
restriction digestion with Xho I, Cla I, Xba I and BamW I. Plasmids featuring successful
cloning events were termed pXP2-3 and underwent extensive sequencing prior to further
use. Large-scale preparation of pXP2-3 was performed using a Qiagen Midi prep kit as
described in section 2.1.11.2.
4.1.4 PREPARATION OF PXP2-3LTNL




The 3.8 kb Xba I fragment of pLTNL was ligated into the Xba I site of pXP2-3 to create




4.1.4.1 Isolation of the Xba / fragment ofpLTNL
The plasmid pLTNL is illustrated in Figure 2.4 and consists of the Thymidine Kinase
gene under the transcriptional regulation of the MCI promoter and a PGK-driven
neomycin phosphotransferase gene. LoxP sites flank the 3.8 kb selection cassette. This
entire region was isolated by overnight digestion of 20pg of pLTNL with 40 units of
Xba I. The reaction mixture was loaded into a single well agarose gel and, following
electrophoresis, the 3.8 kb fragment was isolated using a QIAEX II kit as described in
section 2.1.11.7.
4.1.4.2 Preparation of the pXP2-3 vector
Ten pg of pXP2-3 were digested with 10 units of Xba I for 4 hours. Xba I was heat
inactivated and 1 unit of CAIP added to dephosphorylate the cut ends to minimise vector
self-ligation. Following incubation for 30 minutes at 37°C, CAIP was inactivated by
phenol:chloroform:isoamyl alcohol extraction. The linearised vector was then
precipitated with ethanol and resuspended in TE buffer. An aliquot of the vector and
LTNL insert were then run on a gel to visually assess the yield of each.
4.1.4.3 Cloning ofXba Ifragment ofpLTNL into the pkP2-3 vector
The insert and vector were mixed in an approximate 3:1 ratio and ligation performed as
described in section 2.1.11.8. A negative control ligation reaction containing no insert
was also performed. Five pi of the ligation mix were used to transform 40 pi of
electrocompetent XLI Blue E. Coli as previously described. Colonies were screened by
plasmid miniprep and Xba I digestion. Plasmids featuring successful cloning events
were termed pXP2-3LTNL and prepared on a large scale using a Qiagen Midi-prep kit as
described in section 2.1.11.2.
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4.1.4.4 Destruction of the 5' Xba I site ofPXP2-3LTNL
The plasmid pXP2-3LTNL contained 2 Xba I sites flanking the LTNL insert as
illustrated in Figure 4.2. The cloning strategy for the insertion of the 3' homology arm
necessitated the destruction of the 5' Xba I site. This was achieved by partial digestion
of pXP2-3LTNL with decreasing concentrations of Xba I. The linearised vector was then
run on a gel to separate any plasmids that had been cut at both Xba I sites and the 7.6 kb
single-cut vector isolated from the gel using a QIAEX II kit. The cut ends of the vector
were blunt ended as described in section 2.1.11.9 and contaminating enzyme and dNTPs
removed by phenol:chloroform:isoamyl alcohol extraction and ethanol precipitation. The
linearised vector was then resuspended in TE and re-ligated using the previously
described method. Five pi of the ligation mixture were used to transform
electrocompetent XLI Blue E. coli. This process resulted in the generation of 3 different
populations of plasmids featuring the destruction of either the 5' or 3'Xba I sites or the
original configuration in which both Xba I were present. Restriction digestion mapping
with Xba I and Xho I was used to distinguish between these populations.
4.1.5 PREPARATION OF 3'HOMOLOGY ARM
The initial step in the construction of the 3' homology arm was to sub-clone the region
of the ETb receptor gene spanning from the Hpa I site in intron 3 to the first 54 bp of
exon 5 into the pBluescript® II KS+ vector (illustrated in Figure 4.3). For the short
homology arm of pXPW(NoDT), this fragment was subsequently sub-cloned into the 3'
region of the modified pXP2-3LTNL plasmid linearised with Xba I and Not I (illustrated
in Figure 4.5). For pXPW, the region downstream of the Bse Ri site in intron 4 was
replaced with a diphtheria toxin gene cassette, producing the plasmid pXP4-dt. The
cassette was isolated from the plasmid pCAGGS-dt (illustrated in Figure 2.6) and sub-
cloned into the shuttle vector pSP72polyl (Figure 2.7). The shuttle vector was used to
provide additional restriction sites in the polylinker region to facilitate the later sub-














The Hpa I-Sac I fragment of pAP was isolated and ligated to a pBluescript vector
linearised with Xba I, blunt-ended and then cut with Sac I to produce the plasmid pAP4-




The 2.0 kb Hpa I-Sac I fragment of pXP was isolated by restriction digestion, gel
electrophoresis and use of a QIAEX II kit as described previously. The pBluescript®
KS+ vector was linearised by Xba I restriction digestion followed by blunt ending of the
cut ends using Klenow enzyme as described in section 2.1.11.9. The linearized vector
was then cut with Sac I before extraction with phenol:chloroform:isoamyl alcohol,
ethanol precipitation and resuspension in TE. XLI Blue E. coli transformed by
electroporation with 5 pi of ligation mixture were screened for the presence of the insert
by hybridisation with a PCR-prepared radio-labelled probe. The primers INT3F and
417R were used to amplify the 895 bp region spanning from intron 3 to exon 4 of the
ETb receptor gene. The probe was gel-purified using a QIAEX II kit and labelled with
■? j ... ...
P dCTP as described in section 2.1.11.17. Hybridisation was performed overnight at
68°C on colony lifts of transformed cells prepared as described in section 2.1.11.16.
Positive colonies were picked, grown overnight and plasmid DNA isolated by alkaline
lysis. Plasmids were mapped by restriction digestion with BamH I, Xba I and Eco RI to
confirm the presence and orientation of the Elpa I-Sac I fragment. The results were
subsequently confirmed by direct sequencing of the insert. The resultant plasmid was
termed pXP4-5. Large-scale preparation of pXP4-5 was performed using a Qiagen Midi-
prep kit as previously described.
4.1.5.2 Isolation of the diphtheria toxin gene cassette from pCAGGS-dt
The plasmid pCAGGS-dt (Figure 2.6) contains the diphtheria toxin gene under the
transcriptional regulation of the chicken actin gene promoter region and a rabbit (3-
globin polyadenylation signal. The 2857 bp fragment containing these elements was
isolated by restriction digestion with Spe I, Hind III and BamH I, followed by gel
electrophoresis and use of a QIAEX II kit as previously described. Subsequent cloning
steps for the construction of pAPW required preservation of the 3' Not I site. In order to
achieve this, the Spe l-Hind III fragment of pCAGGS-dt was ligated into a pSP72poly 1
plasmid (illustrated in Figure 2.7) that had been linearised by overnight restriction
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digestion with Xba I and Hind III. pSP72poly 1 contains a Not I site in the polylinker
region 3' to the Hind III site and an Xho I site 5' to the Xba I site destroyed during this
ligation step. This shuttle plasmid was named pCAGGS-dt in pSP72poly 1. Following
electroporation of the ligation mix, the presence and orientation of the CAGGS-dt insert
was confirmed by restriction digestion mapping with the enzymes Xho I and Not I.
4.1.5.3 Preparation ofpXP4-dt
The preparation of p)JP4-dt is illustrated in Figure 4.4. Five pg of p?JP4-5 were digested
overnight with 10 units of foeR I. The enzyme was heat inactivated and the cut ends of
the plasmid blunt ended using Klenow enzyme as previously described. The mixture was
phenol:chloroform:isoamyl alcohol extracted, ethanol precipitated and resuspended in
TE. The linearised plasmid was then further digested with 10 units of Not I to remove
the 300 bp region between the BseR I site and the Not I site in the plasmid polylinker
region. The resultant fragments were separated by gel electrophoresis and the 4.1 kb
linearised vector fragment isolated using a QIAEX II kit. To produce compatible ends
for ligation, CAGGS-dt in pSP72poly 1 was cut with Xho I and blunt-ended as
previously described. This was followed by further digestion with Not I and Pvu I. The
Xho \-Not I fragment of CAGGS-dt in pSP72poly 1 contains the diphtheria toxin gene
with associated promoter and polyadenylation sequences. There is a single Pvu I site
within the vector region of CAGGS-dt in pSP72poly 1. The inclusion of a Pvu I
digestion step produced additional linearised vector fragments with cut ends that were
incompatible with subsequent cloning steps. This technique was utilised to circumvent
the requirement for gel isolation of the Xho I-Not I fragment. The linearised pAP4-5
vector and diphtheria toxin gene cassette were then ligated as described in section
2.1.11.8 and 5 pi of ligation mix used to transform 40 pi of XLI Blue E. coli by
electroporation. Colonies were picked, grown overnight and plasmid DNA prepared by
the alkaline lysis method. The presence and orientation of the inserted diphtheria toxin

















CAAGS-dt in pSP72 poly 1 was digested with Xho I and blunt ended. The Xho \-Not I
fragment was isolated and ligated to a pAP4-5 vector that had been linearised by
restriction digestion with Bse RI, blunt ended and then further digested with Not I. The




Five pg of the construct pXP2-3LTNL were linearised in the 3' polylinker region by
restriction digestion with Xba I and Not I. The 4.8 kb Spe I-Not I fragment of pXP4-dt
was prepared by restriction digestion of 5 pg of pXP4-dt with Spe I, Not I and Pvu I.
Restriction digestion with Pvu I was included to avoid the requirement for gel isolation
of the insert fragment as described earlier. This process is illustrated in Figure 4.5.
Ligation of the vector and insert was performed as previously described and 40 pi of
XLI Blue E. coli transformed by electroporation. Colonies were screened by plasmid
miniprep and Cla I and Not I digestion. Large-scale preparation of pA,P2-3LTNL4-dt
was undertaken using a Qiagen Midi-prep kit as previously described.
4.1.5.5 Preparation ofpXP2-5LTNL
The 3' homology arm of pLPW(NoDT) was prepared by restriction digestion of 5 pg of
pAP4-5 with Spe I, Not I and Pvu I. The -2.0 kb Spe \-Not I fragment was then ligated
with the vector pA.P2-3LTNL linearised in the 3' polylinker region by restriction
digestion with Xba I and Not I. This process is illustrated in Figure 4.5. Ligation was
performed as previously described and 5 pi of the ligation mix were used to transform
XLI Blue E. coli by electroporation. Plasmid DNA isolated from colonies by alkaline
lysis miniprep were screened by restriction digestion mapping with the enzymes Cla I
and Not I. The plasmid was subsequently prepared on a large scale using a Qiagen Midi-





Spe I -Not I fragment
of pXP4-5
Spe I Not I
OR
Spe l-Not I fragment
Figure 4.5
The vector pXP2-3LTNL was linearised by restriction digestion with Xba I and Not I and
ligated to the Spe l-Not I fragment of either pXP4-5 (for pXPW(NoDT)) or pA,P4-dt (for
p>JPW). This process destroyed the Spe \IXba I site but preserved the 3' Not I site. Black
triangle, loxP site; black rectangle, LTNL selection cassette; shaded rectangles, exons.
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4.1.6 PREPARATION OF 5'HOMOLOGY ARM
The 5' polylinker region of pAP2-5LTNL and pAP2-3LTNL4-dt are identical and
contain Xho I and Cla I sites orientated as illustrated in Figure 4.6. The same cloning
strategy for the addition of the long 5' homology arm was, therefore, utilised in the
preparation of pAPW(NoDT) and pAPW. To facilitate cloning, the plasmid pAP (Figure
2.9) was modified by the addition of an Xho I linker into the 5' polylinker region
adjacent to intron 1 to produce pAPXho (Figure 2.10). A native Nae I site located 1454
bp upstream of exon 2 in pAP was used in conjunction with the Xho I site to remove a
11911 bp fragment of intron 1 from pAP for use in subsequent cloning steps (illustrated
in Figure 2.10).
4.1.6.1 Addition ofa Xho I linker site to pXP
Because of a paucity of unique restriction sites within intron 1 of the ETB receptor gene,
an Xho I site was introduced into pAP to facilitate cloning of the 5' homology arm. The
primer XHO I (CCTCGAGGGGCC) was designed to include both an Xho I site and
termini that were compatible with Apa I-cut vector termini. The 5' termini of 2 pg of
this primer were phosphorylated by incubation with 2 units of polynucleotide kinase
enzyme (PNK), 1 x PNK buffer (50mM Tris-HCl pH 7.6, lOmM MgCF, 5mM DTT,
0.1 mM spermidine and 0. ImM EDTA) and ImM ATP at 37°C for 60 minutes. The
enzyme was heat inactivated and the mixture allowed to cool slowly to room
temperature to facilitate annealing of linkers. pAP was then linearised at the Apa I site
within the polylinker region adjacent to intron 1. Following dephosphorylation,
linearised pAP was phenol:chloroform:isoamyl alcohol extracted, ethanol precipitated
and resuspended in TE. 0.5 pg of pAP were then ligated with 2.0 pg of phosphorylated
XHO I linkers as previously described with the addition of ImM ATP to the ligation
reaction. Five pi of the ligation mix were used to transform 40 pi of DH10B E. coli..
Plasmid DNA was isolated from transformed colonies by the alkaline lysis method and
screened by restriction digestion mapping with the enzymes Xho I and Sal 1.
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4.1.6.2 Preparation ofpXPW and pXPW(NoDT)
The preparation of pAPW and pAPW(NoDT) is illustrated in Figure 4.6 and Figure 4.7,
respectively. Five pg of pXP2-3LTNL4-dt and pXP2-5LTNL were linearised by
digestion with Cla I. The vectors were then blunt-ended using CA1P as previously
described. Following phenol:chloroform:isoamylalcohol extraction, ethanol precipitation
and resuspension in TE, the linearised vectors were cut with Xho I. The 5' long
homology arm was prepared by overnight digestion of 10 pg of pXPXho with 20 units of
Turbo™ Nae I (Promega, Southhampton, UK; Product number R7321). Turbo™ Nae I
buffer contains a non-cleavable effector sequence that facilitates the efficient digestion
of slow and resistant sites. Preliminary attempts at restriction digestion of pAPXho
without this buffer had demonstrated that 1 of the 2 Nae I sites was resistant to cleavage,
despite overnight incubation with a tenfold excess of the enzyme. Following digestion,
the reaction mixture was extracted with phenol:chloroform:isoamylalcohol, precipitated
with ethanol and resuspended in TE. The plasmid was then digested with Xho I and the
resultant —11.9 kb Xho l-Nae I fragment separated by gel electrophoresis. The fragment
was recovered using a QIAEX II kit and ligated to the pXP2-3LTNL4-dt and p^P2-
5LTNL vectors as previously described. Five pi of ligation mixture were used to
transform 40 pi of DH10B E. coli and plasmid DNA was isolated from colonies using
the alkaline lysis method. Plasmids were screened for the presence and orientation of the
Xho \-Nae I insert by restriction digestion mapping with Xho I and Sal I. Positive
colonies were subsequently restriction digest mapped in greater detail and sequenced to





The Xho \-Nae I (blunt) fragment of pXPXho was sub-cloned into the pXP4-dt vector to
complete the targeting construct pXPW. Black triangle, loxP site; black rectangle, LTNL
selection cassette; shaded rectangles, exons.
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Figure 4.7
The Xho \-Nae I (blunt) fragment of pXPXho was sub-cloned into the pAP2-5LTNL
vector to complete the targeting construct pXPW(NoDT). Black triangle, loxP site; black





The results of PCR with the primers M230F/584R are illustrated in Figure 4.8.
Following electroporation, 30 colonies were obtained from 150 pi of ligation mixture.
Two colonies were obtained from the equivalent negative control plate. Plasmid DNA
was screened by digestion with BamU I. Successful incorporation of the PCR product
into the vector would be expected to produce an additional band of 956 bp. A single
plasmid (number 21) produced the expected pattern and was termed pXP2-3. These








PCR amplification of 129 ES cell genomic DNA using primers M230F and 584R and
Pfu DNA polymerase. Lane 1, pBluescript/Saw 3AI DNA; Lane 2, negative control (No








BamH I digestion of plasmid DNA following electroporation of M230F/584R PCR
product/LoxP2ROSA vector ligation mix. Lane 21 demonstrates an additional 956 bp
band consistent with successful cloning of the PCR product.
4.1.7.2 Further analysis ofpXP2-3 by restriction digestion mapping
pLP2-3 was further characterised by restriction digestion mapping with the enzymes Xho
I, Cla I, Xba I and BamW I. Double digests with Xho I and Cla I, and Xba I and Cla I
produced identical bands of 956 bp (Figure 4.10) corresponding to the incorporation of
the PCR product into the polylinker region of LOXP2ROSA. Because of the short insert
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Figure 4.10
Restriction digestion mapping of pXP2-3 demonstrating the presence of BamH I sites
flanking the 956 bp M230F/584R insert. Lane 1, Xho I; Lane 2 Xho I + Xba I; Lane 3,
Cla I; Lane 4, Cla I + Xba I; Lane 5, Xba I; Lane 6, BamH I; Lane 7, Lamda DNAIHind
III.
4.1.7.3 Direct sequencing ofpkP2-3
Alignment of the pAP2-3 sequence with the recently published mouse ETB receptor
sequence is illustrated in Figure 4.11 and Figure 4.12.
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DLambdaPZ-3Mi3Ff top*). -254 Exon2 to j-254 Int3CbQttQm~)
atcactgttctaaagtgccagtaagccactggggcattggcctttctgaggagagcctgattgtgccactgtctgcacataa
I I I I I I I I
10 20 30 40 50 60 70 80
aaaaaaaatctcataaaccagctgcacttgtgttacttccagtgtgttctatattggacacaggtgccttttcaaagggcag
I I I I I I I I
90 100 110 120 130 140 150 160
ttcttccttccctctggccgttaatcaccggcactcagtgctcagctcagaaaaatctccgtaaccgaccttcccgtttcct
I I I I I I I I






I I I I I I I I
250 260 270 280 290 300 310 320
30 40 50 60 70 80 90 100
I I I I I I I I
aatcacagngntgagtctttgtgctctaagtattgacaggtaagagtctattctcaggncaaggcgatcct aatccaacat a
• ••••••• | •|•••••••••••••••••••••••••••••••••••••••••••••••|•••••••••••••••••••••••
aatcacagtgctgagtctttgtgctctaagtattgacaggtaagagtctattctcaggccaaggcgatcctaatccaacata
I I I I I I I I I
330 340 350 360 370 380 390 400 410
110 120 130 140 150 160 170 180
I I I I I I I I
caactgttatgtcacttaggagataaactttgcaattcaatacaaccaagctctacctgctagacaaatcattctgtttata
caactgttatgtcacttaggagataaactttgcaattcaatacaaccaagctctacctgctagacaaatcattctgtttata
I I I I I I I I
420 430 440 450 460 470 480 490
190 200 210 220 230 240 250 260 270
I I I I I I I I I
tcttcagatatcgagctgntgcttcttggagtcgaattaaaggaattggggttccaaaatggacagcagtagaaattgtttt
tcttcagatatcgagctgttgcttcttggagtcgaattaaaggaattggggttccaaaatggacagcagtagaaattgtttt
I I I I I I I I
500 510 520 530 540 550 560 570
Figure 4.11
Sequence alignment of the plasmid pA,P2-3 sequenced with the M13F primer (top) with
the published sequence of the ETB receptor gene locus from 254bp upstream of exon 2 to
254bp downstream of exon 3 (bottom).
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pLqmdqP2-3M13RCtQP'). -254 Exon2 to +254 Int3CbQttQm")
10 20 30 40 50 60 70 80
I I I I I I I I
ACTAAGGGAACAAAAGCTGGTNCCGGNCCCCCCCTCGAGGTCNACGGT ATCGATAAGCTTGATATCGAATTCCCCTAGGATA
90 100 110 120 130 140 150 160






170 180 190 200 210 220 230 240
I I I I I I I I
CCAGTAAGCCACTGGGGCATTGGCCTTTCTGAGGAGAGCCTGATTGTGCCACTGTCTGCACATAAAAAAAAAATCTCATAAA
CCAGTAAGCCACTGGGGCATTGGCCTTTCTGAGGAGAGCCTGATTGTGCCACTGTCTGCACATAAAAAAAAAATCTCATAAA
I I I I I I I I
20 30 40 50 60 70 80 90
250 260 270 280 290 300 310 320
I I I I I I I I
CCAGCTGCACTTGTGTTACTTCCAGTGNGTTCTATATTGGACACAGGTGCCTTTTCAAAGGGCAGTTCTTCCTTCCCTCTGG
CCAGCTGCACTTGTGTTACTTCCAGTGTGTTCTATATTGGACACAGGTGCCTTTTCAAAGGGCAGTTCTTCCTTCCCTCTGG
I I I I I I I I I
100 110 120 130 140 150 160 170 180
330 340 350 360 370 380 390 400 410
I I I I I I I I I
CCGTTAATCACCGGCACTCAGTGCTCAGCTCAGAAAAATCTCCGTAACCGACCTTCCCGTTTCCTCTATGCAGTTGCTCGCA
CCGTTAATCACCGGCACTCAGTGCTCAGCTCAGAAAAATCTCCGTAACCGACCTTCCCGTTTCCTCTATGCAGTTGCTCGCA
I I I I I I I I
190 200 210 220 230 240 250 260
420 430 440 450 460 470 480 490




I I I I I I I I
270 280 290 300 310 320 330 340
500 510 520 530 540 550 560 570
I I I I I I I I
CTTTGTGCTCTAAGTATTGACAGGTAAGAGTCTATTCTCAAGCCAAGGCGATCCTAATCCANCATACAACTGGTATGTCACT
• • • • • • • ••• • • • • | • •
TTTGTGCTCTAAGTATTGACAGGTAAGAGTCTATTCTCAGGCCAAGGCGATCCTAATCCAACATACAACTGTTAT GTCACTT
I I I I I I I I
350 360 370 380 390 400 410 420
Figure 4.12
Sequence alignment of the plasmid pA,P2-3 sequenced with the M13R primer (top) with
the published sequence of the ETB receptor gene locus from 254bp upstream of exon 2 to




The 150 pi ligation and negative control plates yielded 123 and 76 colonies respectively.
Successful incorporation of the LTNLXba I fragment into pA.P2-3 was identified by the
presence of an additional 3.8 kb band following digestion with Xba I (data not shown).
Insert orientation was determined by sequencing and further restriction digestion
mapping.
4.1.7.5 Destruction of the 5' Xba I site ofPXP2-3LTNL
Colonies in which the 5' Xba I site was destroyed produced fragments of 4.5 kb and 3.0
kb. Destruction of the 3' Xba I site resulted in fragments of 800 bp and 6.8 kb.
Preservation of both Xba I sites resulted in fragments of 800 bp, 3.8 kb and 3.0 kb.
Plasmid numbers 8 and 25 demonstrated digestion patterns compatible with destruction
of the 5' Xba I site and were selected for further mapping by restriction digestion and
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Figure 4.13
Restriction digestion analysis of 2 clones of p>JP2-3LTNL following destruction of the
5' Xba I site. Lanes 1-8, Clone 8. Lanes 9-16, Clone 25. Lanes 1 and 9, uncut; Lanes 2
and 10, Xba I; Lanes 3 and 11, Xho I; Lanes 4 and 12, Xba I and Xho I; Lanes 5 and 13,
Cla I; Lanes 6 and 14, Cla I and Xba I; Lanes 7 and 15, Not I; Lanes 8 and 16, Not I and
Xba I. Lane 17, LamdaIHind III DNA.
4.1.7.6 Preparation ofpXP4-5
Multiple colonies containing the sub-cloned Hpa I-Sac I fragment of pXP were identified
following hybridisation with the radiolabeled INT3F/417R probe. Plasmid DNA insert
orientation was determined in selected colonies by restriction digestion with Bam HI,
Eco R\ and Xba I. The results are illustrated in Figure 4.14. Ligation of the Hpa I-cut
end to the blunt-ended Xba I site of the pBluescript vector resulted in the formation of a










Restriction digestion analysis of pLP4-5. Lane 1, Bam HI; Lane 2, Eco Rl, Lane 3, Xba
I; Lane 4, Lambda/Hind III DNA.
4.1.7.7 Preparation ofpCAGGS-dt in pSP72 polyl
Plasmid DNA was screened for the presence of the 2857 bp Spe l-Hind III fragment of
pCAGGS-dt by restriction digestion with Xho I and Not I. The results are illustrated in
Figure 4.15. Lanes 3, 6, 10, 11 and 14 demonstrate bands of ~2.8 kb (insert) and ~2.5 kb
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Figure 4.15
Restriction digestion analysis of plasmid DNA with Xho I and Not I following ligation
of the Spe l-Hind III fragment of pCAGGs to pSP72 polyl cut with Xba I and Hind III.
Lane 1, LamdaIHind III DNA; Lanes 3, 6, 10, 11 and 14 demonstrate an additional band
of ~2.8 kb consistent with successful ligation. These plasmids were termed pCAGGs-DT
in pSP72poly 1.
4.1.7.8 Preparation ofpXP4-dt
Correctly orientated inserts within the plasmids were predicted to produced bands of 3.0
kb (vector) and 4.8 kb (insert) following restriction digestion with Spe I and Not I. Lanes
2-10, 12-13, 16-17 and 19-25 demonstrate successful ligation and the resulting plasmid









1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Figure 4.16
Restriction digestion analysis of plasmid DNA with Spe I and Not I following ligation of
pXP4-5 cut with Not I and Bse RI (blunt) to pCAGGs-DT cut with Xho 1 (blunt), Not I
and Pvu I. Lanes 1 and 27, LambdaIHind Ill DNA; Lanes 2-10, 12-13, 16-17 and 19-25
demonstrate successful ligation and the resulting plasmid was termed pLP4-dt. Lane 26,
pLP4-5 cut with Spe I and Not I.
4.1.7.9 Preparation ofpXP2-3LTNL4-dt
Sub-cloning of the Spe I -Not I fragment of pLP4-dt into pLP2-3LTNL resulted in
destruction of the 5' Xba I/Spe I sites and preservation of the 3' Not I site. Plasmids in
which the Spe \-Not I fragment was successfully ligated produced bands of 9.1 kb
(insert) and 3.0 kb (vector) when digested with Cla I and Not I. In contrast, control
plasmids produced bands of 4.3 kb (Cla I -Not I fragment of pLP2-3LTNL) and 3.0 kb










Restriction digestion analysis of plasmid DNA with Not I and Cla I following ligation of
pXP2-3LTNL cut with Xba I and Not I to pAP4-dt cut with Not I, Spe I and Pvu I (lanes
1-24). Lane 25, pXP2-3LTNL cut with Not I and Cla I. Clones 1-7, 10, 13-19 and 21-24
demonstrated successful ligation and were termed pXP2,3LTNL4-dt.
4.1.7.10 Preparation ofpkP2-5LTNL
Plasmids with the Spe I-Not I fragment of pAP4-5 successfully inserted into the pXP2-
3LTNL vector produced bands of 6.3 kb and 3.0 kb when digested with Cla I and Not I








Restriction digestion analysis of plasmid DNA with Cla I and Not I following ligation of
pAP2-3LTNL cut with Xba I and Not I to pAP4-5 cut with Spe I, Not I and Pvu I. Clones
5,6, 9 and 10 demonstrate bands of 3.0 kb and 6.3 kb consistent with successful ligation.
These clones were named pAP2-5LTNL. Lane 11, Lamda/Hind III DNA.
4.1.7.11 Addition ofXho I linker site to p'AP
Successful incorporation of the Xho I linker site into the polylinker of pAP was
evidenced by the appearance of bands measuring -7.2 kb and -8.5 kb following
restriction digestion with Xho I and Sal I. In contrast, digestion of pAP resulted in a
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Figure 4.19
Restriction digestion analysis of plasmid DNA with Xho I and Sal I following addition
of Xho I linker into the Apa 1 site of pAP. Lanes 1 and 22, LambdaIHind III DNA; Lanes
4, 6 11, 14-16 and 19-20 demonstrate successful insertion of linker and were termed
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Figure 4.20
Restriction digestion analysis of pAPXho. Lanes 1 and 11, LambdaIHind III DNA;
Lanes 2-8 confirm successful ligation with liberation of ~3.0 kb band following
digestion with Xho I and Not I; Lane 9, undigested DNA; Lane 10, pAP digested with
Xho I and Not I.
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4.1.7.12 Preparation ofpXPW and pXPW(NoDT)
Representative gels of restriction digestion mapping exercises are illustrated in Figure
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Figure 4.21
Restriction digestion analysis of pLPW. Lane 1, Not I; Lane 2, Xho I; Lane 3, Sal I; Lane
4, Xho I and Not I; Lane 5, Xho I and Sal I; Lane 6, Xho I, Sal I and Not I; Lane 7, Not I
and Sal I; Lane 8, Sal I and Hind III; Lane 9, Xho I and Hind III; Lane 10, Not 1 and
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Hind III; Lane 11, Hind III; Lane 12, p^P2-5LTNL and Hind III; Lane 13, pXP2-








Restriction digestion analysis of pAJPW. Lane 1, Lamda/Hind III; Lane 2, Xho I; Lane 3,
Not I; Lane 4, Sal I; Lane 5, Xho I and Not I; Lane 6, Xho I and Sal I; Lane 7, Sal I and
Not I; Lane 8, Sal I, Not I and Xho I.
4.1.8 DISCUSSION
This chapter has described the construction of the targeting vectors pAPW and
pAPW(NoDT). These vectors were designed to facilitate homologous recombination
within the mouse ETB receptor gene locus in ES cells, resulting in the introduction of
loxP sites flanking exons 2 and 3. In vivo Cre-mediated excision of exons 2 and 3 and
the intervening intronic region was specifically chosen to inhibit ETB receptor
expression because this region contains the only known site for the generation of splice
variants (Shyamala et al., 1993). Although never demonstrated in the mouse, alternative
splicing of ETB receptor RNA has been observed in human brain, lung and heart. I,
therefore, adopted a strategy that minimised the potential for continued expression of
functional splice variants following recombination events within the ETB receptor gene
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locus. Recently, a novel mutation of the ETB receptor gene has been identified in mice
wherein a 318 nucleotide deletion spanning exons 2 and 3 results in the absence of
functional ETB receptors. These mice demonstrate a phenotype similar to Waardenberg
syndrome type 4 (audio-pigmentary defects and Hirschsprung's disease) and have been
proposed as a murine model of this syndrome (Matsushima et al., 2002).
Successful homologous recombination is dependent on a number of factors
(Capecchi, 1989), the most important of which is the length of homology between the
vector and targeted locus (Deng and Capecchi, 1992). The presence of a large region of
intron 1 in the plasmid pAP permitted the design of a targeting vector with a 5'
homology arm of —11.9 kb. The shorter 3' homology arm was in excess of 2 kb. The
total region of homology was, therefore, ~14 kb, close to the size at which the rate of
recombination saturates (Deng and Capecchi, 1992). In contrast, the non-homologous
LTNL selection cassette and loxP sites were less than 3.9 kb in length. Targeting
frequency is also increased through the use of isogenic vector DNA (te Riele et al.,
1992). With the exception of a 956 bp region spanning exons 2 and 3, all elements of the
targeting vectors were constructed from 129/SV genomic DNA. The use of long
homology arms was designed to maximise the frequency of homologous recombination
events and hence minimise the requirement for ES cell colony screening. However, this
design introduced several complicating factors. Firstly, there was a paucity of unique
restriction enzyme recognition sites within intron 1. This necessitated the introduction of
a linker region into the 5' polylinker region of pAP to facilitate cloning of the 5' arm. In
addition, it was necessary to delete the region of intron 1 downstream of the Nae I site. I
predicted that the deletion of this -1.1 kb region would not adversely affect gene
transcription since it contained no known gene regulatory elements. Currently, the only
region of intron 1 known to regulate transcription lays at the exon 1/intron 1 boundary.
A 301 bp deletion of this region results in the null si mutation in mice and rats (Hosoda
et al., 1994). Alternatively, the insertion of a retroposon in this area results in down
regulation of ETB receptor expression by -75% (Ohuchi et al., 1999). In our construct,
the inclusion of the region 288 bp immediately upstream of exon 2 and the region 155
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bp downstream of exon 3, was specifically designed to maintain the presence of any
potential splice acceptor and donor sites that are normally located within 100 bp of
exon/intron boundaries. The use of a very long 5' homology arm also presented
difficulties for the design of 5' external probes for southern blot analysis of targeted ES
cell clones. Very little sequence data were available for the remaining intronic and
upstream regulatory regions of the ETB receptor gene at the time of targeting vector
design. Hence, the identification of suitable restriction sites that might be utilised to
differentiate targeted and wild type clones was problematic. The size of the 5' homology
arm also dictated that the restriction fragments of wild type and targeted loci identified
by an external probe would be lengthy and, therefore, more difficult to resolve by simple
gel electrophoresis. To overcome these difficulties, a PCR-based screening strategy
based around the shorter 3' homology arm to identify homologously targeted clones was
designed (described in chapter 5). Clones identified in this way were then further
screened by southern blot.
Our targeting vector utilised the commonly used neomycin resistance gene
cassette as a positive selection marker. However, several groups have reported concerns
that the promoters used in such selection cassettes may interfere with the normal
expression of targeted and neighbouring genes (reviewed by (Muller, 1999). I, therefore,
flanked the selection cassette with an additional loxP site to facilitate the removal of the
cassette following identification of targeted clones. This was designed such that the
remaining loxP following a recombination event would be positioned downstream of
exon 3, thereby facilitating later in vivo Cre-mediated excision of exons 2 and 3. The
inclusion of a thymidine kinase gene within the cassette additionally permitted the
selection against clones retaining the cassette following Cre-mediated excision.
The vector p^PW contained a diphtheria toxin gene cassette at its 3' end. This
was intended to negatively select against clones have undergone random vector
integration events and to positively select for clones featuring homologous
recombination events. This 'positive/negative' strategy has previously been shown to
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enrich for homologous recombination events up to 10 fold within targeted clones (Yagi
et al., 1990).
Alternative strategies for the construction of the targeting vectors might have
utilised the introduction of synthetic loxP linker sites into the intronic regions at
convenient restriction enzyme recognition sites. The long and short homology arms
might also have been synthesised by PCR using a high fidelity proof-reading DNA
polymerase. Although possible, difficulties with accurately amplifying large fragments
of DNA by PCR are often encountered. This strategy is, therefore, used more commonly
to generate shorter homology arms, albeit with a consequent decrease in targeting
efficiency. Lower rates of targeting efficiency are acceptable if screening procedures are
rapid enough to facilitate the screening of large numbers of colonies. However,
preliminary experiments within our lab had revealed that isolation of ES cell DNA from
96 well plates often did not provide sufficient quantity of DNA for effective screening. It
was, therefore, necessary to expand ES cell colonies into 24 well plates prior to DNA
isolation. The increased workload that this entailed favoured strategies that maximised
targeting efficiency. The influence of homology arm length upon the efficiency of
homologous recombination at the ETB gene locus has recently been exemplified. Our
group has undertaken further targeting of this gene with a |3-galactosidase gene
construct. The 5' homology arm used for this construct consisted of only the final 5 kb
of intron 1. Targeting efficiency of this construct was somewhat poorer at -0.3% (A.
Gordon, University of Edinburgh, personal communication).
The use of conventional cloning techniques in the construction of the targeting
vectors pA.PW and pXPW(NoDT) thus provided a relatively simple, time efficient
strategy. The rapid identification and cloning of the plasmid pAP ensured that all
genomic elements of the constructs could be isolated without significant concerns
regarding the introduction of mutations, since novel mutations in regions distant from




5.1 TARGETING OF THE ETB RECEPTOR GENE ALLELE AND
GERMLINE TRANSMISSION OF THE FLOXED ETB RECEPTOR ALLELE
5.1.1 INTRODUCTION
This chapter will describe the targeting of the ETB receptor gene in ES cells with the
constructs pXPW and pAPW(NoDT). The strategy for the identification of ES cell clones
having undergone homologous recombination events and their subsequent genetic
manipulation to remove selection markers prior to blastocyst injection will also be
described. Finally, the generation of chimaeric mice and the genotyping strategy adopted
for the identification of the targeted allele in their offspring will be outlined.
Following electroporation of the targeting construct, recombination events within
the ES cell genome result in the introduction of a selectable genetic marker. Surviving
ES cell colonies must then be screened to differentiate those cells featuring the desired
homologous integration event from those in which the targeting vector has randomly
inserted into the genome. For the purpose of these experiments, normal expression of
ETb receptors in the absence of Cre-mediated recombination events within the ETB
receptor gene locus was required. Following identification of homologously targeted ES
cell clones, I therefore removed the neomycin resistance/thymidine kinase selection
cassette to prevent interference of this exogenous DNA with the transcription of the
targeted and neighbouring genes. The cassette was removed through the transient
expression of Cre recombinase. Clones in which the thymidine kinase gene was retained
were sensitive to subsequent negative selection with gancyclovir. Further screening was
then undertaken to identify clones featuring loxP sites flanking ('floxing') exons 2 and 3
of the ETb locus. These clones were then expanded and injected into blastocysts from a
donor strain of mice to produce chimaeric pups. The screening strategy adopted to
identify clones following each of these manipulations will now be described.
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5.1.1.1 Screening strategies for the detection ofhomologous recombination events in
ES cells
Southern analysis of targeted clones is generally regarded as the gold standard for the
detection of recombination events, but is time consuming and labour intensive. Defined
restriction sites must also be identified within the targeted and flanking regions to permit
size differentiation of restriction fragments from targeted and non-targeted alleles.
Because little detailed sequence data were available from the flanking regions at the time
of the experiment, I adopted a PCR-based strategy for initial screening of G418-resistant
ES cell colonies, followed by Southern analysis of positive clones. In this approach, one
PCR primer is common to both mutant and wild-type alleles, one primer is specific to
the mutant allele and one primer is specific to the wild type allele (Mantamadiotis et al.,
1998). This approach is described below.
5.1.1.2 PCR screening strategy for the detection of recombination events in ES cells
Genomic DNA prepared from each clone was amplified with 3 separate primer pairs.
The location of regions of the ETb receptor gene and targeting construct complementary
to the 3 primer pairs and the position of the 3' southern blot probe are illustrated in
Figure 5.1 and Figure 5.2. LTNLF (GCCTCTGTTCCACATACACTTCATTC) and
417R (GTAGAAACTGAACAGCCACCAATC) are complementary to unique
sequences within the targeting vector and amplify a 1420 bp region between the
selection cassette and exon 4. The primers Exon 5R
(TGAGGTGAAGGGGAAGCCAACAGAGA) and 5to4R
(GAACAGCTGCCACGTCTC) are complementary to sequences of the ETB receptor
locus downstream of the 3' homology arm. Successful amplification of a genomic
fragment using the LTNLF primer paired with either Exon 5R (for ES cells targeted with
pXPW; 2104 bp) or 5to4R (for ES cells targeted with pXPW(NoDT); 2204 bp) is only
possible in clones having undergone a homologous recombination event. The external
primer 5to4R was utilised instead ofExon 5R to screen ES cells targeted with
pXPW(NoDT) as this targeting vector contains sequences complementary to the Exon
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5R primer. A positive control (78F (TTTGGGTGGTCTCTGTGGTTCTGG) paired with
either Exon 5R or 5to4R) was also included for each clone. This primer pair amplifies
either a 2313 bp (78F/Exon 5R) or a 2413 bp (78F/5to4R) genomic region of the non-



















Panel A: PCR screening strategy for identification of homologous recombination events
following targeting with the pXPW construct.
Panel B: PCR screening strategy for identification of homologous recombination events
following targeting with the pAPW(NoDT) construct. Red rectangles, exons present
within the targeting construct; Yellow rectangles, exons external to the targeted region;
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Figure 5.2
Southern blot screening strategy for the detection of 3' homologous recombination
events following targeting with the constructs p^PW and pXPW(NoDT). Successful
targeting resulted in the introduction of a Hind III site within intron 3. Genomic DNA
was screened following Hind III digestion with a PCR-generated probe external to the
region of homology. Red rectangles, exons present within the targeting construct;
Yellow rectangles, exons external to the targeted region; Orange triangles, loxP sites;
Green rectangle, selection marker (MChThymidine Kinase and PGK:Neomycin
phosphotransferase).
5.1.1.3 Southern blot screening strategy for the detection of3' recombination events
Clones in which homologous recombination events were detected by PCR were further
analysed for 3' recombination events by Southern blotting. The strategy for Southern
blotting is illustrated in Figure 5.2. Targeted clones contain an additional Hind III site at
the 3' end of the LTNL selection cassette. Restriction digestion with Hind III will
produce bands of 4892 bp and 7633 bp in targeted and non-targeted alleles, respectively.
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Restriction fragments were detected by hybridisation with a PCR-generated probe
external to the 3' region of homology, complementary to intron 5.
5.1.1.4 Screening strategy to identify recombination-mediated removal of the
selection cassette from homologously targeted ES cell clones
G418-resistant clones selected by PCR and 3' southern blotting in the first round of
screening were transiently transfected with a Cre recombinase-expression plasmid
(Araki et al., 1995) under a chicken beta actin promoter that was kept in circular form to
prevent genomic integration. This resulted in the initiation of recombination events
within the targeted allele between the 3 loxP sites with consequent removal of either the
selection cassette, exons 2 and 3, or the entire region between the 5' and 3' loxP sites.
The potential patterns of recombination are illustrated in Figure 5.3. Gancyclovir was
then utilised to negatively select against the presence of the thymidine kinase gene.
Clones retaining this gene are able to efficiently activate gancyclovir to the triphosphate
state with consequent inhibition of DNA replication. DNA from gancyclovir-resistant
clones was screened by PCR to confirm both the presence of the loxP site downstream
of exon 3 and the absence of the selection cassette. The presence of the loxP site and
associated polylinker sequence downstream of exon 3 in the targeted allele results in a
net gain of 50bp compared to the wild type allele. The primers 78F and 681R
(AGCCATAAAGTCACAGCCATTC) amplify this region (illustrated in Figure 2.1),
producing bands of 380 bp and 430 bp with the wild type and floxed allele, respectively.
The pattern of recombination events following transient transfection with Cre
recombinase was also used to confirm the functional presence of the 5' loxP site
upstream of exon 2 and hence of a successful 5' homologous recombination event.





Colonies with desired pattern of recombination
May be identified by PCR with the primers
78Fand 681R
Figure 5.3
PCR screening of targeted clones following transient transfection with the Cre
recombinase-expression plasmid pMC-Cre and selection with gancyclovir. Clones
featuring recombination events between loxP sites at positions A and B retain the
selection cassette and are sensitive to negative selection with gancyclovir.
Recombination between loxP sites B and C may be identified by PCR amplification with
the primers 78F and 681R. Bands of 380 bp (wild type allele) and 430 bp (targeted
allele) are observed. Clones featuring recombination between loxP sites A and C are
only able to amplify DNA from the non-targeted wild type allele since this
recombination event removes exon 3 from the targeted allele. Functional evidence of the
presence of the 5' loxP site in a parent clone rests, therefore, on the production of
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recombination patterns compatible with each of these scenarios in colonies derived from
a single parent clone.
5.1.1.5 Screening strategy for the analysis of5' recombination events in
gancyclovir-resistant clones
Clones selected in this manner were subsequently analysed to confirm a 5'
recombination event by further PCR screening and direct sequencing. The primers 81R
(CTTAGAGCACAAAGACTCAGCAC) and 454F are complementary to regions within
intron 1 flanking the 5' loxP site (illustrated in Figure 2.2). Each targeted allele features
a net deletion of 1105 bp in this region (spanning from the Nae I site to 288 bp upstream
of exon 2). This size differential was utilised to confirm 5' homologous recombination
events and PCR products generated during each of the screening reactions were
subsequently isolated and directly sequenced. The PCR primers 78F/681R and
454F/681R were used for sequencing of the 3' and 5' loxP sites, respectively.
5.1.1.6 Generation ofhomozygous 'floxed' ETb receptor mice
The ability of ES cells to contribute to the formation of all cell lineages, including
gametes, was exploited through the in vitro injection of targeted ES cells into developing
wild type blastocysts. Chimaeric blastocysts, comprised of both wild type and targeted
cells, are re-implanted into the uterus of pseudopregnant mice and allowed to develop
into chimaeric pups. In a proportion of such mice, targeted ES cells will contribute to the
formation of germ cells. The targeted allele may, therefore, be inherited by the offspring
of the chimaera. Through intercross of these offspring, mice homozygous for the




5.1.2.1 Electroporation ofES cells
Seventy five pg of the pAPW targeting vector were cut overnight with either 10 units of
Xho I or a combination of 10 units each of Not I and Xho I. pXPW(NoDT) was cut with
10 units of Xho I alone. ES cells and linearised targeting vector were prepared for
electroporation as described in 2.1.13.7.
5.1.2.2 Selection ofG418-resistant ES cell colonies
Twenty four hours post-electroporation, cells were washed twice and the media replaced
with ES cell media supplemented with 200 pg/ml G418 (Boehringer Maanheim,
Germany; Product number 1464981). Selection was continued for 7 days.
5.1.2.3 Picking ofG418-resistant ES cell colonies
Following G418 selection, cultures were washed twice and covered with 7 ml of PBS.
Individual colonies were picked by simultaneous scraping and aspiration with a P20
pipette. Cells were aspirated along with 20 pi of PBS and transferred to a round-
bottomed 96 well plate containing 20 pi of TVP in each well. Plates were then incubated
at 37°C for 2 minutes to dissociate cells. Cells were transferred to the corresponding
well of a second round-bottomed gelatinised 96 well plate containing 150 pi of pre-
warmed ES cell media supplemented with G418 (200 pg/ml) per well. Media was
changed every two days and when an individual well reached confluence, cells were
passaged onto a 24 well plate and diluted with 2ml of media. Following passage, each
clone was ascribed a unique identification number that was maintained throughout all
subsequent experiments. Individual wells were grown to confluence and then split 1:2
onto replica 24 well plates, termed 'DNA' and 'freezing'. Both the 'DNA' and the




5.1.2.4 PCR screening ofG418-resistant ES cell colonies following targeting with
pEPW or pAPW(NoDT)
Genomic DNA was isolated from ES cell colonies as described in section 2.1.13.6. PCR
reactions were performed using the Expand™ system and the primer pairs
LTNLF/417R, LTNLF/Exon 5R or 5to4R and 78F/Exon 5R or 5to4R. Reaction mixtures
were prepared as described in section 2.1.13.11. Cycling parameters were 92°C for 2
minutes, 10 cycles of 92°C for 10 seconds, 60°C for 30 seconds and 68°C for 3 minutes,
followed by 20 cycles of 92°C for 10 seconds, 60°C for 30 seconds and 68°C for 3
minutes plus an additional extension period of 20 seconds per cycle. A final extension
period of 68°C for 7 minutes completed the programme. During the second round of
screening a simplified PCR programme was utilised: 92°C for 2 minutes, 30 cycles of
92°C for 30 seconds, 60°C for 30 seconds and 68°C for 2 minutes, followed by a 10
minute final extension period at 68°C. This protocol was found to amplify the desired
regions without a decrease in detection sensitivity.
5.1.2.5 3' Southern blot ofclones identified by PCR screen
A probe complementary to intron 5 was generated by PCR using the primers 32F/359R
and a genomic DNA template as described in section 3.1.2.1. The probe was purified
and radiolabeled as previously described. Five pg of genomic DNA from the
homologously targeted clones 3B3, 9D3 and 4B2, from the non-homologously targeted
clones 2D1 and 6D3, and from non-targeted E14 ES cells were digested overnight with
10 units of Hind III. Samples were checked for complete digestion of DNA and then the
entire sample was separated by gel electrophoresis. Southern blotting and hybridisation
was performed as described in section 2.1.11.18.
5.1.2.6 Transient transfection of targeted clones with pMC-Cre
Homologously targeted clones identified in the previous round of screening were
electroporated with either 50 pg of pMC-Cre or vehicle using the electroporation
protocol described in section 2.1.13.8. Cells were grown to confluence without G418
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selection then counted and seeded onto 1% geletin-coated petri-dishes (102-105
cells/plate). Negative selection with 2.5pM gancyclovir was maintained for 4-5 days.
Surviving clones were picked onto 96 well plates as previously described then grown to
confluence in 24 well plates before splitting onto 'freezing' and 'DNA' plates.
5.1.2.7 PCR screening ofgancyclovir-resistant clones for the presence of the 3' loxP
site
Recombination-mediated removal of the LTNL selection cassette was identified by
screening genomic DNA by PCR using the primers 78F and 681R and the following
cycling parameters: 92°C for 5 minutes, 30 cycles of 92°C for 30 seconds, 60°C for 30
seconds and 68°C for 2 minutes, followed by final extension at 68°C for 10 minutes.
Reaction mixtures were prepared as described in section 2.1.13.11. PCR products from
wild type and targeted alleles differed in size by 50 bp and were separated by gel
electrophoresis using a 2% agarose gel. For clones used for blastocyst injection, PCR
products were isolated from the gel as previously described and sequenced using the
primers 78F and 681R. Sequencing was performed as described in section 2.1.11.4.
5.1.2.8 PCR screening ofgancyclovir-resistant clones for the presence of the 5' loxP
site
5' recombination events were detected by screening genomic DNA by PCR using the
primers 454F and 81R. The targeted allele features a deletion of an 1166 bp segment of
intron 1, spanning from the Nae I site 1454 bp upstream of exon 2 to a site 288 bp
upstream of the exon 2. Sixty one bp were added to the 5' region (loxP site and
associated polylinker regions) during vector construction, resulting in a net deletion of
1105 bp from the floxed allele. The primers were thus predicted to amplify bands of
~500bp and ~1600bp in targeted and wild type alleles, respectively. The following
cycling parameters were utilised: 92°C for 5 minutes, 30 cycles of 92°C for 30 seconds,
50°C for 30 seconds and 68°C for 2 minutes, followed by final extension at 68°C for 10
minutes. Reaction mixtures were prepared as described in section 2.1.13.11. PCR
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products generated were isolated by gel electrophoresis and recovered using a QIAEX
II ™ kit as described in section 2.1.11.7 for sequencing.
5.1.2.9 Generation ofchimaeric mice
ES cell clones 3B3 (2B5), 9D3 (1B1) and 2D2 (1C1) were prepared and injected into
blastocysts as described in section 2.1.13.9. Chimaeric male offspring were mated with
white BKW strain mice and the progeny screened for germline transmission of the
targeted allele by coat colour. Black mice carry a full complement of C57BL/6
chromosomes derived from the parent blastocyst and do not, therefore, carry the targeted
mutation. In contrast, sandy coloured pups inherit a complement of chromosomes
derived from 129/SV ES cells and hence posses a 1 in 2 chance of carrying the targeted
mutation. The presence of the 3' loxP site in tail tip DNA from sandy coloured pups was
detected by PCR using the primers 78F and 681R as previously described.
5.1.3 RESULTS
5.1.3.1 PCR screen ofG418-resistant ES cell colonies following targeting with
pXPW
155 colonies were picked and screened. A representative PCR screen is illustrated in
Figure 5.4. Clone number 84 (9D3) produced bands with each of the 3 primer pairs,
suggesting a homologous recombination event following targeting with pAPW. Negative
control reactions using wild type ES cell DNA template produced bands only with the
78F/Exon 5R primer pair, as predicted. 4/155 colonies were identified as having
undergone homologous recombination events, giving a targeting efficiency of 2.5%.
Positive clones were defrosted, grown to confluence and split to provide an extra plate
from which further DNA samples were isolated. Of the 4 clones, 1 failed to grow
following defrosting and 2 others no longer tested positive for the homologous
recombination event when PCR screening was repeated. A single clone (9D3) remained
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4I7R 5T04R 5TO4R 417R 5T04R 5T04R 417R 5TO4R 5T04R
Figure 5.4
Representative primary PCR screen of targeted ES cell clones (9D3 and 9D4) and non-
targeted control E14 ES cells. Each of the 3 primer pairs amplified specific regions of
the ETb receptor locus in clone 9D3, indicating a homologous recombination event.
Clone 9D4 demonstrates non-homologous integration of the targeting construct. E14 ES
cells produce PCR bands only with the primer pair complimentary to the wild type
allele. This genotyping strategy is illustrated in Figure 5.1.
5.1.3.2 PCR screen ofG418-resitant ES cell colonies following targeting with either
pkPW or pkPW(NoDT)
Because only a single homologously targeted clone survived following targeting with
pAPW, targeting was repeated using pAPW and pXPW(NoDT). This permitted
examination of the effects upon targeting efficiency of both the inclusion of the
diphtheria toxin gene and of the site of vector linearization. Following G418 selection,
the number of surviving ES cell colonies was of the rank order pXPW(NoDT)>pXPW
(Xho I+Not I-cut)> pAPW (Xho I-cut). 307/ 400 colonies picked survived, of which 97
were screened by PCR as previously described. The frequency of homologous
recombination events using each of the targeting constructs is shown in Table 5.1.
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Targeting efficiency was of the rank order pXPW(NoDT)>pAPW (Xho I+Not I-cut)>









pAPW Xho I+Not I-cut 1/26 3.84
pXPW Xho I-cut 0/18 0
TOTAL 6/97 6.18
Table 5.1
The six clones identified were 1B1, 1C1, 2D2, 3B3, 3C3 and 4B2. Of these, 2D2 and
3B3 were defrosted and re-grown. Each clone remained positive with all 3 primer pairs
when PCR screening was repeated. Transient transfection with pMC-Cre was
undertaken in clones 9D3 (identified from the first targeting screen), 2D2 and 3B3.
5.1.3.3 3' Southern blot ofhomologously targeted clones identified by PCR screen
The results of Southern blotting of genomic DNA following Hind III digestion are
illustrated in Figure 5.5. Clones 3B3, 4B2 and 9D3, identified by PCR as having
undergone homologous recombination reactions, demonstrate bands of ~4.9 kb (targeted
allele) and ~7.6 kb (wild type allele). Non-targeted ES cells and the non-homologously












9D3 6D3 E14 XIHind III
Figure 5.5
3' Southern blot of homologously targeted (9D3, 3B3, 4B2), non-homologously targeted
(2D1, 6D3) and wild type E14 ES cell genomic DNA following Hind III restriction
digestion. A PCR-generated external probe (32F/359R) complementary to intron 5 was
utilised to detect restriction fragments in each case. The upper panel demonstrates a ~4.9
kb fragment in addition to the wild type ~7.6 kb band in homologously targeted clones.
The Southern blot was repeated (lower panel) following a prolonged period of
electrophoresis to improve separation of bands and permit accurate sizing.
5.1.3.4 Gancyclovir selection of clones following transient transfection with pMC-
Cre
All clones electroporated without pMC-Cre died under gancyclovir selection, but
propagated normally in the absence of gancyclovir. Survival in clones transiently
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transfected with pMC-Cre was dependent upon the initial seeding density and the
efficiency of recombination-mediated removal of the selection cassette. Clone survival
on plates seeded with 102, 103 and >103 cells was -10%, -20% and 0%, respectively.
5.1.3.5 PCR screen ofgancyclovir-resistant clones for removal of the LTNL
selection cassette and presence ofthe 3' loxP site
The number of gancyclovir-resistant colonies picked following transfection of
heterologously targeted clones with pMC-Cre is illustrated in Table 5.2 along with the
relative proportion of colonies in which the desired recombination event was detected by
PCR screening with the primers 78F and 681R.
PARENT NO. COLONIES NO. OF NO. POSITIVE % POSITIVE
CLONE PICKED SURVIVING WITH 78F/681R WITH 78F/681R
COLONIES PRIMERS PRIMERS
9D3 150 95 3 3.15
2D2 48 36 3 8.33
3B3 96 62 5 8.06
TOTAL 294 193 11 5.70
Table 5.2
A typical genotyping reaction is illustrated in Figure 5.6. Targeted and wild type alleles
were identified as 430bp and 380 bp bands, respectively. From the 11 clones identified,
3 were selected for further analysis of 5' recombination events. 3B3 (2B5), 9D3 (1B1)
and 2D2 (1C1) were defrosted and screening for the 3' loxP site repeated. All clones
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Figure 5.6
PCR screening for the presence of the 3' LoxP site. The primers 78F and 681R were
utilised to screen targeted ES cells (clone 3B3) following transient transfection with the
pMC-Cre plasmid. Lane 1, DNA size marker; Lanes 11 and 14 demonstrate an
additional band of 430 bp, consistent with Cre recombinase-mediated removal of the
LTNL selection cassette and preservation of the 3' LoxP site. The PCR products
amplified from the targeted and wild type alleles were of similar intensity, suggesting
similar DNA concentrations. PCR products were isolated and sequenced to confirm the
sequence of the 3' LoxP site and wild type alleles.
5.1.3.6 PCR screen ofgancyclovir-resistant clones for the presence of the 5' loxP
site
3B3 (2B5), 9D3 (1B1) and 2D2 (1C1) were screened by PCR for evidence of 5'
recombination events using the primers 454F and 81R. Amplification of the targeted and
wild type allele produced bands of 500bp and 1600bp, respectively in all clones







PCR screening to confirm the presence of the 5' LoxP site. The primers 454F and 81R
were used to screen ES cell DNA following Cre recombinase-mediated removal of the
LTNL selection cassette. Lane 1, non-targeted E14 ES cell DNA; Lane 2, insufficient
template DNA; Lane 3, clone 3B3; Lane 4, clone 9D3. DNA from targeted clones 3B3
and 9D3 demonstrate the presence of both wild type (~1600 bp) and targeted (500 bp)
ETb receptor alleles, confirming 5' recombination of the targeting construct within the
ETb receptor gene. PCR products were isolated and sequenced to confirm the sequence
of the 5' LoxP site.
5.1.3.7 Sequence of5' and 3' loxP sites
The 5' loxP site upstream of exon 2 and the 3' loxP site downstream of exon 3 contained
no additional mutations in the clones 3B3 (2B5), 9D3 (1B1) and 2D2 (1C1). Sequence
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90 100 110 120 130 140 150 160
I I I I I I I I
TATCCGGATCCAGAGGGTCATGACCCACAGGTTGAGAATCACTGTTCTAAAGTGCCAGTAAGCCACTGGGGCATTGGCCTTT
170 180 190 200 210 220 230 240
I I I I I I I I
CTGAGGAGAGCCTGATTGTGCCACTGTCTGCACATAAAAAAAAAATCTCATAAACCAGCTGCACTTGTGTTACTTCCAGNGT
250 260 270 280 290 300 310 320
I I I I I I I I
GTTCTATATTGGACACAGGTGCCTTTTCAAAGGGCAGTTCTTCCTTCCCTCTGGCCGTTAATCACCGGCACTCAGNGCTCAG
330 340 350 360 370 380 390 400 41
I I I I I I I I I
CTCANAAAAATCTCCGNAACCGACCTTNCCGTTTCCTNTATGCANNTGCTCGCNNAGGACTGGCCATTTGGAGCTGANATGT
420 430 440 450 460 470 480 490
I I I I I I I I
GTAAGCTGGTGCCCTTCATACNNAANGCTTNTGNGGGAATNACANNNCTNNNTNTTTNTNNTNTNNNNNNNNCCCTCANCAC
500 510 520 530 540 550 560 570
I I I I I I I I
NTGNGATTNCCNCANAANCCCTTNTNTNTNAAGGGCNCCNNNTNCNNATNTNNNNTNCNNNTGGGNCNNTCNTTTNNNNNNN
Figure 5.8
Sequence alignment of genomic DNA isolated from the clone 3B3 (2B5) and sequenced




LOXPCtool- 3B3 Z&E 3' LoxPf bottom1
TTTANNNCTGTCCCGANNCCATAGGTTTTGATATGATTACGTCGGACTACAAAGGAAAGCCCCTAAGGGTCTGCATGCTTAA
I I I I I I I I
10 20 30 40 50 60 70 80
TCCCTTTCAGAAAACAGCCTTCATGCAGGTACGTTCACTTTGCTTGTTCTTTCTGCACTTTCCTTATAAATATTTCACTATT
I I I I I I I I
90 100 110 120 130 140 150 160
TCCCCCAGTTCCCCACCTTGGTAGGCTATTGATTTATTACTACCTTTGGCATAAATTAAGAGTTTGGATCCTAGTTCTAGCT
I I I I I I I I





I I I I I I I I
250 260 270 280 290 300 310 320
AGAGTCAGGATAATTACTTCTCCAAGAACACCCTGGGGATCCAGATAAATCAAGTTCCTGCAAGAATGGCTGTGACT
I I I I I I I I
330 340 350 360 370 380 390 400
Figure 5.9
Sequence alignment of genomic DNA isolated from the clone 3B3 (2B5) and sequenced




5.1.3.8 Generation ofchimaeric mice and analysis ofprogeny
Six chimaeras were derived from clone 9D3 (1B1), 4 from 2D2 (1C1) and 3 from 3B3
(2B5). All chimaeras were male with the exception of a single female derived from
clone 9D3 (1C1). This sex bias reflects the use of XY karyotype ES cells. Female
chimaeric mice are often infertile (Bronson et al., 1995) and were not used further.
Three distinct coat colours were observed in the F, progeny. Black mice and dark brown
mice were found not to carry the targeted mutation, as predicted. The presence of the 3'
loxP site was identified in sandy coloured pups by PCR screening of tail-tip DNA with
the primers 78F and 681R as previously described. Mice heterozygous for the targeted
allele produced bands of 380 bp and 430 bp from wild type and targeted alleles,
respectively. Mice heterozygous for the targeted allele were subsequently intercrossed to
produce homozygous floxed ETb receptor mice. Homozygous floxed offspring were
produced in the expected Medelian frequency (1/4 of pups) from these intercrosses. A









1 2345 6789 10
Figure 5.10
PCR genotyping with the primers 78F and 681R of an F1 intercross of Flox/W mice.
Floxed ETb receptor allele 430 bp; Wild type ETB receptor allele 380 bp. Lane 1
Flox/W; Lane 2 No DNA; Lane 3 Flox/W; Lane 4 W/W; Lane 5 Flox/Flox; Lane 6
Flox/W; Lane 7 Flox/Flox; Lane 8 W/W; Lane 9 Flox/W; Lane 10 Flox/Flox. Flox =
targeted ETB receptor allele; W = wild type ETB receptor allele.
5.1.4 DISCUSSION
This chapter has described the targeting of ES cells with pAPW and p)JPW(NoDT) and
the subsequent generation of mice homozygous for the floxed ETB receptor allele.
Identification of homologous recombination events following transformation of ES cells
is typically achieved by Southern blot hybridisation. Such screening strategies involve
the identification of homologous recombination events in both the 3' and 5' homology
arms through the use of probes external to homology regions present within the targeting
construct. An alternative approach is to use a PCR-based strategy based on 3 primers
(Mantamadiotis et al., 1998), as previously described. The successful amplification of a
genomic fragment between the common primer and specific mutant allele primer is then
dependent upon a homologous recombination event at the target locus. Although prone
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to false positive results, this method is often utilised to quickly screen large numbers of
G418 resistant clones that may subsequently be analysed in greater detail by Southern
blot. In addition, PCR offers advantages over Southern blotting for detection of loxP
sites within the mutant allele following removal of the selection marker, when the size
differential between wild type and mutant alleles is small. In our assay, the floxed allele
featured an additional 50 bp consisting of the 3' loxP site and associated polylinker
region. Because of the similar size of PCR products amplified from targeted and wild
type alleles in this reaction, the amplification rate is likely to be similar from each allele.
PCR screening thus provides an additional method of quickly detecting the random
insertion of multiple copies of the targeting construct by analysis of the signal intensity
of the PCR product (Mantamadiotis et al., 1998). In our screen, both the wild type and
floxed allele produced bands of equal intensity, suggesting that only a single copy of the
targeting construct was integrated into the ETB receptor allele.
Southern blotting to confirm homologous recombination of the 5' arm of either
p>*,PW or pXPW(NoDT) was problematic due to the large size of the homology arm and
lack of available sequence data from flanking regions at the time of the experiment.
These factors limited the availability and identification of unique restriction enzyme
recognition sites within and external to the targeting construct. For this reason,
confirmation of 5' recombination events was determined by PCR amplification and
direct sequencing of the 5' loxP site in candidate clones following removal of the
selection cassette. Functional evidence of the presence of the 5' loxP site (and hence, of
5' recombination events) was also provided by the pattern of Cre-mediated
recombination following transient transfection of targeted clones with pMC-Cre. All
clones selected demonstrated patterns of recombination that involved both the 5' and 3'
loxP sites.
In order to screen targeted ES cell colonies for homologous recombination
events, it is imperative that the screening technique utilised is of sufficient sensitivity to
detect a single recombination event within a single genome equivalent. The detection
sensitivity of our PCR-based screening method was assessed using a mouse genomic
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DNA template spiked with a plasmid DNA template homologous to the ETb locus at a
concentration equivalent to a single copy per single genome (data not shown). Our
results demonstrated that the PCR reactions utilised were of sufficient sensitivity to
detect a single homologous targeting event within a single genome equivalent.
A number of homologously targeted clones identified during the first round of
screening did not subsequently test positive following defrosting and expansion.
Although not investigated thoroughly, it is likely that such clones were a heterogeneous
population of homologously and non-homologously targeted cells prior to freezing. The
presence of the selection cassette within the ETb receptor gene locus may have conferred
a selective growth disadvantage in homologously targeted cells. Hence, when the colony
was expanded further, homologously targeted cells were overgrown by non-
homologously targeted cells. In the presence of large quantities of non-homologously
targeted cells, competition for PCR substrate may have then decreased the detection
sensitivity of the screening reaction.
This finding necessitated a second round of targeting and permitted investigation
of the effects upon targeting efficiency of the inclusion of the diphtheria toxin gene
cassette and of the site of vector linearization. Previous studies (Yagi et al., 1990) have
demonstrated up to 10-fold enrichment of ES cells featuring homologous recombination
events following gene targeting with vectors containing a diphtheria toxin gene cassette.
Fewer colonies survived following targeting with pXPW cut with Xho I compared to
those targeted with p^PW cut with Xho I and Not I, or pAPW(NoDT). From this, I
predicted that the inclusion of the diphtheria toxin gene, and its 'protection' through
retention of the pBluescript vector at the 3' end of the targeting construct, had decreased
survival of clones following non-homologous recombination events. However, the
relative proportion of homologous recombination events (2.5% and 3.4% in clones
targeted with pAPW vs. 9.4% in those targeted with pAPW(NoDT)) was not increased by
the presence of the diphtheria toxin gene. The reasons underlying this observation were
not investigated further but did reflect the subsequent experience of other groups within
our institute (Dr Andrew Smith, University of Edinburgh, personal communication).
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This finding may represent insufficient transcription of the diphtheria toxin gene cassette
in non-homologously targeted clones, possibly through gene silencing by methylation.
Gene expression may also be compromised by events occurring during the
recombination process itself. It is well recognised that host DNA modifying enzymes
may degrade the linear ends of targeting constructs. Removal of the pBluescript vector
from pAJPW by digestion with both Xho I and Not I exposed the 3' end of the diphtheria
toxin gene to such events. However, I observed no increase in the efficiency of
homologous recombination in clones targeted with constructs in which the 3' end of the
diphtheria toxin gene was protected by the pBluescript vector. Despite the apparent
absence of effect of inclusion of the diphtheria toxin gene, the targeting efficiencies
observed may not reflect true values, since less than one third of the total G418-resistant
colonies harvested were screened. The first 97 samples screened yielded sufficient
numbers of homologously targeted clones to obviate the need for further screening and
time constraints prevented further analysis.
Following initial screening for 3' recombination events, colonies were transiently
exposed to Cre recombinase to catalyse recombination reactions between loxP sites.
Gancyclovir was used to negatively select against clones in which the selection cassette
had been retained. Clone survival was dependent upon both the efficiency of
recombination-mediated removal of the selection cassette and on initial seeding density.
All colonies transfected with pMC-Cre and seeded at densities of>103 cells/plate were
killed. This may represent a 'bystander' effect, wherein individual colonies in close
contact with one another die as a result of activation of gancyclovir to the triphosphate
state in adjacent colonies in which the thymidine kinase gene is retained. In plates
seeded with 102 and 103 cells, ~ 20% of cells survived gancyclovir selection. This
suggests that recombination events between the loxP sites flanking exons 2 and 3
occurred more frequently than those involving the loxP site flanking the selection
cassette. This is likely to result from the shorter distance between these 2 sites.
Blastocyst injection of the selected clones produced chimeras in each case.
However, germline transmission was only achieved from chimeras originally derived
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from the 3B3 (2B5) clone. The reasons underlying this are not clear, but may relate to
the degree of differentiation of the ES cells injected into the blastocyst. Although
morphologically identical, I cannot discount the possibility that the clones in which
germline transmission was not observed were more differentiated than the 3B3 (2B5)
clone. Clones differentiated beyond a certain stage may lose the ability to contribute to
the germ cell lineage and hence chimeras generated from such clones will not transmit
the targeted allele. The F1 offspring of chimaeric mice in whom the floxed ETB receptor
allele was present demonstrated normal growth and fertility. The floxed allele was stably
transmitted in the predicted Medelian frequency throughout subsequent intercrosses,
permitting the breeding of homozygous floxed ETB receptor mice (Flox/Flox -/-).
Intercross of homozygous floxed mice produced no piebald offspring, indicating that
sufficient ETB receptor expression was maintained from transcription of the targeted
allele to permit normal embryogenesis.
This chapter has described the generation of homozygous floxed ETB receptor mice
through targeting of the ETB receptor allele in ES cells. PCR screening for homologous
recombination events in ES cells and for loxP sites following removal of the selection
cassette is a reliable and effective method for genotyping ES cells and mice.
Additionally, PCR screening permits the assessment of copy number differences




6.1 REDUCED 125l ET-1 BINDING TO ENDOTHELIAL CELLS FROM
FLOX/FLOX TIE2 MICE
6.1.1 INTRODUCTION
The study of gene function through the use of animal models of gene-inactivation and
gene over-expression has revealed many novel insights. However, many genes have
non-redundant roles during embryogenesis in addition to their function during adult life.
Whole animal knockout of such genes results in a lethal phenotype, precluding study of
gene function in the adult animal. Binary transgenic systems provide a mechanism by
which gene expression is dependent upon two interacting elements and may be utilised
to circumvent such problems. The Cre/loxP system (Orban et al., 1992, Sauer and
Henderson, 1989) is the best characterised of these and may be utilised to spatially
regulate mammalian gene expression in vivo. LoxP sites introduced into the genome
using standard gene targeting techniques undergo recombination only when Cre
recombinase transgenes are co-expressed within a cell. Cell type-specific expression of
the Cre recombinase transgene thus limits recombination events to the cell type or tissue
of interest. In addition to avoiding the lethal phenotype associated with whole
knockouts, this approach may be used to examine the effects of gene-inactivation in an
individual cell type in vivo without the confounding effects of gene-inactivation in other
tissues. Biological questions may, therefore, be addressed with an exquisite accuracy not
possible with conventional gene knockout or pharmacological approaches.
6.1.1.1 Endothelial cell specific knockout of the ETB receptor
Selective deletion of genes from vascular ECs became possible following the
identification of promoter and enhancer elements that limit Cre transgene expression to
this cell type (Schlaeger et al., 1997). The murine Tie2 gene encodes a tyrosine kinase
receptor for angiopoietin I, an angiogenic factor required for normal vascular
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development (Suri et al., 1996). The Tie2Cre transgene mirrors endogenous expression
of this receptor (Kisanuki et al., 2001) and consists of the 2.1 kb promoter region of the
Tie2 gene, a Cre recombinase cDNA with a metallothionine poly A signal, and a 10.1 kb
enhancer fragment of the Tie2 gene. Crosses of Tie2Cre transgenic mice with both lacZ
(Kisanuki et al., 2001) and GFP (Constien et al., 2001) floxed reporter mice have
demonstrated that recombination events in F1 offspring are limited to ECs and to cells of
the haematopoietic lineage. Recently however, recombination events have also been
noted in the germ cells of female mice featuring a floxed allele and the Tie2 Cre
transgene (Constien et al., 2001, Koni et al., 2001). This has necessitated the use of
selective breeding strategies to maintain the EC-specificity of recombination events.
To achieve EC-specific down-regulation of the ETB receptor, I have crossed mice
homozygous for the floxed ETB allele with Tie2Cre transgenic mice (a kind gift of
Professor M. Yanagisawa, University of Texas). Male F1 mice heterozygous for both the
floxed ETb allele and the Tie2Cre transgene were then crossed with homozygous and
heterozygous female floxed ETB receptor mice. This breeding strategy provided
littermates of each genotype (Flox/Flox Tie2, Flox/Flox -/-, W/W Tie2 and W/W -/-) and
minimised the variation in genetic background between experimental animals. This
breeding strategy is illustrated in Figure 6.1. In addition, a number of F2 intercrosses of
Flox/Flox Tie2 mice were established to generate mice homozygous for the recombined
ETb receptor allele. To assess the extent of recombination within the ETB receptor locus
and subsequent down-regulation of ETB receptor expression in EC-specific knockout
mice, pulmonary EC were isolated and l25I-ET-l binding measured in the presence or
absence of an ETA receptor antagonist. The ETB receptor is hypothesised to act as a
clearance receptor for circulating ET-1 (Fukuroda et al., 1994). Plasma ET-
1 concentration was, therefore, also measured in EC-specific ETB receptor knockout mice
to assess the effect upon circulating ET-1 concentration.
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Breeding Strategy for experimental animals
El Flox/Flox 5* x W/W Tie2/Tie2 £
Flox/W Tie2/-
F2 Flox/W Tie2/- 3* x Flox/Flox J or Flox/W §
Flox/Flox Tie2/- Flox/Flox -/- Flox/W -/- Flox/W Tie2/-
W/W Tie2/- W/W -/-
Breeding Strategy for piebald animals
Fi Flox/W Tie2/- & x Flox/W Tie2/- §
Flox/Flox Tie2
F2 Flox/Flox Tie 2 3^ x Flox/Flox Tie2
Flox/Flox Tie2 (1/4 piebald)
Figure 6.1
Schematic of breeding strategy used to produce EC-specific ETB receptor knockout mice
(Flox/Flox Tie2), wild type and single transgenic control animals (upper panel).
Recombination events within germ cells of female mice featuring a floxed allele and the





6.1.2.1 Genotyping offounder and offspring mice
Tail DNA was isolated from mice as described in section 2.1.13.10. Genotyping was
performed by PCR analysis using the primers 454F
(TCAGTTGTAATGAGACACAGAC) and 681R
(AGCCATAAAGTCACAGCCATTC) and an amplification protocol identical to that
described in section 2.1.13.11. These primers are complementary to regions flanking the
targeted allele. In the wild type allele this primer pair amplifies the 2197 bp region
spanning from 1496 bp upstream of exon 2 to intron 3. The targeted allele features a
deletion of a 1166 bp segment of intron 1, spanning from the Nae I site 1454 bp
upstream of exon 2 to a site 288 bp upstream of exon 2 (illustrated in Figure 6.2). Sixty
one bp were added to the 5' region and 50 bp to the 3' region (loxP sites and associated
polylinker regions) during vector construction, resulting in a net deletion of 1055 bp
from the floxed allele. Thus, wild type and floxed ETB receptor alleles produce bands of
2197 bp and 1142 bp respectively, when amplified with these primers. Tail DNA also
contains a small proportion of DNA from EC of the tail vasculature. Recombination
events within the floxed EC ETB receptor gene result in the deletion of a further 956 bp
and the appearance of a 186 bp PCR band. This genotyping strategy is illustrated in
Figure 6.2. Representative samples of PCR products from wild type, floxed and






PCR-based genotyping strategy. PCR products of 2197 bp, 1092 bp and 186 bp are
amplified from wild type, floxed and recombined alleles, respectively.
6.1.2.2 Genotyping for the Tie2Cre transgene
Offspring of Flox/Flox -I- and W/W Tie2/Tie2 crosses and subsequent offspring were
genotyped for the presence of the Tie2Cre transgene by PCR of tail tip DNA as
previously described (Kisanuki et al., 2001). The primers Tie2 98F
(CGCATAACCAGTGAAACAGCATTGC) and Tie2 101R
(CCCTGTGCTCAGACAGAAATGAGA) are complimentary to regions with the Cre
coding region and Tie2 promoter region, respectively. DNA was amplified for 35 cycles
using the following programme: 94°C for 1 minute, 60°C for 1.5 minutes, 72°C for 2




6.1.2.3 Isolation ofpulmonary endothelial cell-enriched populations from murine
lung tissue
Enriched populations of pulmonary endothelial cells were prepared as described in
section 2.1.17.1 according to the general method previously described by Dong (Dong et
al., 1997). A 100 pi aliquot of the suspension was taken for Bradford measurement of
protein concentration (Bradford, 1976) and a 700 pi aliquot used for subsequent binding
experiments.
6.1.2.4 Pulmonary endothelial cell1251ET-1 binding
0.5 p.Ci of l25I ET-1 (Amersham Pharmacia Biotech UK Ltd, Little Chalfont, UK;
Product number IM223) were diluted in 2 ml of HEPES-Ringer/0.2% BSA buffer and
100 pi (5 x 104 cpm) of the resultant solution added to 700 pi of cell suspension. The
suspension was then diluted to a final volume of 1ml by the addition of a further 200 pi
of HEPES-Ringer/0.2% BSA buffer. Unlabelled ET-1 (final concentration 3 x 10 9M),
A192621 (a selective ETB receptor- antagonist; final concentration 3 x 10~7M) or A-
147627 (a selective ETA receptor antagonist; final concentration 3 x 10"7M) was then
added and the mixtures incubated for 90 minutes at room temperature. GSL I-B4-coated
magnetic beads were prepared as described in section 2.1.17.2. Approximately 107 beads
were added and the suspension incubated for a further 30 minutes with gentle mixing at
4°C to bind ECs. Bound cells were recovered with a magnetic particle concentrator and
washed twice with ice-cold PBS/0.2% BSA solution. 125I ET-1 binding was measured in
a y-counter over a 60 second period and expressed as cpm/50pg membrane protein.
Binding in the presence of ET-1 was used as an index of non-specific binding, whilst
binding in the presence of A-147627 represented specific ETB receptor binding.
6.1.2.5 Measurement ofplasma ET-1
The low plasma concentration of ET-1 precludes direct measurement by
radioimmunoassay (RIA). ET-1 was, therefore, extracted from plasma using the
previously described acetic acid extraction technique (Rolinski et al., 1994). Briefly, 1
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ml of mouse plasma was mixed with 1 ml of 20% acetic acid and applied to a Varian
C18 Bond Elute column (Varian Inc., Lexington, USA). Columns were washed with
10% acetic acid and ethyl acetate. ET-1 was eluted in 1.5 ml of elution buffer (1 volume
of 0.05M NH4HCO3 in 4 volumes of methanol) and the sample concentrated by
evaporating to dryness under nitrogen followed by resuspension in 100 pi of RIA buffer
(3.853 g NaH2P04, 18.07 g Na2HP04, 2.927 g NaCl, 1 g BSA, 1 ml Triton X-100 and
100 mg sodium azide in 1000 ml deionised H20, pH 7.4). RIA was performed on the
concentrated sample using a Peninsula Laboratory kit for determination of plasma ET-1
(Peninsula Laboratories Europe Ltd., St. Helens, UK). In short, 100 pi of standard,
sample or control was incubated overnight with a rabbit anti-mouse ET-1 antibody. The
following day a known concentration of 125I ET-1 (Peninsula Laboratories, product
number Y6901) was added and the tubes incubated for a further 16 hours. On day 3, the
immune complexes were precipitated with Amerlex™ donkey anti-rabbit antibody. The
precipitates were counted in a y counter, a standard curve constructed and the unknown
values read from the curve. All measurements of plasma [ET-11 were performed by Neil
Johnston (Department of Clinical Pharmacology, University of Edinburgh).
6.1.3 RESULTS
6.1.3.1 Genotyping ofoffspring
A typical genotyping PCR reaction for the ETB receptor gene allele is illustrated in
Figure 6.3 and for the Tie2 transgene in Figure 6.4. Heterozygous mice (Flox/W Tie2)
demonstrate 3 bands: A 2197 bp band amplified from the wild type allele, a 1142 bp
band amplified from the non-recombined floxed allele, and a 186 bp band amplified
from recombined floxed alleles present within a sub-population of tail-derived cells.
Flox/Flox Tie2 mice exhibit bands of 1142 bp and 186 bp (floxed allele and recombined
allele) whilst Flox/Flox -/- mice exhibit only the 1142 bp band. A single band of 2197 bp
was amplified from homozygous wild type mice. Piebald offspring were produced with
the predicted Medelian frequency (1/4 of offspring) by some F2 intercrosses and
demonstrated only the 186 bp recombined allele band (Figure 6.5). The presence of the
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Representative genotyping PCR for the ETB receptor allele using the primers 454F and
681R and tail tip DNA as template. Lane 1 W/W Lane 2 Flox/W Lane 3




Representative PCR products obtained using the primers Tie2 98F and Tie2 101R to
detect the presence of the Tie2-Cre transgene in a tail tip DNA template. Lanes 1, 2, 7,
transgene absent; Lanes 3-6, 8, transgene present; Lane 9, control DNA from W/W
Tie2/Tie2 mouse.
6.1.3.2 Genotype and phenotype ofpiebald mice
Two of the 3 F2 Flox/Flox Tie2 breeding pairs produced offspring with a piebald
appearance in 1/4 of the pups. Piebald offspring were of normal size at birth, but failed
to thrive thereafter and died shortly after weaning from intestinal obstruction (illustrated
in Figure 6.5). Littermates of piebald mice were of normal pigmentation and
demonstrated normal growth and development. Evidence of the recombined allele was





F2 intercross of Flox/Flox Tie2 mice results in offspring with piebald appearance and
intestinal obstruction consistent with complete knockout of ETB receptor expression.
PCR genotyping with the primers 454F/681R demonstrates only the recombined allele in
piebald mice. An EC-specific ETB receptor knockout genotype (Flox/Flox Tie2/-) is
illustrated for comparison.
6.1.3.3 Pulmonary EC 1251ET-1 binding
125I ET-1 binding was significantly decreased in Flox/Flox Tie2 pulmonary EC
compared with wild type controls following incubation with 3 x 10 7M A147627
(cpm/50 pg membrane protein ± SEM; Flox/Flox Tie2 581 ± 67; W/W -/- 3175 ± 268;
/?<0.001; n = 3 in both groups). Total 125I ET-1 binding and l25I ET-1 binding following
incubation with 3 x 10 7M A192621 did not differ significantly between Flox/Flox Tie2
and W/W -/- pulmonary EC (total binding Flox/Flox Tie2, 6783 ± 1507; W/W -/-, 8224
± 2880; p = 0.68. Binding in presence of A192621 Flox/Flox Tie2, 4023 ± 806; W/W -/-
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, 3445 ± 522; p = 0.58; n = 3 in each group). These results are illustrated in Figure 6.6.
























Mi F/F Tie 2
*p < 0.001
Total + A192621 + ABT627
Figure 6.6
125 I ET-1 binding of isolated pulmonary EC. Binding in the presence of the selective ET^
receptor antagonist ABT627 (3 x 10"7M) was significantly decreased in Flox/Flox Tie2
cells compared to W/W -/- cells (p<0.001). Total 125I ET-1 binding and binding in the
presence of the selective ETB receptor antagonist A192621 (3 x 10"7M) did not differ
significantly between groups (n = 3 in all groups).
6.1.3.4 Plasma ET-1 concentration
Plasma ET-1 concentration was significantly increased in Flox/Flox Tie2 mice
compared with controls (mean plasma |ET-11 pg/ml ± SEM; Flox/Flox Tie2 12.40 ±
2.95; W/W -/- 2.94 ± 0.83; W/W Tie2 2.95 ± 0.85; Flox/Flox -/- 4.05 ± 0.54; p < 0.001;
n = 6 in each group) This result is illustrated in Figure 6.7. The limited number and
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Plasma ET-1 concentration is increased in Flox/Flox Tie2 mice compared to wild type
and single transgenic littermate controls (mean plasma [ET-11 pg/ml ± SEM; Flox/Flox
Tie2 12.40 ± 2.95; W/W -/- 2.94 ± 0.83; W/W Tie2 2.95 ± 0.85; Flox/Flox -/- 4.05 ±
0.54; p < 0.001; n = 6 in each group).
6.1.4 DISCUSSION
In order to examine the role of the EC ETB receptor in cardiovascular homeostasis in
vivo, I have developed the Flox/Flox Tie2 mouse model in which expression of the ETB
receptor is selectively down regulated in EC. EC-specific knockout was achieved by
intercross of 2 separate mouse strains. Floxed ETB receptor mice feature loxP sites
flanking exons 2 and 3 of the ETB receptor gene. These mice were bred to transgenic
mice in which the expression of a Cre recombinase transgene was restricted to EC
through the use of Tie2 promoter/enhancer elements. Thus, only EC contain loxP sites
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and co-express the Cre recombinase enzyme, thereby limiting recombination events to
this cell type.
I developed a PCR-based method of rapidly genotyping tail tip DNA from EC-
specific ETb receptor knockout mice. This method was able to identify wild type, floxed
and recombined alleles from a single PCR reaction. Previous PCR methods developed in
our laboratory to genotype floxed ETB receptor ES cells and floxed ETB receptor mice
were unable to identify the recombined allele because the primers used (78F/681R)
flanked only the 3' loxP site of the targeted allele. Following cross breeding of floxed
ETb receptor mice with Tie2Cre mice, recombination events would be predicted to occur
within the floxed allele of ECs, removing the region between the 5' and 3' loxP sites,
including the region complimentary to the 78F primer. Hence, a second primer pair
(454F/681R), complimentary to sequences flanking the 5' and 3' loxP sites, was
designed. Tail tip DNA will contain a small proportion of DNA derived from EC of the
tail vessels. The recombined allele was easily detected by PCR in mice homozygous for
the floxed allele and the Tie2 transgene and direct sequencing of this PCR product
confirmed the predicted post-recombination sequence. In mice heterozygous for the
floxed and wild type alleles (Flox/W Tie2), the recombined allele was fainter,
presumably reflecting the lower concentration of DNA template. However, in the
context of evidence for continued presence of both a floxed and a wild type allele, the
additional presence of the recombined allele provides good evidence that a sub-
population of cells from the tail had undergone recombination events. Tissue staining of
reporter mouse strains bearing the Tie2Cre allele (Constien et al., 2001, Kisanuki et al.,
2001) indicate that this subpopulation is likely to represent EC and I have confirmed,
through binding studies, that ETB receptor expression is down-regulated in pulmonary
EC. However, I have been unable to isolate sufficiently pure populations of EC from tail
or lung samples to conclusively demonstrate that the recombined allele is exclusively
present in EC. Isolation of tissue that does not contain either ECs or cells of the
haematopoietic lineage, in order to demonstrate the absence of recombination events in
non-EC, has also proven difficult.
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To assess the extent of functional ETB receptor down-regulation in EC through
Cre/loxP-mediated recombination, I have performed a combination of binding and
functional pharmacological studies (described in chapter 7). EC ETB receptor-specific
binding was assessed using l25I ET-1 in EC-enriched cell populations following
incubation with the selective ETA receptor antagonist A147627. 125I ET-1 binding in EC-
enriched populations from Flox/Flox Tie2 mice was decreased by -80% compared to
wild type ECs. This represents an at least 80% reduction in EC ETB receptor expression,
since some of the remaining 125I ET-1 binding may be mediated by ETB receptors on
contaminating SMC. Contamination of enriched EC populations with SMC was assessed
by measurement of both total l25I ET-1 binding and binding in the presence of the
selective ETB receptor antagonist A192621. Unlike EC, SMC express both ETA and ETB
receptors and would be expected to bind significant quantities of ET-1 in the presence of
A192621. Total l25I-ET-l binding was decreased in Flox/Flox Tie2 preparations, but this
difference did not reach significance. In the presence of A192621 l25I-ET-l binding was
still present, but there was no significant difference in binding between wild type and
Flox/Flox Tie2 EC populations. Taken together, these results confirm SMC
contamination of enriched EC populations and suggest that the extent of contamination
was comparable between groups. It is likely, therefore, that a significant portion of
residual ETB receptor-dependent binding observed in the Flox/Flox Tie2 group is
derived from contaminating SMC in which normal ETB receptor expression is
maintained. I have not isolated SMC-enriched populations to directly assess 125I ET-1
binding in Flox/Flox Tie2 and wild type mice. However, there were no abnormalities of
pigmentation or gut development and SMC ETB receptor-mediated tracheal contraction
was maintained in Flox/Flox Tie2 mice (described in chapter 7), suggesting that
expression of non-EC ETB receptors was sufficient to maintain normal physiological
responses. The results of these experiments have, therefore, demonstrated that Cre/loxP
recombination within the ETB receptor locus is sufficient to down regulate functional
ETb receptor expression by greater than 80% in vivo. This finding strongly suggests that
the floxed ETB receptor mouse is a useful tool for assessing the functional consequences
of cell type-specific ETB receptor down regulation.
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Attempts to further assess the degree of ETB receptor down-regulation by
visualisation of tissue staining with ETB receptor antibodies were unsuccessful (data not
shown). No commercially available antibody was able to reliably reproduce the pattern
of ETb receptor expression seen in 'knock-in' ETB-lacZ reporter mice (Adele Gordon,
University of Edinburgh, personal communication). Furthermore, attempts to quantify
ETb receptor protein concentration from preparations of pulmonary, aortic and renal
tissue by western blot analysis using commercial antibodies also lacked specificity.
EC-specific ETB receptor knockout mice demonstrate a ~4 fold increase in
plasma ET-1. The ETB receptor has been proposed as a clearance receptor for ET-1
(Fukuroda et al., 1994) and my data suggests that EC ETB receptors contribute
importantly to this process. Clearance of ET-1 occurs predominantly in the lung and
liver (Fukuroda et al., 1994). The relative importance of non-EC ETB receptor-mediated
clearance may be examined with further tissue-specific ETB receptor knockout models.
An alternative hypothesis is that deletion of ETB receptors could result in an increase in
the production of ET-1. ET-1 production has not been studied in other models of ETB
receptor deficiency (Berthiaume et al., 2000, Gariepy et al., 2000), although in the
rescued rat model (Gariepy et al., 2000), ETB genotype was the only significant
independent variable found to correlate with plasma [ET-1 ]. On the other hand,
clearance of 125I ET-lhas been shown to be impaired in heterozygous ETB receptor
knockout mice (Berthiaume et al., 2000). It is likely, therefore, that the increase of
plasma [ET-1] in our model represents defective clearance, rather than significantly
increased production.
Tie2Cre transgenic mice represent a novel genetic tool for the analyses of the
EC-lineage and for EC-specific gene targeting (Kisanuki et al., 2001). However, several
groups have recently reported Cre-mediated recombination events in the germline of
female mice expressing both the Tie2 Cre transgene and a floxed allele (Constien et al.,
2001, Koni et al., 2001). This process results in the presence of a recombined
maternally-derived allele in all cells of the developing embryo. The mechanism
underlying the loss of spatial regulation of Cre recombinase expression in germ cells is
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currently unknown, but may result from demethylation events that occur during
gametogenesis. I utilised the phenomenon of germ cell recombination to deliberately
generate mice that were homozygous for the recombined ETB receptor allele in all cell
types to test the hypothesis that exons 2 and 3 of the ETB receptor gene were necessary
for functional ETB receptor expression. Theoretically, expression of functional ETB
receptors may have been maintained in these mice despite recombination-mediated
removal of these coding regions. This may occur through the expression of truncated yet
functional ETB receptor protein or through 'skipping' of the mutated region by aberrant
splicing (reviewed by (Muller, 1999). Splice variants of human, but not murine, ETB
receptor RNA have been demonstrated (Shyamala et al., 1993). However, the
appearance of the piebald lethal phenotype in mice homozygous for the recombined
allele confirmed that deletion of exons 2 and 3 via Cre-loxP-mediated recombination is
sufficient to prevent normal ETD receptor function. Since completion of these
experiments, a novel deletion mutation spanning exons 2 and 3 has been identified in
ETB receptor-deficient mice (Matsushima et al., 2002). The demonstration of the piebald
phenotype in F2 offspring does not, however, imply 100% efficiency of Cre-mediated
recombination events within EC of Flox/Flox Tie2 mice. All piebalds were derived from
gametes in which a single recombination event during gametogenesis resulted in the
formation of a null ETB receptor allele. However, the results of my binding studies
would suggest that Cre-mediated recombination is sufficient to down-regulate ETB
expression by >80%.
The frequency of germ cell recombination events appears variable. I have
intercrossed F2 Flox/Flox Tie2 mice (pair 55, data not shown) and observed no evidence
of the piebald phenotype in the offspring, suggesting that there was no germ cell
recombination in this pairing. In other F2 intercrosses, piebald mice have been produced
in the expected Medelian 1:4 ratio. The precise timing of possible germ cell
recombination events has also not been determined. I have observed offspring of Flox/W
Tie2 female mice which are heterozygous for the recombined allele but do not possess
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the Tie2 transgene. This would suggest that recombination events occur during
gametogenesis prior to segregation of the floxed allele and Tie2 transgene.
The phenomenon of germ cell recombination secondary to loss of normal spatial
regulation of transgene expression does not appear to be limited solely to the Tie2Cre
transgene. The VSMC-specific Cre transgene (smooth muscle-myosin heavy chain (SM-
MHC)-Cre) has also been shown to initiate recombination events in female germ cells
(Professor Gary Owens, personal communication). It has been proposed that this may
occur secondary to transplacental transfer of Cre recombinase from uterine SMC into the
developing embryo during early gestation. Were a similar mechanism of transplacental
transfer of EC-derived Cre responsible for this phenomenon, I might expect that all
offspring homozygous for the floxed allele would be piebald. In fact, I noted several
offspring from F2 intercrosses featuring non-recombined floxed alleles. Germ cell
recombination is also observed in the offspring of male mice carrying both a floxed
allele and the inner medullary collecting duct-specific Cre transgene, Aquaporin2-Cre
(AQ2Cre). However, in these animals, GFP reporter mice have demonstrated that this
transgene is also expressed in the testis of adult animals (D. Kohan, University of Utah,
personal communication), suggesting that this process may reflect the normal spatial
pattern of AQ2 promoter activity, rather than dysregulation during gametogenesis.
Germ cell recombination events may be utilised to maximise the likelihood of
complete knockout of gene expression in EC (Constien et al., 2001). F2 offspring will
feature a single null allele in all cells, with conditional knockout of the remaining allele
in EC only. This strategy may be utilised when complete loss of expression is required
to produce the desired phenotype. However, care must be taken to ensure that
homozygous knockout of the gene in other cells does not influence the phenotypical trait
under investigation. Data from heterozygous ETB receptor knockout mice suggests that
blood pressure is increased and clearance of ET-1 is impaired (Berthiaume et al., 2000,
Berthiaume et al., 2000, Berthiaume et al., 1998) following deletion of a single allele.
For this reason, I specifically undertook breeding strategies that minimised the potential
for heterozygous knockout of the ETB receptor in the offspring.
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This chapter has described the generation and genotyping of Flox/Flox Tie2 mice
and demonstrated significant down-regulation of ETB receptor-dependent ET-1 binding
in pulmonary EC from these animals. Plasma ET-1 concentration is increased in





7.1 ENDOTHELIAL CELL SPECIFIC KNOCKOUT OF THE MOUSE ETB
RECEPTOR RESULTS IN SALT-INSENSITIVE HYPERTENSION AND
IMPAIRED VASODILATATION TO ETB RECEPTOR AGONISTS AND
ACETYLCHOLINE
7.1.1 INTRODUCTION
The importance of ETB receptors in the regulation of blood pressure and the molecular
and cellular mechanisms through which such regulation may occur, remains
controversial. Renal tubular, vascular and central nervous system ETB receptors have
been implicated in cardiovascular homeostasis (Gariepy et al., 2000, Mosqueda-Garcia
et al., 1993, Strachan et al., 1999). The aim of this study was to determine whether
endogenous EC ETB receptor signalling contributed significantly to vascular tone in the
mouse and, if so, whether this effect was important for the determination of blood
pressure. Renal tubular ETB receptors have been proposed as important regulators of
natriuretic pathways under conditions of high salt (Gariepy et al., 2000). The
contribution of EC ETB receptors expressed in the vasa recta of the renal medulla to this
process was also investigated. Previously available loss of function models feature
down-regulation of ETB receptor expression in all tissues concurrently. The relative
importance of vascular EC ETB receptors in the control of blood pressure and natriuresis
in the mouse has not, therefore, been assessed without the confounding influence of
simultaneous loss of renal tubular and VSMC ETB receptor signalling. Selective ETB
receptor antagonists are also unable to block EC ETB receptors in vivo without
concurrent blockade of ETB receptors in other cell types. Cell type-specific down-
regulation of ETb receptor expression, therefore, provides a unique and powerful method
by which to examine the relative contribution of ETB receptor signalling in a single cell
type to the regulation of complex physiological systems such as the control of blood
pressure, natriuresis or endothelial function.
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ETb receptors are expressed on both ECs and VSMCs of the vasculature (Gray et
al., 2000). EC ETB receptors mediate vasodilatation (Takayanagi et al., 1991) through
signal transduction mechanisms that result in the release of NO (Namiki et al., 1992)
and/or dilator prostagladins. In contrast, activation of VSMC ETB receptors initiates a
complex cascade of events resulting in a rise in [Ca2+Ji5 and ultimately, cellular
contraction (Sumner et al., 1992). In a given vessel or vascular bed, it is hypothesised
that the balance between endogenous activation of vasoconstrictor VSMC ETB receptors
and vasodilator EC ETB receptors will determine the overall response of the vessel to
ETb receptor agonists, including ET-land S6c. This balance may differ between vascular
beds, providing a potential mechanism for the differential regulation of vessel tone and
hence, blood flow. In humans, the net effect of endogenous ETB receptor activation in
the forearm circulation is one of vasodilatation (Verhaar et al., 1998) and the results of
these local studies have since been confirmed in the systemic circulation (Strachan et al.,
1999). Studies of localised vascular circuits in vivo have not been performed in the
mouse. However, in the rescued ETB receptor-deficient rat, pulmonary artery pressure
(PAP) and total pulmonary resistance are increased, suggesting that in the rodent
vascular ETB receptors also exert a net vasodilator effect (Ivy et al., 2001).
The phenotypical effects of alterations in vascular gene expression may be
assessed using the technique of small vessel myography (Mulvany and Halpern, 1976,
Mulvany et al., 1978). This technique permits investigation of the mechanical,
morphological and pharmacological properties of vessels in vitro. The response to the
highly selective ETB receptor agonist S6c of aortic and tracheal rings isolated from mice
featuring down regulation of EC ETB receptor expression (FIox/Flox Tie2) were
compared to those of wild type and single transgenic littermates. To demonstrate that
S6c-evoked responses were due to activation of ETB receptors, comparison was made
with vessel rings from the same animals following pre-incubation with the selective ETB
receptor antagonist A192621 (Douglas, 1997) at a dose previously shown to inhibit ETB
receptor-mediated tracheal constriction (Hay et al., 2001). Endothelial function was
assessed by measurement of the vasodilator response to ACh and the influence of acute
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blockade of NOS activity upon NE-induced vasoconstriction was studied. Endothelium-
independent vasodilatation to the diazeniumdiolate NO donor deta/NO was measured to
ensure that any changes in vasodilatation were not due to alteration of the sensitivity of
VSMC to NO. This compound was specifically chosen because, unlike sodium
nitroprusside, it decomposes spontaneously to generate NO (Horstmann et al., 2002)
requiring no prior metabolism. The long duration of action additionally permitted the
construction of stable concentration response curves (De Vriese et al., 2002).
In order to accurately assess the specific role of the EC ETB receptor in the
regulation of vascular tone and blood pressure, preservation of SMC and other non-EC
ETB receptor signalling was required. In the trachea, both ETA and SMC ETB receptors
mediate bronchoconstriction (Henry, 1993). ETB receptor-mediated bronchoconstriction
occurs through direct activation of airway SMC and through augmentation of
cholinergic nerve-mediated responses (Carr et al., 1997). Bronchoconstriction in
response to selective ETB receptor agonists was measured, therefore, to provide evidence
of the functional preservation of SMC ETB receptor signalling and hence, of the cell-
specificity of recombination events.
7.1.2 METHODS
7.1.2.1 In vivo measurement ofblood pressure
Male mice were fed either a standard chow diet (0.8% Na+ content) or high salt diet
(7.6% Na+ content) for a minimum of 21 days following weaning. Mean arterial pressure
(MAP) was measured via an indwelling carotid cannula under conscious unrestrained
conditions in 8-12 week old mice as described in section 2.1.16. Measurements were
performed in a quiet room on days 2 and 3 post-surgery to permit adequate recovery and
minimise the post-surgical stress response. Blood pressure was recorded continuously
for 90 minutes using a pressure transducer. The first 30 minutes of each recording was
disregarded to minimise the effects of acute stress when connecting the transducer.
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7.1.2.2 In vitro vascular responses ofaortic and tracheal rings
Experiments were performed on segments of aorta and trachea isolated as described in
section 2.1.15.1 from adult mice age 8-10 weeks (24.2-37.4 g). Vessels were mounted in
wire myograph chambers as described in section 2.1.15.2 and incubated with 6 ml of
fresh PSS solution at 37°C constantly bubbled with 95%/5% 02/C02. Aortic and tracheal
rings underwent a KPSS 'wake-up' protocol as described in section 2.1.15.3. In aortic
preparations, a single pre-constriction with 3 x 107M NE followed by relaxation with 10"
6M ACh was also performed. In order to eliminate any effects related to changes in
vessel tension during the course of the experiments, a baseline tension of 1.5 g (7.36
mN) for aortic rings and 0.5 g (2.45 mN) for tracheal rings was restored prior to the
construction of each dose response curve.
7.1.2.3 Isolated aortic rings
Cumulative additions of NE in half-log increments (10"8M-3xl0"6M) were made
allowing the maximal response to each dose to plateau prior to subsequent additions.
From this data, the dose of NE required to produce 80% of the maximal NE-induced
contraction (EC80) was calculated. Following a 10 minute washout period with PSS,
rings were pre-constricted to their ECg0 with NE and a concentration response curve to
cumulative half-log increments of ACh constructed (10"9M-3xl0~6M). Relaxation in
response to ACh was expressed as a percentage of the ECg0 tension. Vessels then
underwent one of the following 3 protocols: In the first protocol, a further
preconstruction with EC80 was followed by construction of a cumulative concentration
response curve to half log increments of deta/NO (10 7M-3xl04M) to assess
endothelium-independent vasodilatation. In the second and third protocols, vessels were
incubated with either 10 7M A192621 or vehicle (DMSO; 1:1000 dilution) for 20
minutes. To examine the effect of EC-specific ETB receptor down regulation upon
responses to ETB receptor-selective agonists, pre-constriction with ECg0 NE was
performed, followed by addition of 10"7M S6c. Vasodilatation was calculated as a
percentage of the ECg0 tension. In the third protocol, incubation with A192621 or vehicle
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was followed by construction of a second ACh concentration response curve. Rings
were then incubated with the NOS inhibitor L-NAME (10"4M) for 30 minutes and the
NE concentration response curve repeated. At the end of the experiment, aortic rings
were contracted with KPSS to assess the viability of the preparation and provide a
reference contraction for analysis of the NE concentration response curve. These
protocols are illustrated in Figure 7.1, Figure 7.2 and Figure 7.3. Data from vessels were
rejected if the ECgo pre-constriction exceeded >140% of the maximal NE-induced
contraction or if they failed to dilate by >50% in response to ACh. A failure to dilate by
>50% was taken as evidence of significant endothelial damage during vessel mounting.
7.1.2.4 Tracheal rings
The standard 'wake-up' protocol described in section 2.1.15.3 was followed by
construction of a concentration response curve with half log increments of carbachol (10"
8M-3x10 5M). Responses were allowed to plateau prior to addition of subsequent doses.
Rings were then washed for 20 minutes in PSS prior to incubation for 20 minutes with
either 10 7M A192621 or vehicle. A cumulative concentration response curve to half-log
increments of S6c was then constructed (10 nM-10 7M) and the rings washed prior to a
final contraction with KPSS. All contractile responses were compared to a final KPSS
reference contraction for data analysis. This protocol is illustrated in Figure 7.4.
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Protocol 1: In vitro wire myograph protocol for the assessment of responses of aortic
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Protocol 2: In vitro wire myograph protocol for the assessment of responses of aortic
rings to NE, ACh and the endothelium-independent NO donor deta/NO.
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Figure 7.3
Protocol 3: In vitro wire myograph protocol for the assessment of the responses of aortic
rings to ACh following selective ETB receptor antagonism and to NE following
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In vitro wire myograph protocol for the assessment of tracheal contraction in response to
carbachol and the selective ETB receptor agonist S6c.
7.1.2.5 Analysis of results
P values for MAP were derived using 2 factor analysis of variance (ANOVA) with
Bonferroni post-test analysis. S6c-induced vasodilatation was compared using repeated
measures ANOVA with Dunnett's Multiple Comparison post-test analysis. P values for
concentration response curves were obtained by 2 factor ANOVA. A probability value
ofp<0.05 was considered statistically significant. Geometric mean log EQqvalues were
calculated from linear regression analyses of data sets. All analysis was performed using




7.1.3.1 In vivo blood pressure
Mean arterial pressure was significantly elevated in Flox/Flox Tie2 compared with
control mice when fed either a normal or high salt diet (MAP ± SEM; Flox/Flox Tie2
137.2 ± 6.4 (n = 5); W/W -/- 113.7 ± 4.7 (n = 6; p<0.05). Pre-treatment with a high salt
diet for 3 weeks did not significantly increase blood pressure in either wild type or
Flox/Flox Tie2 mice above that observed on a normal salt diet (High salt diet; Flox/Flox
Tie2 141.0 ± 6.7 (n = 5); W/W -/- 118.3 ± 5.0 (n = 4; p=0.48 compared to normal salt
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Figure 7.5
MABP measured via in-dwelling carotid cannula in mice under conscious unrestrained
conditions. Mice were fed a standard (0.8% NaCl) or high salt (0.76% NaCl) chow diet
from weaning for a minimum of 21 days prior to BP measurement. MABP was
measured on days 2 and 3 post-surgery. MABP was significantly increased in Flox/Flox
Tie2 mice compared to wild type controls on both a normal and high salt diet. High salt
diet had no significant additional effect upon MABP (MABP mmHg ± SEM; 0.8% NaCl
diet Flox/Flox Tie2, 137.2 ± 6.4 (n = 5); W/W -/-, 113.7 ± 4.7 (n = 6; p<0.05); 7.6%
NaCl diet Flox/Flox Tie2, 141.0 ±6.7 (n = 5); W/W -/-, 118.3 ± 5.0 (n = 4; p=0.4S
compared to normal salt diet).
7.1.3.2 Aortic vasoconstriction to NE
NE produced concentration-dependent contraction of aortic rings in all groups. NE-
induced contraction did not differ between groups (logEC^ ± SEM: Flox/Flox Tie2, 7.32
± 0.15; W/W -/-, 7.43 ± 0.22; W/W Tie2, 7.36 ± 0.19; Flox/Flox -/-, 7.40 ± 0.21; p
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=0.50; EMax ± SEM; Flox/Flox Tie2, 76.09 ± 5.78; W/W -/-, 85.66 ± 9.50; W/W Tie2,
63.80 ± 6.23; Flox/Flox 69.47 ± 7.25; p = 0.19; n = 16 in each group). These results are























Contraction of aortic rings in response to NE. LogEQo ± SEM: Flox/Flox Tie2, 7.32 ±
0.15; W/W -/-, 7.43 ± 0.22; W/W Tie2, 7.36 ±0.19; Flox/Flox -/-, 7.40 ±0.21; EMax ±
SEM; Flox/Flox Tie2, 76.09 ± 5.78; W/W -/-, 85.66 ± 9.50; W/W Tie2, 63.80 ± 6.23;




7.1.3.3 Aortic vasodilatation to ACh
ACh-induced concentration-dependent relaxation of aortic rings in all groups. There was
a significant rightwards shift of the concentration-response curve in aortic rings from
Flox/Flox Tie2 mice (logEC^ ± SEM: Flox/Flox Tie2, 6.76 ± 0.08; W/W -/- 6.87 ±0.10;
W/W Tie2 7.04 ± 0.07; Flox/Flox -/- 6.82 ± 0.09; /?<0.011); There was a trend towards a
decreased maximal ACh-induced relaxation in Flox/Flox Tie2 rings that did not reach
statistical significance (EMax ± SEM: Flox/Flox Tie2, 70.29 ± 3.44; W/W -/-, 75.19 ±
3.41; W/W Tie2, 79.67 ± 2.82; F/F -/-, 82.08 ± 3.64; p=0.07; n = 16 in each group).









Aortic vasodilatation in response to ACh. ACh-induced vasodilatation was significantly
impaired in Flox/Flox Tie2 aortic rings compared to control vessels (LogECgo ± SEM:
Flox/Flox Tie2, 6.76 ± 0.08; W/W -/-, 6.87 ± 0.10; W/W Tie2, 7.04 ± 0.07; Flox/Flox -/-
6.82 ± 0.09; p<0.011; n = 16 in each group).
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7.1.3.4 Effect ofacute ETB receptor inhibition upon aortic vasodilatation to ACh
Prior incubation with A192621 significantly inhibited ACh-induced vasodilatation in
aortic rings from W/W -/- mice but not Flox/Flox Tie2 mice (logEC^ ± SEM; W/W -/-,
6.76 ± 0.06; W/W -/- with A192621, 6.38 ± 0.08; p<0.001; Flox/Flox Tie2, 6.30 ± 0.04;
Flox/Flox Tie2 with A192621 6.33 ± 0.06; p>0.05; EMax ± SEM; W/W -/-, 90.30 ± 3.05;
W/W -/- with A192621, 73.11 ±3.22; /xO.001; Flox/Flox Tie2, 76.84 ± 2.86; Flox/Flox
Tie2 with A192621, 72.86 ± 2.50; p>0.05; n = 6 in each group). These results are




















Aortic vasodilatation in response to ACh following incubation with either the selective
ETb receptor antagonist A192621 (10 7M) or vehicle. Prior incubation with A192621
significantly inhibited ACh-induced vasodilatation in aortic rings from W/W -/- mice but
not Flox/Flox Tie2 mice (logEQo ± SEM; W/W -/-, 6.76 ± 0.06; W/W -/- with
A192621, 6.38 ± 0.08; /?<0.001; Flox/Flox Tie2, 6.30 ± 0.04; Flox/Flox Tie2 with
A192621 6.33 ± 0.06; p>0.05; n = 6 in each group).
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7.1.3.5 Aortic vasodilatation to deta/NO
The endothelium-independent NO donor, deta/NO, produced concentration-dependent
relaxation of aortic rings preconstricted to EC80 with NE. There was no significant
difference in deta/NO-induced vasodilatation between wild type and Flox/Flox Tie2
mice (logEC^ ± SEM: Flox/Flox Tie2, 5.46 ± 0.09; W/W -/-, 5.51 ± 0.07; n = 6 in each















Vasodilatation of aortic rings in response to Deta/NO. There was no significant
difference in endothelium-independent vasodilatation between aortae of wild type and
Flox/Flox Tie2 mice (LogEC*, ± SEM: Flox/Flox Tie2 5.46 ± 0.09; W/W -/- 5.51 ±
0.07; n = 6 in each group; /x>0.05).
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7.1.3.6 Aortic vasoconstriction to NE following inhibition ofNOS
NE-induced contraction of aortic rings was increased following inhibition of NOS with
L-NAME in W/W -/- (p<0.001) and Flox/Flox Tie2 (p<0.01) mice. Contraction
following L-NAME was increased to a greater extent in W/W -/- aortic rings compared
to Flox/Flox Tie2 aortic rings (logEC* ± SEM; W/W -/-, 7.15 ± 0.15; W/W -/- with L-
NAME, 8.15 ± 0.06; Flox/Flox Tie2, 7.47 ± 0.06; Flox/Flox Tie2 with L-NAME, 7.87 d




























Contraction of aortic rings in response to NE following incubation with L-NAME (10
4M) was significantly increased compared to incubation with vehicle (LogEC^ ± SEM;
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Figure 7.11
Contraction of aortic rings in response to NE following incubation with L-NAME (10
4M) was significantly increased compared to incubation with vehicle (LogEC*, ± SEM;
Flox/Flox Tie2 7.47 ± 0.06; Flox/Flox Tie2 with L-NAME 7.87 ± 0.07; n = 6 in each
group; /?<0.05).
7.1.3.7 Aortic vasodilatation to S6c
The vasodilator response to 10 7M S6c was significantly attenuated in Flox/Flox Tie2
mice compared to W/W -/-, W/W Tie2 and Flox/Flox -/- littermates (mean % dilatation
± SEM; Flox/Flox Tie2, 6.38 ± 1.78; W/W -/-, 16.69 ± 1.30; W/W Tie2, 20.42 ± 3.77;
Flox/Flox -/-, 16.73 ±2.81; £><0.05, n = 10 in each group). Following incubation with
A192621, aortic rings from control animals demonstrated no significant differences in
S6c-induced vasodilatation compared to Flox/Flox Tie2 aortic rings incubated with
vehicle (W/W -/- with A192621, 5.69 ±3.17; W/WTie2 with A192621, 3.17 ± 3.30;
Flox/Flox -/- with A192621, 4.44 ± 2.49; p>0.05, n = 10 in each group). Prior incubation
with A192621 significantly inhibited the vasodilator response of W/W -/-, W/W Tie2
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and Flox/Flox -/- vessels (p <0.05), but not Flox/Flox Tie2 vessels (Flox/Flox Tie2 with
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Figure 7.12
In vitro S6c-induced vasodilatation of aortic rings. Dilatation in response to S6c (as a
percentage of NEg0) was significantly impaired in aortae from Flox/Flox Tie2 mice
(mean % dilatation ± SEM; Flox/Flox Tie2, 6.38 ± 1.78; W/W -/-, 16.69 ± 1.30; W/W
Tie2, 20.42 ± 3.77; Flox/Flox -/-, 16.73 ±2.81; p<0.05, n = 10 in each group). Following
incubation with the selective ETB receptor antagonist A192621, S6c-induced
vasodilatation of aortae from W/W -/-, W/W Tie2 and Flox/Flox -/- mice did not differ
significantly from untreated Flox/Flox Tie2 aortae (W/W -/- with A192621, 5.69 ± 3.17;
W/W Tie2 with A192621, 3.17 ± 3.30; Flox/Flox -/- with A192621, 4.44 ± 2.49; p >
0.05; n = 10 in each group).
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7.1.3.8 Tracheal constriction to S6c
With the exception of piebald mice, tracheal rings isolated from each genotype of mice
demonstrated dose dependent contraction in response to S6c (illustrated in Figure 7.13).
There was no significant difference in the response of Flox/Flox Tie2 tracheas compared
to tracheas isolated from W/W -/- or W/W Tie2 mice (EMax ± SEM; W/W 20.07 ±
2.88; W/WTie2, 15.73 ± 2.05; Flox/Flox -/-, 10.67 ± 2.17; Flox/Flox Tie2, 18.74 ±
2.24; LogEQo ± SEM; W/W -/-, 9.54 ± 0.42; W/W Tie2, 9.10 ± 0.30; Flox/Flox -/-, 9.23
± 0.47; Flox/Flox Tie2, 9.22 ± 0.29; p>0.05 in all groups; n = 16 in each group). In
contrast, tracheas from piebald mice demonstrated no contractile response to S6c (EMax-
0.84 ± 0.44; n = 4). Prior incubation with A192621 significantly attenuated the S6c-
induced contractile response of tracheas from all genotypes (EMax in the presence of
A192621 ± SEM; W/W -/-, 5.36 ± 1.92; W/W Tie2, 2.95 ± 0.76; Flox/Flox -/-, 0.17 ±
0.49; Flox/Flox Tie2, 3.23 ± 1.25; n = 16 in each group; /?<0.001).
7.1.3.9 Tracheal constriction to carbachol
Maximal carbachol-induced tracheal contraction was significantly impaired in Flox/Flox
Tie2 and piebald mice (E^ ± SEM; W/W -/- 190.1 ± 7.90; W/W Tie2, 192.4 ± 7.88;
Flox/Flox -/-, 188.6 ±5.41; Flox/Flox Tie2, 153.5 ± 3.72; piebald, 146.7 ±8.26.
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Figure 7.13
In vitro S6c-induced constriction of tracheal rings. S6c-induced tracheal constriction in
Flox/Flox Tie2 mice did not differ significantly from W/W -/- and W/W Tie2 controls
(maximal contraction expressed as % of maximal contraction with KPSS ± SEM; W/W -
/-, 20.07 ± 2.88; W/W Tie2, 15.73 ± 2.05; Flox/Flox -/-, 10.67 ± 2.17; Flox/Flox Tie2,
18.74 ± 2.24; n = 16 in each group, /?>0.05). S6c-induced constriction was significantly
impaired in piebald mice and following incubation of tracheal rings from other
genotypes with A192621 (piebald, -0.84 ± 0.44; W/W -/- with A192621, 5.36 ± 1.92;
W/W Tie2 with A192621, 2.95 ± 0.76; Flox/Flox -/- with A192621, 0.17 ± 0.49;
Flox/Flox Tie2 with A192621, 3.23 ± 1.25; p <0.001; n = 16 in each group except












In vitro carbachol-induced constriction of tracheal rings. Maximal carbachol-induced
tracheal contraction (as percentage of KPSS-induced contraction) was significantly
impaired in Flox/Flox Tie2 and piebald mice (EMax ± SEM; W/W -/- 190.1 ± 7.90; W/W
Tie2 192.4 ±7.88; Flox/Flox -/- 188.6 ± 5.41; Flox/Flox Tie2 153.5 ±3.72; piebald
146.7 ± 8.26; p< 0.005; n = 16 in all groups except piebald (n = 8)).
7.1.4 DISCUSSION
I have examined resting blood pressure and the in vitro vascular and tracheal responses
of mice featuring EC-specific down-regulation of ETB receptor expression. EC-specific
down-regulation of ETB receptor expression results in hypertension in mice that is
unaffected by increasing dietary salt. Previous models of ETB receptor deficiency
(Berthiaume et al., 2000, Gariepy et al., 2000, Murakoshi et al., 2002, Ohuchi et al.,
1999) and pharmacological ETB receptor blockade (Giardina et al., 2001, Pollock, 2001,
Pollock and Pollock, 2001, Wessale et al., 2002) also demonstrate hypertension. In each
of these models under conditions of normal salt, the increase in blood pressure tends to
be relatively modest. The degree of hypertension observed in our EC-specific ETB
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receptor-deficient mice (MAP ~140 mmHg) is similar to that of rats treated with
A192621 (MAP ~144 mmHg) (Giardina et al., 2001), but greater than that observed in
the rescued ETB receptor-knockout rat (MAP ~125 mmHg) (Gariepy et al., 2000) and
mouse (MAP~123 mmHg (Murakoshi et al., 2002). When these models were exposed
to high salt, blood pressure became further elevated (MAP ~170 mmHg). This response
may result from loss of normal ETB receptor-mediated inhibition of ENaC activity in the
distal nephron, with consequent inappropriate reabsorbtion of sodium (Gariepy et al.,
2000). The results of my studies suggest that the EC ETB receptor exerts a tonic
hypotensive effect under normal and salt-loaded conditions but that preservation of
distal tubular ETB receptor signalling is protective against salt-induced hypertension.
The response of Flox/Flox Tie2 mice to complete ETB receptor blockade following high
salt diet and the effect of addition of ENaC-selective doses of amiloride may now be
examined to determine the precise contribution of distal tubular ETB receptor signalling
to salt sensitivity. Using the floxed ETB receptor mouse developed for this study, distal
tubular cell-specific knockout of the ETB receptor is also now possible through crosses
with AQ2Cre transgenic mice (Nelson et al., 1998). Blood pressure under normal salt
and high salt conditions in these animals will help to further define the importance of
distal tubular ETB receptors in the response to salt.
A loss of endothelium-dependent ETB receptor-mediated vasorelaxant pathways
may also contribute to salt-sensitive increases in blood pressure. Previous groups have
demonstrated that these pathways are upregulated during high salt conditions (Giardina
et al., 2001). In my study, blood pressure was slightly increased in Flox/Flox Tie2 mice
following a high salt diet. A similar increase was also observed in wild type mice on a
high salt diet. It is unclear, therefore, whether the small blood pressure difference
represents a non-specific response to high salt or was directly related to loss of EC ETB
receptor-dependent vasorelaxant pathways in Flox/Flox Tie2 mice. Loss of ETB
receptor-dependent vasodilatation may affect blood pressure through alteration of
peripheral vascular resistance or through changes in sodium handling within the kidney.
ET-1 activates ETB receptors in the renal medulla increasing medullary blood flow
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(Gurbanov et al., 1996) and promoting natriuresis. This effect is mediated via the release
of NO (Hoffman et al., 2000) and ETB receptor-dependent medullary vasodilatation
appears to be particularly important under high salt conditions (Pollock et al., 2000,
Pollock and Pollock, 2001, Vassileva et al., 2003). Specifically, the medullary ETB
receptor is thought to regulate the relationship between perfusion pressure and
natriuresis during high salt conditions (Vassileva et al., 2003). I have demonstrated that
EC-specific ETB receptor down-regulation does not result in significant salt sensitivity.
However, whether the pressure-natriuresis-diuresis relationship remains normal
following loss of medullary vasa recta EC ETB receptors is unknown. EC-specific mice
also exhibit increased plasma ET-1 concentration. The relative contribution of ETA
receptor-mediated responses to the hypertensive phenotype will provide an interesting
avenue of further investigation. Whilst our results suggest that the EC ETB receptor
mediates a tonic hypotensive effect under normal and high salt conditions, measurement
of MAP in single transgenic littermates is also required to ensure that the observed blood
pressure effect is not due to either the presence of the Tie2Cre transgene or genetic
manipulation of the ETB receptor gene locus itself.
Aortic rings from EC-specific ETB receptor knockout mice demonstrate impaired
vasodilatation in response to S6c. S6c-induced vasodilatation in wild type mice is
significantly inhibited by the selective ETB receptor antagonist A192621, suggesting that
this response is ETB receptor-dependent. Taken together, these results imply the
functional absence of vasodilator EC ETB receptors in Flox/Flox Tie2 mice.
Vasodilatation following ETB receptor activation is likely to be endothelium-dependent
and mediated through the generation of NO and/or dilator prostaglandins (Ohuchi et al.,
1999) (Giardina et al., 2001). Studies in humans demonstrate that ETB receptor-mediated
vasodilatation in the forearm is dependent upon the release of NO and that inhibition of
prostaglandin synthesis has little effect (Verhaar et al., 1998). In the mouse the evidence
is less clear. The increase in blood pressure following acute ETB receptor blockade in
wild type mice may be attenuated by pre-treatment with indometacin but not NG-
monomethyl-L-arginine (Ohuchi et al., 1999), suggesting that tonic ETB receptor-
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mediated vasodilatation depends upon the release of dilator prostaglandins. ETB
receptor-dependent vascular NO release may also be important, however, since rescued
ETb receptor knockout mice are hypertensive and fail to increase vascular tissue NOx
levels following carotid artery ligation (Murakoshi et al., 2002). The difference in these
observations may represent strain-specific differences, or differences between the
vascular beds studied. However, the results of my study also suggest that loss of ETB
receptor signaling results in a decrease in NO bioavailability. I examined in vitro
endothelium-dependent and endothelium-independent vasodilatation in aortic rings and
found that Flox/Flox Tie2 mice exhibit impaired ACh-induced vasodilatation compared
to wild type littermates. Impaired vasodilatation in response to ACh is a recognised
marker of endothelial dysfunction (Haynes and Webb, 1998) and may be secondary to a
decrease in EC-derived NO .To examine whether EC-specific ETB receptor knockout
mice have decreased bioavailability of NO as a result of loss of endogenous ETB
receptor signaling, I examined contraction of aortic rings before and following inhibition
of NOS with L-NAME. In wild type vessels, inhibition of NO synthesis resulted in a
marked potentiation of NE-induced vasoconstriction. In contrast, the increase following
NOS inhibition in Flox/Flox Tie2 mice was much smaller, suggesting that in these mice
NO contributes to resting vascular tone to a lesser extent. In addition, vasodilatation to
ACh was inhibited in wild type vessels following acute pharmacological antagonism of
ETb receptors. This is likely to be a result of EC ETB receptor blockade since
pharmacological ETB receptor antagonists had no additional effect upon ACh-induced
vasodilatation in Flox/Flox Tie2 mice, in which VSMC ETB receptor signalling is
maintained. Endothelium-independent vasodilatation, as assessed by vasodilatation in
response to deta/NO, did not, however, differ between wild type and Flox/Flox Tie2
mice. This implies that the sensitivity of VSMC to NO did not differ between genotypes.
Taken together, these results suggest that the basal release of NO from the aortic
endothelium is decreased as a result of EC-specific ETB receptor down regulation. The
increased blood pressure observed in EC-specific ETB receptor knockout mice may also
have contributed to endothelial dysfunction through non-ETB receptor-dependent
mechanisms. However, Ryan and colleagues (Ryan et al., 2002) recently reported no
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correlation between endothelial function and blood pressure in a variety of commonly
used experimental mouse strains. Of note in their study was the finding that strains with
markedly impaired aortic responses to ACh (e.g. 129X1/SV) were found not to have
generalised endothelial dysfunction when vasodilatation to other endothelium-dependent
dilators was assessed. Significant differences in ACh response between resistance and
conductance vessels within individual strains were also seen. To examine resistance
vessel function, I performed pilot studies in mesenteric arterioles at the start of
phenotyping but trauma to the endothelium during mounting of these small vessels
resulted in marked variation in endothelium-dependent vasodilatation within a single
genotype. Hence, the aorta was utilised for all subsequent studies. It is thus currently
unclear whether our findings represent generalised endothelial dysfunction, or rather a
specific impairment of ACh signalling in the aorta. Such a phenomenon might occur
were the ETB receptors to exert a permissive influence upon muscarinic receptor
signalling. Interestingly, I have observed impaired contractile responses of tracheal rings
to the cholinergic agonist carbachol in EC-specific and complete (piebald) ETB receptor
knockout mice. The mechanism underlying this response is unclear, but may point to a
specific interaction between the ETB receptor and muscarinic receptors. At present, I
cannot discount the possibility that genes that influence muscarinic receptor signalling
have not preferentially segregated with the modified ETB receptor gene. Thus, despite
the use of littermates as controls, small differences in genetic background may still have
influenced blood pressure and vascular responses.
Several mechanisms may underlie the decrease in NO bioavailability observed
following EC-specific ETB receptor down-regulation. Normally ET-1, via activation of
the EC ETb receptor, induces expression of eNOS protein, eNOS mRNA and production
of nitrite species (Zhang et al., 1999). Thus, despite an increase in ET-1 concentration in
Flox/Flox Tie2 mice, loss of EC ETB receptor signalling may result in down-regulation
of eNOS expression. This finding has been reported in the pulmonary vasculature of
rescued ETB receptor knockout rats (Ivy et al., 2001). eNOS content was reduced and
NO production diminished in this model, with a resultant increase in PAP. A diminished
210
Chapter 7
pool of eNOS may impair the generation of NO via non-ETB receptor-mediated
pathways, producing generalised endothelial dysfunction. I observed impaired ACh-
induced vasodilatation following acute pharmacological ETB receptor antagonism. In the
absence of a hypothetical ETB receptor-dependent permissive effect upon muscarinic
receptor activity, this finding might suggest that ETB receptor-mediated NO release
contributes importantly to basal vascular tone irrespective of eNOS protein content. The
bioavailability of NO may be also be diminished by an increase in the production of
reactive oxygen species (ROS) following ETB receptor inhibition or down-regulation.
Recently, an increase in vascular NADPH oxidase activity has been described in
transgenic mice featuring EC-specific overexpression of preproET-1 (Dr E. Schriffrin,
Montreal, personal communication). The increase in plasma ET-1 concentration in
Flox/Flox Tie2 mice may have similarly upregulated NADPH oxidase activity with a
consequent increase in ROS.
Were a decrease in NO bioavailability the cause of the impaired response to
ACh, it might have been predicted that NE-induced aortic vasoconstriction would be
potentiated in EC-specific ETB receptor knockouts. I found no difference in the
contractile response to NE between Flox/Flox Tie2 and wild type mice prior to
inhibition of eNOS with L-NAME. However, the response to NE was decreased in W/W
Tie2 mice and, although not statistically significant, there was also a trend towards
greater ACh-induced vasodilatation in this genotype. The mechanisms underlying this
observation are unclear, but perhaps suggest greater endogenous NO release in W/W
Tie2 mice.
The pattern of Cre expression in Tie2-Cre transgenic mice may be used to predict
the pattern of ETB receptor down-regulation in Flox/Flox Tie2 mice. Double transgenic
Tie2-Cre CAG-CAT-Z mice only express lacZ following Cre-mediated recombination.
Staining patterns in these mice (Kisanuki et al., 2001) suggest limitation of
recombination events to ECs and to mesenchymal cells of the atrioventricular canal and
proximal cardiac outflow tract (reviewed in section 2.1.3.1). To confirm the tissue-
specific pattern of ETB receptor down-regulation, I performed functional studies in
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tracheal rings isolated from Flox/Flox Tie2 mice and littermate controls. Both ETB and
ETa receptors mediate contractile responses to ET-1 in the mouse trachea (Hay et al.,
2001). My results, using the selective ETB receptor agonist S6c, confirm that the ETB
receptor is an important mediator of tracheal constriction. This response may be
completely blocked by the selective ETB receptor antagonist A192621. S6c-induced
tracheal constriction was maintained in Flox/Flox Tie2 mice and was inhibited by
A192621, consistent with maintenance of normal expression of ETB receptors in SMC.
In contrast, piebald mice demonstrated no response to S6c, in keeping with previous
studies (Hay et al., 2001). ET-3 has been shown to elicit a bi-phasic contractile response
in tracheal preparations. The initial phase is mediated via ETB receptors and is followed
by a second, ETA receptor-mediated phase (Hay et al., 2001). The absence of S6c-
induced tracheal contraction in piebald mice further demonstrates that S6c is a selective
agonist of the ETB receptor in the trachea. Thus, I did not utilise selective ETA receptor
selective antagonists during our studies of tracheal responses.
I measured blood pressure under conscious unrestrained conditions via an in¬
dwelling carotid arterial cannula. This method permits the chronic direct measurement
of systolic, diastolic and mean blood pressure and heart rate without the confounding
cardio-depressant influence of most commonly used anaesthetic agents (Davisson et al.,
1998). I performed blood pressure measurement on days 2 and 3 following surgery.
Problems with maintaining patency of the carotid cannulae for periods of greater than 5
days, despite daily flushing with heparin, precluded more prolonged recovery periods.
Implantable telemetry devices for blood pressure measurement are now generally
regarded as the 'gold standard' method for in vivo blood pressure monitoring and can
provide recordings for up to 60 days (Butz and Davisson, 2001, Carlson and Wyss,
2000). These devices have demonstrated that restoration of normal circadian rhythm and
normalisation of blood pressure and heart rate following surgery can require 5-7 days
(Butz and Davisson, 2001). I observed no significant changes in blood pressure from
days 1 to 5 in a limited sub-group of our mice, but I cannot discount that a further fall in
blood pressure may occur at a later time point. The technique of carotid arterial
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cannulation has several limitations. In common with all surgical procedures, there is an
immediate associated mortality and morbidity, predominantly consisting of
haemorrhage, cerebral infarction and post-operative infection. This is largely dependent
upon the skill of the surgeon and in our hands was <10% of operated animals. However,
late surgical complications were also apparent. These consisted of cerebral
ischaemia/infarction during flushing of the cannula with heparinised saline and late
blockage of the cannulae. Overall, around 40% of animals initially operated upon did not
yield data. To overcome the limitations of this methodology, future studies might adopt
the use of implantable telemetric devices for measurements of blood pressure using a
modified technique in which the pressure-sensing catheter is located in the thoracic
rather than the abdominal aorta (Butz and Davisson, 2001). Alternative methods for the
in vivo measurement of systolic blood pressure include tail cuff plethysmography.
However, this method requires extensive training, heating and restraint and, although
well established in the rat, the small diameter of the mouse tail and the significant stress
response associated with measurements, results in large variations in the observed
pressure within groups. This method might, therefore, also be considered too insensitive
to detect small but significant differences between experimental groups.
In summary, this chapter has described the effects upon blood pressure and in
vitro vascular function ofEC-specific ETB receptor knockout mice. These mice
demonstrate hypertension that is unaffected by dietary salt, suggesting that the EC ETB
receptor exerts a tonic hypotensive effect in the mouse and that salt-sensitivity is
determined by IMCD ETB receptors. Additionally, I noted impaired aortic vasodilatation
to ACh and evidence to suggest a decrease in NO bioavailability following EC ETB
receptor downregulation. Finally, ETB receptor-mediated tracheal constriction in these






The endothelin system is a key regulator of cardiovascular homeostasis and plays an
important role in the pathogenesis of hypertension (Cardillo et al., 1999, Schiffrin, 1999)
and cardiac failure (Krum et al., 2001, Luscher et al., 2002). However, despite initial
promise as novel therapeutic agents, endothelin antagonists have not shown significant
benefit in most long-term clinical trials in cardiac failure in humans. Although part of
this failure may be ascribed to side effects related to the dose of the endothelin
antagonist studied, considerable debate still remains over whether non-selective
antagonism of endothelin receptors offers significant therapeutic advantages over
selective ETA receptor antagonism. To answer this question requires a more complete
understanding of the complex physiological role of the ETB receptor. The ETB receptor
serves multiple functions in the adult animal, including mediating vasodilatation
(Takayanagi et al., 1991), vasoconstriction (Sumner et al., 1992), modulation of sodium
reabsorbtion in the distal nephron (Gariepy et al., 2000) and clearance of ET-1 from the
circulation (Fukuroda et al., 1994). Each of these functions may independently influence
blood pressure and the response to salt loading. Current models of ETB receptor
deficiency and in vivo pharmacological studies are unable to differentiate the relative
contribution of each of these functions to the complex homeostatic process of blood
pressure control, since all ETB receptors are blocked concurrently in these approaches.
Hence, it has not been possible to assess the relative importance of ETB receptors located
on different cell types in the regulation of vessel tone, blood pressure and clearance of
ET-1. To address these critical questions, I have developed a mouse model that permits
the tissue-specific down-regulation of ETB receptor expression (Bagnall et al., 2003,
Bagnall et al., 2000). The 'floxed' ETB receptor mouse features loxP sites located in
intronic regions flanking exons 2 and 3 of the ETB receptor gene, permitting cell specific
removal of essential coding regions when crossed with mice in which expression of a
Cre recombinase transgene is spatially restricted. The phenotypical effects of loss of ETB
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receptor function within an individual cell type, in the context of normal ETB receptor
function in all other cells, can, therefore, be examined. Detailed pharmacological studies
of different tissue-specific ETB receptor knockouts may also be used to permit precise
cellular localisation of key regulatory functions and enable definition of the relative
importance of ETB receptor signalling in each cell type. My specific interest lay in
understanding the role of the EC ETB receptor in the control of blood pressure, vascular
tone and the clearance of ET-1 from the circulation. In humans, activation of EC ETB
receptors results in the release of NO (Verhaar et al., 1998), with the potentially
beneficial cardiovascular effects of vasodilatation and inhibition of platelet aggregation.
Preservation of ETB receptor signalling through the use of selective ETA receptor
antagonists, may, therefore, have advantages over non-selective antagonists. To
investigate the relative importance of EC ETB receptor signalling, I have crossed the
'floxed' ETb receptor mouse with the Tie2Cre transgenic mouse (Kisanuki et al., 2001)
to produce offspring in which ETB receptor down-regulation is limited to EC and cells of
the haematopoietic lineage. This thesis has described the generation of the 'floxed' ETB
receptor mouse and early experiments in the phenotyping of the EC-specific ETB
receptor knockout mouse. I have conducted experiments to confirm down-regulation of
EC ETb receptor expression and maintenance of ETB receptor function in non-EC. I have
examined the effects of EC-specific ETB receptor knockout upon resting blood pressure
under normal and salt-loaded conditions, vascular responses to ETB receptor agonists,
NE, ACh and NO donors, and upon the circulating concentration of ET-1 in the plasma.
These findings are summarised below:
8.1.1 GENERATION OF FLOXED ETB RECEPTOR MICE AND MICE
FEATURING ENDOTHELIAL CELL-SPECIFIC ETB RECEPTOR DOWN-
REGULATION
LoxP sites flanking exons 2 and 3 of the ETB receptor gene were introduced into the ETB
receptor gene locus through gene targeting events in ES cells. The targeting construct
was prepared from fragments of the ETB receptor genome isolated from a X phage
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129/SV mouse genomic library, combined with selection cassettes encoding for
neomycin resistance, thymidine kinase and diphtheria toxin genes. Targeting events
within the ETB receptor locus were identified by selection with neomycin and screening
by PCR and southern blotting used to detect homologous recombination events. The
neomycin/thymidine kinase selection cassette was subsequently removed by initiation of
a recombination reaction between loxP sites flanking the cassette. Clones underwent
further selection with gancyclovir to remove clones retaining the thymidine kinase gene,
followed by a second round of screening by PCR, and then were extensively sequenced
prior to injection into blastocysts. Germline transmission of the targeted locus was
achieved in a single clone (3B3 (2B5)) and the offspring of this mouse were intercrossed
to produce mice homozygous for the floxed ETB receptor allele. Floxed ETB receptor
mice were of normal appearance, birth weight and longevity, consistent with
maintenance of functional ETB receptor expression during embryogenesis (Gariepy et
al., 1996). The genetic background of floxed mice was ~50:50 129/SV:BKW strain.
To generate mice in which the expression of ETB receptors was down-regulated
in EC, 'floxed' ETB receptor mice were crossed with Tie2Cre transgenic mice (Kisanuki
et al., 2001). When tail DNA was screened with PCR primers flanking the ETB receptor
gene, heterozygous Flox/W Tie2/- mice demonstrated bands of 186 bp in addition to the
floxed and wild type bands, consistent with recombination events within the ETB
receptor gene locus in a proportion of cells. The recombined allele band was brighter
when tail DNA derived from Flox/Flox Tie2 mice was amplified and direct sequencing
of this band confirmed the predicted post-recombination sequence of the ETB receptor
gene. The results of previous reporter mouse studies (Constien et al., 2001, Kisanuki et
al., 2001) using Tie2Cre transgenic mice suggest that these recombination events were
present in the EC of the tail vasculature and I confirmed decreased ETB receptor-
mediated binding in EC (described in section 8.1.3). Mice featuring complete knockout
of the ETb receptor demonstrated only the recombined allele band.
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8.1.2 RECOMBINATION-MEDIATED REMOVAL OF EXONS 2 AND 3 OF THE
ETb RECEPTOR GENE IS SUFFICIENT TO PREVENT EXPRESSION OF
FUNCTIONAL ETB RECEPTORS
Mice featuring gene knockouts that retain coding sequences within the targeted region
have the potential for continued expression of truncated or mutated proteins. Such
proteins may themselves be functional or assume transdominant interactions with other
proteins, resulting in unexpected phenotypical outcomes (reviewed by (Muller, 1999).
To investigate whether recombination between loxP sites flanking exons 2 and 3 of the
ETB receptor gene was sufficient to prevent expression of functional ETB receptors, I
utilised the then unexpected phenomenon of germ cell recombination. Consistent with
the recent findings of other groups (Constien et al., 2001, Koni et al., 2001), I have
noted germline recombination events in certain, but not all, female mice featuring the
Tie2 Cre transgene and a floxed allele. Through intercross of offspring heterozygous for
the recombined allele, I generated mice of piebald appearance that die shortly after
weaning from aganglionic megacolon. PCR analysis of tail tip DNA from these animals
demonstrated only the recombined allele. The phenotype of these mice was identical to
that of the complete knockout (Gariepy et al., 1996), demonstrating that exons 2 and 3
are necessary for the expression of functional ETB receptors. Functional absence of ETB
receptors in piebald mice was confirmed in tracheal rings, which, in contrast to control
and EC-specific ETB receptor knockout mice, demonstrated loss of normal ETB receptor-
mediated contraction. A lack of ETB receptor-mediated tracheal contraction in piebald
mice has previously been demonstrated by other groups (Hay et al., 2001). Recently, the
requirement for exons 2 and 3 for the expression of functional ETB receptors has been
further demonstrated in a separate model. Mice featuring a spontaneous deletion of 318
nucleotides within this region develop aganglionic megacolon, abnormal pigmentation
and deafness (Matsushima et al., 2002). This phenotypical pattern is similar to that of
the human Waardenburg syndrome type 4 in which mutations of the ETB receptor gene
have been described. Taken together, these data confirm that my strategy for the
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recombination-mediated excision of exons 2 and 3 of the ETB receptor gene was an
appropriate technique to genetically inhibit functional ETB receptor expression.
8.1.3 ET-1 BINDING BY PULMONARY EC IS SIGNIFICANTLY DECREASED
IN FLOX/FLOX TIE2 MICE
To confirm that the recombined allele observed on genotyping was derived from ECs,
ETb receptor binding and functionality was examined in Flox/Flox Tie2 mice. Isolated
populations of pulmonary EC from Flox/Flox Tie2 mice demonstrated significantly
reduced ETB receptor-mediated binding of 125I ET-1. Binding in the presence of the
selective ETA receptor antagonist A147627 was decreased by ~82% in EC and total
binding of ET-1 was decreased by ~18%, although this latter figure did not reach
significance. These results suggest that down-regulation of ETB receptors in EC was
successfully achieved to an extent comparable to that of other Cre-LoxP knockout
models (Orban et al., 1992). However, the actual degree of ETB receptor down
regulation in EC may have been even greater. My results demonstrate that pulmonary
EC-enriched populations contain at least some contaminating pulmonary SMC cells.
ETb receptor expression, and hence 125I ET-1 binding, will be preserved such cells,
thereby producing an over-estimation of the remaining ETB receptor expression. The
extent of contamination appears to be consistent in both wild type and Flox/Flox Tie2
populations. Other groups have examined expression of ETB receptors in ETB receptor-
deficient models by direct visualisation following tissue staining with ETB receptor
antibodies (Gariepy et al., 2000), or by RT-PCR of total mRNA from tissues using ETB
receptor-specific primers. Despite attempts with several commercially available ETB
receptor monoclonal antibodies, I have been unable to convincingly demonstrate
absence of EC ETB receptor staining. This is likely to be due to several factors. Firstly,
although I have demonstrated that recombination-mediated removal of exons 2 and 3 of
the ETb receptor gene is sufficient to prevent expression of functional ETB receptors,
mutated non-functional ETB receptors may still be expressed at the cell surface. Such
non-functional proteins may still provide epitopes for ETB receptor antibodies. Secondly,
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most ETb receptors are expressed upon the surface of the cell and hence spatial
separation of ETB receptors expressed upon the cell membranes of EC and adjacent
VSMC is extremely difficult. To avoid this problem, our group has generated an ETB
receptor-LacZ 'knock-in' mouse (Adele Gordon, University of Edinburgh, personal
communication) that includes a nuclear localisation signal. This mouse will enable
precise definition of the cellular location of ETB receptors found in close proximity to
one another, such as in the vasculature and renal medulla (reviewed by (Kotelevtsev and
Webb, 2001)). Further methods to co-localise EC staining and ETB receptor staining
might include the use of EC-specific antibodies, such as those to VE-cadherin (CD 144),
vascular endothelial growth factor and CD 146. Alternatively, in-situ hybridisation or
electron microscopic autoradiography might also be used to confirm EC-specific ETB
receptor down-regulation. With each of these methodologies, a mosaic pattern of EC
ETb receptor down-regulation may be seen (discussed in 8.2.2). The interpretation of
such results must, therefore, also take into account the results of functional studies. The
functional studies performed for this thesis are entirely consistent with significant EC-
specific down regulation of ETB receptor expression.
8.1.4 AORTIC VASODILATATION TO ETB RECEPTOR AGONISTS IS
IMPAIRED IN FLOX/FLOX TIE2 MICE
Bolus injection of ET-1 or S6c in the rat typically induces a transient fall in systemic
blood pressure that is quickly followed by a sustained increase in blood pressure. The
transient period of vasodilatation has been attributed, although not specifically shown, to
be secondary to activation of EC ETB receptors. Loss of this response has been used as a
biological assay of inhibition of ETB receptor function (Gariepy et al., 2000, Wessale et
al., 2002). However, unlike most other species, previous studies in the mouse have
demonstrated no transient fall in BP following bolus ET-1 injection (D'Orleans-Juste et
al., 2002). In order to examine whether ETB receptor agonists induce vasodilatation in
the mouse, I examined the in vitro response of aortic rings to S6c. S6c produced a
modest vasodilatation of aortic rings from wild type mice that was ETB receptor-
dependent. This response was significantly impaired in Flox/Flox Tie2 mice (6.38% vs.
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16.6%) suggesting that EC ETB receptors mediate this response and that the Flox/Flox
Tie2 mouse is a model of EC ETB receptor deficiency. The mechanisms underlying the
difference in response to exogenous endothelin receptor agonists between the rat and
mouse are unclear. However, the increase in blood pressure in the mouse following loss
of ETb receptor activity suggests that the ETB receptor exerts a tonic hypotensive effect.
This effect may be obscured when pharmacological doses of agonists are infused.
8.1.5 FUNCTIONAL EXPRESSION OF SMOOTH MUSCLE CELL ETB
RECEPTORS IS MAINTAINED IN FLOX/FLOX TIE2 MICE
EC-specific ETB receptor knockout mice are of normal coat colour and demonstrate
normal growth, development and longevity. These findings are consistent with
continued expression of ETB receptors within epidermal melanocytes and ganglionic
neurons. I investigated whether functional expression of ETB receptors was maintained
in other non-EC cell types, such as SMC. Maximal S6c-induced tracheal constriction of
Flox/Flox Tie2 mice was not significantly different to that of wild type mice (18.7% vs.
20.1%). S6c-induced responses were completely inhibited by the selective ETB receptor
antagonist A192621, indicating that this response was ETB receptor-mediated. Taken
together, these findings suggest that the Flox/Flox Tie2 mouse maintains expression of
functional ETB receptors in non-EC. However, although the expression level of ETB
receptors in tracheal SMC is sufficient to produce normal responses to S6c, I have not
directly assessed whether expression levels are similar to those of wild type mice.
Unfortunately, there are no published data available regarding the tracheal responses of
heterozygous ETB receptor knockout mice to inform whether tracheal contraction is
impaired. However, vascular responses to ETB receptor-selective agonists are
significantly reduced in heterozygous ETB receptor knockouts (Berthiaume et al., 1998),
suggesting that continued expression from both ETB receptor alleles is required to
maintain normal physiological activity. As previously discussed, the high levels of non¬
specific binding seen with ETB receptor antibodies have complicated direct measurement
of ETb receptor protein concentration by western blotting. Thus, currently, this method
is unlikely to be of sufficient sensitivity to detect changes in ETB receptor expression in
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non-EC. An alternative approach might be to perform RT-PCR of vascular tissue or to
measure ETB receptor mRNA levels by RNase protection assay following removal of the
endothelium. However, PCR screening of isolated non-EC populations to demonstrate
the absence of the recombined allele is problematic because of the almost ubiquitous
presence of either EC or cells of the haematopoietic lineage in tissue preparations.
8.1.6 ENDOTHELIAL CELL-SPECIFIC ETB RECEPTOR KNOCKOUT MICE
DEMONSTRATE IMPAIRED ACETYLCHOLINE-INDUCED AORTIC
VASODILATATION AND DECREASED BIOAVAILABILITY OF NITRIC OXIDE
Enhanced endogenous ETB-receptor mediated vascular relaxation has been proposed as a
possible protective mechanism that prevents hypertension following a high salt diet
(Giardina et al., 2001). Previous investigators have demonstrated impaired endothelium-
dependent NO-mediated vasodilatation in rats treated for 5 days with a selective ETB
receptor antagonist (Giardina et al., 2001). The degree of endothelial dysfunction was
significantly increased in rats additionally fed a high salt diet. Such animals also
demonstrated a higher mean arterial pressure than animals treated with either an ETB
receptor antagonist or a high salt diet alone. I investigated whether endothelium-
dependent vasodilatation was impaired in EC-specific ETB receptor knockout mice fed a
normal salt diet. Aortic rings from Flox/Flox Tie2 mice demonstrated a significant
rightwards shift of the ACh concentration-response curve. The reduced ACh-induced
relaxation may be due either to impaired release of vasorelaxant factors from the
endothelium or to a decrease in the sensitivity of VSMC to these factors. I used deta/NO
to demonstrate that exogenous NO-donor drugs elicit normal endothelium-independent
vasodilatation in Flox/Flox Tie2 mice. Taken together, these data indicate that EC-
specific ETb receptor knockout results in impaired endothelium-dependent
vasodilatation to ACh. Although this has been demonstrated in the rat following
pharmacological ETb receptor blockade (Giardina et al., 2001), this is the first time that
this phenomenon has been described in the mouse. This response may represent
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generalised endothelial dysfunction as a result of EC ETB receptor deficiency or a
specific defect of ACh-induced vasodilatation.
Generalised endothelial dysfunction in EC-specific ETB receptor knockout mice
might result from impaired NO bioavailability secondary to loss of normal endogenous
EC ETb receptor signalling. Rescued ETB receptor deficient rats demonstrate down-
regulation of eNOS protein expression and diminished NO production in the lung, with a
consequent increase in PAP (Ivy et al., 2001). The ETB receptor is thus thought to
mediate ET-1-induced increases in eNOS expression. Similar down-regulation of eNOS
activity may, therefore, occur in the aorta following EC ETB receptor down-regulation. I
examined the contribution of NO-mediated vasodilatation in vitro by measuring NE-
induced aortic vasoconstriction before and following inhibition of eNOS with L-NAME.
In Flox/Flox Tie2 mice, the leftwards shift of the NE concentration response curve
following L-NAME was attenuated compared to wild type littermates. This suggests that
endogenous bioavailability of NO is decreased following EC ETB receptor down-
regulation. Although this may result from a decrease in eNOS protein and consequent
NO production, the decrease in ACh-induced vasodilatation of wild type vessels
following acute ETB receptor antagonism would suggest a mechanism independent of
changes in eNOS protein content. Decreased bioavailability of NO might instead result
from loss of endogenous ETB receptor-mediated NO production, or an increase in
reactive oxygen species. Mice featuring EC-specific overexpression of a human
preproET-1 cDNA transgene have recently been shown to exhibit an increase in the
production of reactive oxygen species (Dr E. Schriffrin, Montreal, personal
communication). The increased plasma ET-1 concentration in Flox/Flox Tie2 mice may,
therefore, have produced a similar effect.
An alternative hypothesis to explain the decrease in ACh-induced vasodilatation
is that there is a specific, hitherto unidentified, permissive interaction between vascular
ETb receptors and muscarinic receptors. I have demonstrated impaired carbachol-
mediated tracheal vasoconstriction in EC-specific ETB receptor knockout mice. The
mechanisms underlying this response are also unclear but indicate putative evidence of
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such an interaction in other tissues. Specific interactions in the lung between cholinergic
neurones and ETB receptor-mediated responses have been noted previously. ET-1
enhances cholinergic nerve-mediated tracheal contraction in the rat through activation of
pre-junctional ETA and ETB receptors, leading to an increase in ACh release from
cholinergic nerve endings (Knott et al., 1996). To further investigate the possibility that
loss of EC ETb receptor signalling modulates ACh-induced responses, I examined ACh-
induced vasodilatation following acute ETB receptor antagonism in wild type mice and
in EC-specific knockouts. Acute pharmacological ETB receptor blockade also produced
a rightwards shift of the concentration response curve to ACh in wild type mice but not
Flox/Flox Tie2 mice. This suggests that the VSMC ETB receptor does not influence the
vasodilator response to ACh and that, therefore, any permissive interaction is mediated
by EC ETb receptors.
8.1.7 ENDOTHELIAL CELL-SPECIFIC ETB RECEPTOR KNOCKOUT MICE
EXHIBIT HYPERTENSION THAT IS UNAFFECTED BY INCREASING
DIETARY SALT
Previous rodent studies have demonstrated the importance of endogenous ETB receptor
signalling in the regulation of blood pressure under normal and high salt conditions
(Berthiaume et al., 2000, Gariepy et al., 2000, Giardina et al., 2001, Murakoshi et al.,
2002, Ohuchi et al., 1999, Pollock, 2001, Wessale et al., 2002). Collectively, this data
suggests that endogenous ETB receptor activation exerts a hypotensive effect in the
rodent and this effect appears to assume greater importance under conditions of salt
loading. The ETB receptor is, therefore, likely to play an important role in the protection
against salt-induced increases in blood pressure and ETB receptor deficiency can be
regarded as a single locus cause of severe salt sensitivity (Gariepy et al., 2000).
However, the relative contribution and importance of ETB receptors expressed upon
different cell types to both resting blood pressure and blood pressure in the face of high
salt has not previously been evaluated. Indeed, this question cannot be easily addressed
with any of the previously available in vivo models because they each feature concurrent
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ETb receptor blockade in all tissues. I have measured the resting blood pressure of mice
featuring EC-specific down-regulation of ETB receptor expression under normal and
salt-loaded conditions. My data suggests that loss of EC ETB receptor signalling results
in hypertension in mice fed a normal salt diet and that the EC ETB receptor exerts a tonic
hypotensive effect. These findings are consistent with previous models of ETB receptor
deficiency (Berthiaume et al., 2000, Gariepy et al., 2000, Murakoshi et al., 2002,
Ohuchi et al., 1999) and pharmacological blockade (Giardina et al., 2001, Pollock, 2001,
Wessale et al., 2002), and the increase in blood pressure (MAP ~140 mmHg) suggests
that EC ETb receptor activation normally accounts for ~25 mmHg of the resting blood
pressure. When earlier models of ETB receptor deficiency have been exposed to high salt
loads, there are further marked increases in blood pressure (MAP ~170 mmHg (Gariepy
et al., 2000, Giardina et al., 2001, Pollock and Pollock, 2001)). The novel finding of this
study is that preservation of non-EC ETB receptor expression is protective against salt-
induced increases in blood pressure. ETB receptors located in the IMCD are likely to
mediate the protection against salt through tonic inhibition of ENaC activity (Gariepy et
al., 2000), suggesting an autocrine ET-1/ETB receptor signalling mechanism
(Kotelevtsev and Webb, 2001) within the renal medulla. This hypothesis may be tested
further by treatment of EC ETB receptor-deficient mice on high salt diet with a selective
ETb receptor antagonist and examining the response of any exaggerated blood pressure
increase to treatment with amiloride.
8.1.8 PATHOPHYSIOLOGY OF HYPERTENSION IN ENDOTHELIAL CELL
ETB RECEPTOR-DEFICIENT MICE
Although this study has demonstrated that the EC ETB receptor contributes significantly
to vascular tone and blood pressure, the predominant site at which this occurs has not
been identified. Loss of endogenous ETB receptor-mediated vasodilatation in resistance
arterioles may have led to an increase in peripheral vascular resistance. Alternatively,
loss of renovascular EC ETB receptor signalling, particularly within the medulla may
also have influenced blood pressure. Regulation of sodium and water excretion by the
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kidney directly depends upon blood flow and vascular resistance within the glomeruli
and vasa recta found in the cortex and medulla. Loss of ETB receptors expressed upon
EC of the vasa recta may have altered the pressure-natriuresis-diuresis relationship
(Vassileva et al., 2003). Thus, subtle changes in ET-1/ETB natriuretic and diuretic
pathways, whilst not producing overt salt sensitive hypertension, may have altered the
'set point' of blood pressure. Perhaps the most important question remaining is the
extent to which ETA receptor activation contributes to the hypertension observed in EC
ETb receptor-deficient mice. The increase in plasma ET-1 may have produced an
increase in ETA receptor signalling with consequent increase in peripheral vascular
resistance, both in the peripheral and renal vasculature. In particular, alteration of the
balance between ETA and ETB receptor signalling in the afferent and efferent glomerular
arterioles may have a significant impact upon GFR (discussed in section 8.2.4). The
importance of ETA receptor signalling in previous genetic and pharmacological models
of ETb receptor deficiency remains controversial (Berthiaume et al., 2000, Gariepy et
al., 2000, Matsumura et al., 2000, Pollock and Pollock, 2001) (reviewed in section
8.2.3) and the effects upon blood pressure and renal haemodynamics of treatment of
Flox/Flox Tie2 mice with selective ETA receptor antagonists will be an interesting
addition to the current debate.
8.1.9 PLASMA ET-1 CONCENTRATION IS INCREASED FOLLOWING
DOWN-REGULATION OF ENDOTHELIAL CELL ETB RECEPTORS
Clearance of ET-1 is mediated by ETB receptors and occurs predominantly in the lungs
and liver (Fukuroda et al., 1994). Each of these organs contains a large population of EC
and I wanted to investigate whether this cell type contributed to clearance of ET-1.
Flox/Flox Tie2 mice demonstrate a 4-fold increase in plasma ET-1 concentration
suggesting that the EC ETB receptor contributes importantly to this process. However, 1
have not yet excluded the possibility that the increase in plasma ET-1 concentration is
secondary to an increase in the production of ET-1. This could have occurred through
loss of feedback mechanisms that might normally follow internalisation of clearance
ETb receptors. This question may be addressed by performing clearance studies using
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l25I ET-1 in EC-specific knockout mice. Furthermore, I have not investigated the extent
to which ETb receptors on non-EC contribute to the process of clearance. This could be
analysed in future cell type-specific ETB receptor knockout models and in EC-specific
knockouts additionally treated with ETB receptor antagonists. However, the magnitude
of increase in ET-1 concentration is comparable to that of rescued ETB receptor rats
(Gariepy et al., 2000) and in models following chronic ETB receptor antagonism,
suggesting that EC may be the predominant cell type mediating clearance.
8.2 LIMITATIONS OF THE CURRENT STUDY
Many of our initial findings now need to be studied in greater detail to explore the
underlying mechanisms of the observed phenotype. However, there are a number of
limitations to the approach that I have taken and to murine models of cardiovascular
disease in general.
8.2.1 GENETIC BACKGROUND
The genetic background of the model in question may have profound effects upon the
observed phenotype. Current experience with ES cell isolation and manipulation dictates
the use of 129/SV ES cells, since these are the simplest to maintain in an
undifferentiated state in cell culture prior to gene targeting. Following production of
chimaeric mice, germline transmission of the targeted allele is usually tested by crossing
chimaeras with a further pure-bred strain, such as the BKW. Targeted offspring will,
therefore, possess a mixed 129/SV and BKW background. In contrast, most transgenic
mouse lines are produced on a C57/BL6J background. Intercross of targeted and
transgenic lines thus leads to further mixing of genetic background with potentially
profound influences upon cardiovascular phenotype (Ryan et al., 2002). To minimise the
effect of heterogeneity of genetic background upon the observed phenotype, I utilised
single transgenic and wild type mice from the same litters as experimental controls.
However, I cannot exclude the possibility that segregation of key genes influencing
cardiovascular phenotype may have differed between double transgenic and control
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littermates. Breeding of double transgenic mice onto a pure genetic background may be
achieved by multiple backcrosses and detailed comparison of the influence of different
genetic backgrounds may then be made. The genetic background may also influence the
frequency of germline recombination events in female Flox/W Tie2/- mice and hence
achievement of purebred background may provide a mechanism for simplification of
breeding strategies.
8.2.2 CRE-LOXP APPROACHES TO CONDITIONAL GENE EXPRESSION
Analysis of cell type-specific receptor function is critically dependent upon both the
efficiency of recombination events within a cell and the restriction of such events solely
to the cell type of interest. Ideally, Cre-mediated recombination occurs in both alleles of
the gene of interest, resulting in complete knockout of target gene expression in the
desired cell-type. Conversely, expression in all other cells should be unchanged from the
wild-type pattern. Leaky or deregulated transcription of the Cre recombinase transgene
will result in unwanted recombination events in other cell types. At worst, this may
result in lethality, but more commonly will complicate interpretation of the observed
phenotypical outcomes. This problem was exemplified in this study by the unexpected
finding of germline recombination events in some female mice featuring the Tie2Cre
transgene and a floxed allele. Although this may be advantageous for studies in which
100% knockout of target allele from EC is desirable and heterozygous knockout in other
cells is inconsequential (Constien et al., 2001), in our study it necessitated revision of
the original breeding strategy. Because I wished to achieve normal expression of ETB
receptors in non-EC, I undertook breeding that only introduced the Tie2Cre transgene
through the male germline and screened all control experimental animals by PCR for the
presence of the recombined allele. To further ensure normal expression of ETB receptors
in non-EC, I designed a targeting vector that minimised the loss of intronic elements
from the targeted allele. This design decreased the chances of inadvertently removing
key gene transcription regulatory elements. I have demonstrated normal functional
responses of SMC ETB receptors within the trachea of EC-specific ETB receptor
knockout mice. However, I have not yet examined ETB receptor binding in multiple
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tissues to ensure that 'leaky' expression of Cre recombinase from adjacent EC has not
initiated unwanted recombination events. As new ETB receptor antibodies become
available, it may be possible to more accurately quantify the expression of ETB receptors
in non-EC.
8.2.3 INCREASE IN PLASMA ET-1
EC-specific ETB receptor knockout mice are hypertensive under conditions of normal
and high salt, suggesting that EC ETB receptors mediate a tonic vasodilator role.
However, the contribution of EC ETB receptors to clearance of ET-1 complicates
interpretation of this finding. The increased plasma ET-1 concentration in Flox/Flox
Tie2 mice may result in increased signalling through ETA receptors, with consequent
vasoconstriction and increased blood pressure. The importance of increased ETA
receptor signalling in ETB receptor-deficient models remains contentious. In rescued ETB
receptor-deficient rats fed a high salt diet, acute treatment with a selective ETA receptor
antagonist did not normalise blood pressure, but the fall in blood pressure was greater
than that observed in control rats (Gariepy et al., 2000). In contrast, hypertension
following selective ETB receptor antagonism and high salt was completely reversed by 7
days treatment with an ETA receptor antagonist (Pollock and Pollock, 2001). These
different findings may reflect a difference between pharmacological and genetic models
of ETb receptor deficiency, but clearly require further clarification.
Sustained hypertension throughout development and the increase in plasma ET-1
concentration secondary to EC ETB receptor deficiency may also have altered
endothelial function and promoted vascular hypertrophy. Hypertensive models featuring
an increase in vascular preproET-1 commonly demonstrate vascular hypertrophy to a
greater extent than might be expected for the degree of hypertension (Schiffrin et al.,
1995). It is unknown whether increased plasma ET-1 resulting from abnormal clearance
produces a similar synergistic effect upon vascular growth. I have not examined whether
the aorta or resistance vessels of Flox/Flox Tie2 mice demonstrate significant vascular
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hypertrophy or whether tissue preproET-1 levels are increased, but this may have
contributed to the impairment of ACh-induced vasodilatation.
8.2.4 EFFECT OF ENDOTHELIAL CELL-SPECIFIC ETB RECEPTOR
DEFICIENCY UPON GLOMERULAR FILTRATION RATE
The kidney plays a central role in cardiovascular homeostasis, specifically in the long-
term control of blood pressure. The regulation of sodium and water excretion by the
kidney depends directly upon blood flow and vascular resistance within the glomeruli
and vasa recta found in the cortex and medulla. In the medulla, ET-1 activates ETB
receptors, increasing medullary blood flow (Gurbanov et al., 1996) and promoting
natriuresis. This effect is mediated via the release of NO (Hoffman et al., 2000) and ETB
receptor-dependent medullary vasodilatation appears to be particularly important under
high salt conditions (Pollock et al., 2000, Pollock and Pollock, 2001, Vassileva et al.,
2003). In the cortex, afferent arteriolar responses are mediated by both ETA and ETB
receptors, whilst efferent arteriolar constriction is predominantly ETB receptor-mediated
(Endlich et al., 1996). However, although exquisitely sensitive to exogenous ET-1, an
endogenous ETA-mediated vasomotor tone has been difficult to demonstrate in the
rodent kidney. Selective ETA receptor antagonists do not alter renal vascular resistance
in normotensive anaesthetised rats (Matsuura et al., 1997, Qiu et al., 1995). In contrast,
selective ETB receptor antagonists decrease RBF and increase RVR by ~20% (Matsuura
et al., 1997) and GFR is markedly decreased in ETB receptor deficient rats. Taken
together, this data suggests an overall tonic vasodilator role for glomerular ETB receptors
(Hocher et al., 2001) and that the regulation of renal vascular and glomerular tone may
be more dependent upon endogenous activation of ETB receptors than ETA receptors.
Thus, the balance between vasodilator EC and vasoconstrictor VSMC ETB receptors
within the afferent and efferent arterioles may have influenced the blood pressure of
Flox/Flox Tie2 mice through changes in the pressure-natriuresis-diuresis relationship.
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8.2.5 COMPENSATORY EFFECTS OF OTHER BLOOD PRESSURE
REGULATORY PATHWAYS
The regulation of blood pressure is a complex process involving multiple neurohormonal
pathways. Because recombination of the ETB receptor gene in the target cell occurs
during embryogenesis, I cannot exclude the possibility that other blood pressure
regulatory mechanisms may have compensated for loss of EC ETB receptor expression.
This may have resulted in a less severe phenotype than perhaps was observed.
Alternatively, the hypertension resulting from EC-specific down regulation of ETB
receptor expression during development may have produced pathophysiological changes
in, for example, blood vessel structure. This in turn may have adversely altered
endothelial function and the response to other vasoactive hormones, exaggerating the
observed phenotype through non-ETB receptor-dependent mechanisms. This criticism
may be levelled at all genetic models of hypertension in which there is no temporal
regulation of gene inactivation. However, 'floxed' ETB receptor mice may also be used
to examine the effects of loss of all ETB receptors in the adult mouse without the
confounding effects of ETB receptor down-regulation during development. Adenovirus-
mediated delivery of Cre recombinase to 'floxed' mice or inducible expression of Cre
transgenes may each be used to down-regulate ETB receptor expression in the adult
animal. Such approaches will offer further insight into the pathophysiology of
cardiovascular disease.
8.3 SUMMARY
This thesis has described the generation of the 'floxed' ETB receptor mouse. Through
crosses with tissue specific Cre recombinase expressing transgenic mouse lines, this
model permits the selective down-regulation of ETB receptor expression in the cell type
of interest. I have demonstrated EC-specific down-regulation of ETB receptor expression
following intercross of 'floxed' ETB receptor mice with Tie2-Cre transgenic mice.
Binding studies in isolated pulmonary EC demonstrate a significant reduction of ETB
receptor-mediated binding whilst in vitro tracheal SMC contraction to ETB receptor-
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selective agonists is maintained. EC-specific ETB receptor knockout mice are
hypertensive on a normal salt diet but do not exhibit salt sensitivity. Plasma ET-1
concentration is increased and in vitro aortic vasodilatation to ACh is impaired, probably
as a result of decreased bioavailability of NO. These findings suggest that the EC ETB
receptor mediates a tonic hypotensive effect in the mouse and contributes importantly to
the process of clearance of ET-1.
The floxed ETB receptor mouse was conceived with the intention of determining
the relative importance of ETB receptors expressed upon different cell types to the
regulation of blood pressure. I have now demonstrated that endogenous EC ETB receptor
activation lowers blood pressure. The organ (kidney vs. peripheral resistance arterioles)
in which EC ETB receptors exert this effect has not yet been determined, but may be
investigated using this model and other tissue-specific ETB receptor knockouts produced
from the floxed ETB receptor mouse. The ETB receptor is likely to protect against salt-
induced changes in blood pressure through 3 major mechanisms: regulation of distal
tubular sodium re-absorption by IMCD cells, up-regulation of endothelium-dependent
vasorelaxant pathways in resistance arterioles or medullary vasa recta, and by regulation
of glomerular and medullary blood flow. The detailed phenotyping of EC-, VSMC- and
IMCD-specific ETB receptor knockouts will allow definition of the importance of each
cell type, and their likely interactions, in each of these pathways, permitting further
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W/W -/-, Flox/Flox -/- and Flox/Flox Tie2 mice (n = 3) were sacrificed, frozen and
longitudinally sectioned. Autoradiographic binding studies using the selective ETB
receptor ligand, BQ3020 (Amersham Biosciences, UK) were performed as described
(Davenport and Kuc, 2002). Briefly, 30 pm sections were incubated with 0.1 pmol of
[125IJ-BQ3020. Non-specific binding was determined in the presence of excess
unlabelled BQ3020. Autoradiograms were exposed for 6 days at room temperature prior
to development.
10.1.2 RESULTS
Qualitative ETB receptor expression was visualised using the radiolabeled ETB receptor
ligand |125I|-BQ3020 (Figure 10.1). W/W -/- and Flox/Flox -/- mice demonstrated
intense ETB receptor-mediated binding within the kidney, liver and lung. Binding of
[125I]-BQ3020 in Flox/Flox -/- mice in the absence of the Cre recombinase transgene was
indistinguishable from that of W/W -/- mice. In EC-specific KOs, binding was
substantially reduced within the lung parenchyma, but could be clearly seen within the
SMC layer surrounding bronchioles. Binding was also detected in gut epithelial cells and
the heart. Binding was substantially reduced within the renal medulla of Flox/Flox Tie2
mice, presumably as a result of decreased ETB receptor expression on vasa recta EC. The
liver of Flox/Flox Tie2 mice showed only a moderate reduction in ETB receptor-




Autoradiographic analysis ofW/W -/- (i) Flox/Flox -/- (ii) and Flox/Flox Tie2 (iii) mice
following labelling with [125I]-BQ3020. K = kidney, Li = liver, H = heart, G = gut, L =
lung.
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